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Abstract 
The continuous formation of various types of blood cell throughout the 
lifetime to replenish the loss of the short-lived blood cells is a vital process for the 
survival and development of an individual. The process is complex and highly 
regulated whereby a hierarchy of hematopoietic progenitor cells in the bone marrow 
proliferate and differentiate along multiple, distinct heamatopoietic cell lineages, 
including proliferation and differentiation of myeloid precursor cells into mature 
granulocytes and macrophages. Nevertheless, the mechanism controlling this 
multistep process is not well understood. Any abnormality in the normal 
developmental program for blood cell formation results in severe hematological 
diseases, including leukemia which appear to be associated with blocks in cell 
differentiation. 
WEHI 3B (JCS) myeloid leukemia cell line could be induced to terminal 
differentiate along monocytic lineage by biochanin A, and along both monocytic and 
granulocytic lineages by midazolam. However, little is known about the molecular 
mechanism underlying the induced myeloid leukemia cell differentiation. In the 
present study, a modified RNA fingerprinting by arbitrarily primed PCR (RAP-PCR) 
method was used to identify genes that are differentially regulated during biochanin A 
induced JCS cells differentiation. Two rounds of dot blot hybridization screening 
procedures were adopted to eliminate the false positives that were identified as 
differentially expressed genes by RAP-PCR. 184 differentially amplified fragments 
were identified and isolated in the original fingerprint. After two rounds of dot blot 
hybridization screening, 14 differentially amplified fragments were selected for 
further analysis. 5 fragments were shown to be differentially expressed during 
biochanin A induced JCS cells differentiation by RT-PCR analysis. All of these 
fragments were downregulated at 1 hour, 5 hours and 48 hours after induction of JCS 
cells differentiation by biochanin A. Three of these fragments were also 
downregulated during midazolam induced JCS cells differentiation, suggesting that 
the downregulation of those three genes may be associated with both biochanin A-
and midazolam-induced JCS cells differentiation. The expression of all of the five 
differentially expressed genes were detected ubiquitously in various mouse tissues, 
iv 
including lung, heart, kidney, spleen, thymus, bone marrow, brain and postnatal day-
20 mouse brain. One of these fragments share over 70% homology with the deduced 
amino acid sequence of the human VT4 protein of which the function has not been 
characterized by any published data yet. Nevertheless, it was suggested that the 
sequence of VT4 protein is related to that of the yemanuclein-alpha protein in 
Drosophila malanogaster, which was proposed to exhibit certain DNA binding 
activity, which in tum suggesting the putative function of the VT4 protein. The 
remaining four fragments are putative novel genes, sharing no homology with any 
nucleotide or amino acid sequence ofknown genes. 
The expression of those fragments was also detected in mouse embryos at 
various stages. Of these, two were expressed in 9.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. 
embryos with a particularly high expression level in 15.5 d.p.c embryo, one was 
expressed in 15.5 d.p.c. and 17.5 d.p.c., and the rest two were only expressed in 15.5 
d.p.c embryos. The differential expression of these genes in mouse embryos 
suggested that these genes may be involved in the mouse embryo development as 
well. 
Our study result in the identification of candidate genes that may be involved 
in the induced myeloid leukemia cell differentiation process by RAP-PCR and 
examination of the pattem of the gene expression during the course of induction of 
differentiation. Further analysis is required to characterize the identified novel genes 
and determine their functional role in the differentiation process. Hopefully, the 
appreciation of the molecular mechanism controlling the induced myeloid leukemia 
cell differentiation may help us gain better understanding of the regulation ofmyeloid 
cell differentiation and the abnormality that afflicts it; and therefore provide new 
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CHAPTER O N E . . . 
General Introduction 
1-1 The Blood Cells Formation - Hematopoiesis 
Human contain approximately 6 litres of blood, accounting for 7% of body 
weight (Stevens, 1997). The blood contains many types of cells with very different 
functions. Blood cells can be classified as red or white. Red blood cells constitute 
about 45% of this volume and white cells about 1%, the rest being the liquid blood 
plasma. The red blood cells remain within the blood vessels and transport O2 and CO2 
bound to hemoglobin. The white blood cells combat infection and, in some case, 
phagocyte and digest debris. In addition, the blood contains large numbers of 
platelets, which are not entire cells but small detached cell fragments derived from the 
cortical cytoplasm of large cells called megakaryocytes. Platelets adhere specifically 
to the endothelial cell lining of damaged blood vessels, where they help repair 
breaches and aid in the process of blood clotting. All blood cells, however, have 
certain similarities in their life history. Like the other granulocytes, neutrophils 
circulate in the blood for only a few hours before migrating out of capillaries into the 
connective tissue or other specific sites, where they survive for a few days and then 
die. Macrophages, by contrast, can persist for months or perhaps even years outside 
the bloodstream, where they can be activated by local signals to resume proliferation. 
However, most mature blood cells have a short life span, which usually die several 
days or weeks, and little or no proliferative capacity. Therefore, large numbers of 
different cell lineages have to be continuously regenerated in the body throughout 
normal life. Many cells from different lineages also have to be produced in 
emergency situations, such as infections or following sudden loss of bloods. The 
formation of different types of blood cells, hematopoiesis, is essential for the normal 
development and survival of an individual (Sachs, 1987). 
. Chapter 1 
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Blood cell formation involves complex controls in which the production of 
each type ofblood cell is regulated individually to meet changing needs. However, it 
is still not clear how they choose among alternative developmental pathways. It is of 
great medical importance to understand how these controls operate. Our ultimate 
interest are the mechanisms that involved in achieving the coordinated production of 
the eight main types ofblood cells and how these critical events of differentiation are 
committed and the regulation of cellular maturation. 
1.1.1 Hierarchy of hematopoiesis 
The production of mature blood cells throughout life is accomplished by the 
highly regulated, multi-stage developmental process, the hematopoiesis, which 
generate at least eight distinct lineages that differentiate into mature cells types of 
blood including monocytes, granulocytes, lymphocytes, mekaryocytes, and 
erythrocytes (Figure 1.1). In common with other rapidly regenerating tissue, the 
hematopoietic system is organised on a hierarchy basis. All types of blood cells 
produced throughout life derive from pluripotent stem cell, which in adult reside 
predominantly in the bone marrow. This cell make up a significant percentage 
(approximately 10%) of the umbilical cord blood cells of a newbom and less than 1% 
o f the blood cells of an adult (Stevens, 1997). The pluripotent stem cells normally 
divide frequently to produce more stem cells, self renewal to replace the loss of 
bloods. While stem cells are capable of self-renewal, they undergo differentiation to 
generate more developmentally restricted progenitor cells committed irreversibly to 
one of the various hematopoietic lineages. The committed progenitor cells become 
progressively restricted to one of at least eight distinct lineages during their terminal 
differentiation to mature blood cells. 
The production of mature blood cells throughout life involves the highly 
regulated progression through successive stages, involving commitment to a specific 
cell lineage, terminal differentiation of lineage restricted progenitors and growth 
arrest. Commitment is thought to involve a finite number of cell divisions, during 
which the cells execute a predefined program of gene expression changes, eventually 
generating a terminally differentiated cell (Berg, 1996). 
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Figure 1.1 Scheme of hematopoiesis with regulators. All blood cells 
originate from the pluripotent stem cell (PPSC). The amount of proliferation and direction 
of differentiation is determined by cell-to-cell contact in the bone marrow microenvironment 
and the protein regulators (cytokines) produced in response to the bodies needs (Reproduced 
from Stevens, 1997). 
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The pluripotent stem cell (PSC), under influence of myeloid growth factors, 
will begin to proliferate and transform into the colony-forming unit-granulocyte, 
erythrocyte, monocyte, and megakaryocyte (CFU-GEMM). This myeloid progenitor 
cell is committed to the myeloid hematopoietic cell line. The CFU-GEMM cell is 
destined to become a granulocyte, erythrocyte, monocyte, or megakaryocyte. If 
influenced by lymphoid growth factors such as IL-7 and SCF, the PSC will proliferate 
and differentiate into a lymphoid stem cell (LSC), which is found primarily in the 
lymphatic system of the body. This lymphoid progenitor cell is committed to the 
lymphoid hematopoietic cell line. The LSC will become either a B lymphocyte, a T 
lymphocyte, a killer (K) lymphocyte, or a natural killer (NK) lymphocyte. The CFU-
GEMM progenitor cell then responds to specific cell line growth factors to become 
the corresponding cell. The myeloid growth factors are called colony-stimulating 
factors (CFUs), with a cell line designation such as G-CSF for granulocyte growth 
factors or M-CSF for monocyte growth factors. Growth factors and cells produced 
are concerted according to body needs. 
Depending on the specific stimulation, the CFU-GEMM will become a 
colony-forming unit-granulocyte monocyte (CFU-GM), colony-forming unit-
eosinophil (CFU-Eo), colony-forming unit-basophil (CFU-Baso), colony-forming 
unit-erythroid (BFU-E). The CFU-GM can be directed to differentiate into a 
neutrophilic granulocyte and the monocyte has a common precursor cell, the CFU-
GM. The other two granulocytic cells, the eosinophilic and basophilic granulocytes, 
have their own committed CFU-Eo and CFU-Baso. 
Under the influence ofGM-CSF, the CFU-GEMM will become the CFU-GM. 
This progenitor cell then responds to granulocyte colony-stimulating factor (G-CSF) 
to become the colony-forming unit-granulocyte (CFU-G), which is the neutrophilic 
granulocytic committed blast cell called myeloblast. This cell is then further 
differentiate into the promyelocyte, myelocyte, and metamyelocyte and maturing into 
a fmal functional segmented neutrophilic granulocyte. The polysegmented 
neutrophilic granulocyte, which is also called the polymorphonuclear (Poly, PMN, or 
Seg) cell, functions to destroy bacteria invading the body. If the predominating 
growth factor influencing the CFU-GM is the M-CSF, the CFU-GM becomes the 
monoblast (CFU-M). This cell divides and matures into promonocyte and final 
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functional cell, the monocyte. The monocyte is an extremely important component in 
the body's response to infection. The monocyte is a major phagocytic cell of the body 
that not only destroys the invading organism or substance but also relays information 
about the invader to other cells of the body. 
If the CFU-GEMM responds to IL-5 and unknown eosinophil CSFs, it will 
become the CFU-Eo. This is a committed progenitor cell that will develop only into a 
promyelocyte, an eosinophilic metamyelocyte, and a segmented eosinophil. Some 
believe that this cell derives from the CFU-GM; however, this diagram will support 
the evidence of a CFU unique to the eosinophil. The CFU-Eo is involved in 
hypersensitivity reactions and is seen in association with allergies, colds, and parasitic 
infections. 
In response to an unknown colony-stimulating factor-basophil (Baso-CSF), the 
CFU-GEMM will become the CFU-Baso. This will then become a promyelocyte, a 
basophilic myelocyte, a basophilic metamyelocyte, and a segmented basophil. The 
basophil mediates hypersensitivity reactions such as allergies and colds. 
The megakaryocyte, in the bone marrow, is the parent cell of the platelet found 
in the peripheral blood. Under the influence of a colony-stimulating factor-
megakaryocyte (Mega-CSF), CFU-GEMM will differentiate into the CFU-Mega or 
megakaryoblast, which will develop into a promegakaryocyte and a megakaryocyte 
and will eventually produce platelets. Platelets are cytoplasmic fragments of the 
megakaryocyte. Platelets form the initial plug of an injured blood vessel to mediate 
blood coagulation. 
Under the influence of the hormone erythropoietin (EPO) the CFU-GEMM 
progenitor cell will differentiate into a BFU-E. This BFU-E will progress through 
five maturational stages before becoming a mature erythrocyte. 
The PSC can be driven by lymphoid growth factors in the direction of the 
LSC. The LSC will then become a specific type of lymphocyte. The LSC is 
influenced by various factors to proliferate and mature in the thymus to become a T 
lymphocyte or a B lymphocyte (Stevens, 1997). 
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1.1.2 Malfunction in the process of hematopoiesis 
-hematologic neoplasia - Leukemia 
Hematopoiesis is an equilibrium between self-renewal and differentiation. 
Dying cells are replaced by new tissues, and termination of cell growth after reaching 
the most mature stages, all of these events come in harmony during normal infancy 
and adulthood (Sachs, 1982). However, abnormalities in this normal developmental 
program of blood cell formation, an upset of the balance between proliferation and 
differentiation of stem cells and progenitor cells results in various types of 
hematological diseases including oncogensis that lead to leukemia (Sachs, 1996). 
Leukemias are a group of neoplastic conditions characterized by the 
accumulation of malignant myeloid or lymphoid cells, arrested at distinct stages of 
development, in the bone marrow and peripheral blood. Leukemia is defined as the 
uncontrolled proliferation or expansion of hematopoietic cells that do not retain the 
capacity to differentiate normally to mature blood cells (Sawyers, et al., 1991). 
Leukemia cells escape from the balanced control of proliferation, maturation, and cell 
survival characteristic of the normal hematopoietic system. 
Normally, hematopoietic precursor cells proliferation and differentiation 
proceeds to a point where proliferation ceases and differentiation goes to completion. 
Finally, mature blood cells undergo programmed cell death leading to apoptosis, each 
normal stem cell division generates one daughter stem cell and one cell that is 
condemned to terminal differentiation and a cessation of cell division. If the stem cell 
simply divides more rapidly, terminally differentiated cells will still be maintained. 
The development of leukemias occurs such that the transformed stem cell 
generating a steadily growing daughter cells is remained as stem cells, or the process 
of differentiation is deranged so that daughter cells retain an ability to carry on 
dividing indefinitely and avoid being discarded at the end of the production line, 
resulting in uncontrolled growth and a relative block in terminal differentiation 
leading to accumulation of immature blood cells, and the normal supply of blood 
cannot be maintained. 
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Factors involved in the development of leukemia are still under investigation; 
however, evidence indicates that three components may be responsible for the 
development of disease. They include genetic alteration (normal genes to malignant 
genes or proto-oncogenes to oncogenes or inactivation of a gene whose protein 
product suppress cancer), exposure to certain viruses, and an initiating event, such as 
exposure to a carcinogenic substance. 
1.1.2.1 Classification of leukemia 
Leukemia is mainly classified into acute and chronic leukemia. 
Acute 
Acute myeloid (myeloblastic) leukemia (AML) 
_Acute lymphoblastic leukemia (ALL)  
Chronic 
Chronic myeloid (granulocytic leukemia) (CML/CGL) 
Chronic lymphocytic (lymphatic) leukemia (CLL) 
Other chronic lymphoid leukemias, e.g. hairly cell, prolymphocytic, lymphonWleukemia 
_syndromes  
_Myelodysplastic syndromes  
Acute leukemia, in which there are over 50% myeloblasts or lymphoblasts in 
the bone marrow at clinical presentation, is further subdivided into AML and ALL on 
the basic of morphology and cytochemistry. 
Acute leukemias are very aggressive. The onset is rapid; mostly immature 
cells (blasts) are seen; the white blood cell count varies from low to high; and the 
prognosis is often poor. Acute myelogenous leukemia is most common in the first 
few months of life and again in the mid to late years of life. As with any acute illness, 
the onset is sudden and aggressive, often resembling an acute infection. The patient 
presents with fever, malaise, and ulcers of the mouth and throat. The AML blasts 
from different patients show considerable heterogeneity with respect cytologic 
features. Based on morphological and cytochemical characteristics of maturation, 
AML cases are further subdivided into eight variants. According to the French-
American-British (FAB) scheme (1985), ALL is subdivided on a morphological basis 
and classified into Li, Lz and L3 types. Immunophenotyping, chromosome and gene 
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rearrangement studies are also used to distinguish AML from ALL and to subclassify 
them. 
Classification of acute leukemia according to the FAB group 
^ ^ L ALL 
Mo undifferentiated Li blast cells small, uniform high nuclear 
to cytoplasmic ratio 
Ml without maturation L2 blast cells larger, heterogenous, lower 
nuclear to cytoplasmic ratio 
M2 with granulocytic maturation L3 vacuolated blasts, basophilic cytoplasm 
(usually B-ALL) 
M3 acute promyelocytic NB Both Li and L2 include cases of c-
M4 granulocytic and monocytic maturation ALL, pre-B-ALL, null-ALL and T-ALL, 
M5 monoblastic or monocytic which are indistinguishable on 
M6 erythroleukemia conventional (Romanowsky) morphology 
_^7 megakaryoblastic  
The chronic leukemias comprise two main types, chronic myeloid leukemia 
(CML) and chronic lymphocytic (lymphatic) leukemia (CLL). CML, also called 
chronic granulocytic leukemia (CGL), is typically found in individuals older than 50 
years of age. CML is characterised by the chromosomal translocation 
(9;22)(q34;qll), known as Philadelphia translocation. Other chronic types include 
hairy cell leukemia, prolymphocytic leukemia and various leukemia;'lymphoma 
syndromes. In addition, there are a variety of myelodysplastic syndromes, some of 
which are regarded as chronic or ‘smouldering’ forms of leukemia and others as 'pre-
leukemia'. 
Classification of chronic myeloid leukemias 
1 Chronic myeloid leukemia, Ph positive (CML, Ph+)(chronic granulocytic leukemia, 
CGL) 
2 Chronic myeloid leukemia, Ph negative (CML, Ph-) 
3 Juvenile chronic myeloid leukemia 
4 Chronic neutrophilic leukemia 
5 Eosinophilic leukemia 
- j _ ^ r o n i c myelomonocytic leukemia (CMML)  
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Classification of the chronic lymphoid leukemias 
]BTell T cell 
B-chronic lymphocytic leukemia (B-CLL, T-chronic lymphocytic leukemia (T-CLL) 
CLL) (large granular lymphocyte leukemia) 
B-prolymphocytic leukemia (B-PLL) !-prolymphocyte leukemia (T-PLL) 
Hairy cell leukemia (HCL) Adult T-cell leukemiay'lymphoma 
Plasma cell leukemia  
The leukemia cell population in ALL and AML probably result from clonal 
proliferation by successive divisions from a single abnormal stem or progenitor cell. 
In acute leukemia the blast cells fail to differentiate normally but are capable of 
further divisions. Their accumulation results in replacement of the normal 
hematopoietic precursor cells of the bone marrow by myeloblasts or lymphoblasts 
and, ultimately, in bone marrow failure. The clinical condition of the patient can be 
correlated with the total number of leukemic cells in the body. 
The acute leukemias comprise over half of the leukemias seen in clinical 
practice. ALL is the common form in children; its incidence is highest at 3-4 years, 
falling off by 10 years. AML occurs in all age groups. It is the common form of 
acute leukemia in adults, including the elderly, and is the usual type to complicate 
myelodysplasia and other hematological disease. AML forms only a minor fraction 
(10-15%) of the leukemias in childhood. CML comprises <20% of all the leukemias 
and is seen most frequently in middle age (Hoffbrand, et al, 1993). Since the blasts 
from different patients show considerable heterogeneity with respect cytologic 
features, the case is complicated and nasty. 
1.1.2.2 Differentiation therapy - a new hope in the 
treatment of leukemia 
Recent advances in the biology of hematopoiesis so far have only a minor 
impact on the clinical management of leukemia. At present, chemotherapy is still the 
mainstay in elimination of leukemic cells. Other conventional therapies include 
surgery, radiotherapy, chemotherapy and immunotherapy or administration of 
peripheral blood progenitor or umbilical cord blood. Tumor cell are genetically 
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unstable and may be one cause of the heterogeneity of tumors. Therefore, common 
metabolic alterations may not be able to act as a target for a single anticancer agent 
(Hozumi, 1994). 
On the other hand, it was proved that malignant cells can retain the genetic 
basis for differentiation. They can complete the normal process of growth, 
differentiation and growth arrest when appropriately stimulated (Sachs, 1982). It has 
been shown recently that malignant state can be suppressed in various tumor cells 
including leukemia cells by inducing terminal differentiation by various compounds 
both in vitro and in vivo into mature cells. The differentiated cells were demonstrated 
to lose their abilities for proliferation and tumorigenicity. This created the basis for 
the clinical use of differentiation therapy. The suppression of malignancy by inducing 
differentiation can bypass genetic abnormalities that give rise to malignancy, 
suggesting that induction of terminal cell differentiation by certain inducers is an 
alternate approach to cancer therapy or differentiation therapy of cancer (Sachs, 1996; 
Hozumi, 1994). 
It was proposed that leukemic cells can be caused to mature by certain steroid 
hormones, small amounts of X rays and low doses of cancer chemotherapies like 
cytosine arabinoside, adriamycin and methotrexate. Other compounds include 
insulin, some vitamins, bacterial lipopolysaccharide and certain compounds from 
plants : lectins and some phorbol esters can also induce differentiation. When 
administered singly or in combination or together with normal differentiation factor, 
such compounds can induce differentiation in differentiation defective clones. Such 
compounds tum on some or even a combination of genes needed for cell 
differentiation (Sachs, 1982). 
Induced differentiation is a practical method for the treatment of cancer. 
Researchers hope to induce leukemic cells to relinquish their malignant phenotype 
and enter a program of normal cellular differentiation and death. The first step was 
made by Leo Sachs. He demonstrated that cell lines derived from murine leukemia 
were able, in in vitro assays, to be differentiated by inducing agents, even when 
chromosomal defects were present (Degos, 1993). For acute promyelocytic leukemia, 
this ambition has already been realized with the clinical use of retinoic acid 
derivatives. It is observed that when treated with all-trans retinoic acid acute 
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promyelocytic leukemia patients can achieve complete remissions of leukemia, 
presumably by inducing differentiation of the leukemic cells (Sawyers, et al, 1991). 
With differentiation therapy, the leukemic cell mass is reduced and allow 
restoration of normal hematopoiesis (Olsson, et al., 1996). Differentiation therapy in 
leukemia is only limited to acute promyelocytic leukemia (APL), it is still in the 
preliminary phase. There are different pathways of gene expression for inducing 
differentiation by different compounds. Therefore, in order to enhance the progress in 
identifying new approaches to therapy and to optimize strategies for treatment, the 
basic studies on hematopoiesis and leukemia is a must (Sachs, 1996). Improved 
understanding of the mechanisms regulating hematopoiesis including myeloid gene 
expression and myeloid cell maturation may lead to additional novel strategies for 
treatment of leukemias (Shapiro, et al., 1995). 
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1.2 Understanding the pathogenesis of leukemia 
It is generally accepted that leukemogenesis is a complex process. 
Complexities abound, as well as unanswered questions. Leukemogenesis represents 
deregulation of the mechanisms of cellular developmental control, it results from 
genetic change that disregulate the normal balance among survival, proliferation, and 
differentiation of hematopoietic cells. These processes are subject to regulation by 
hematopoietic growth factors, which stimulate a range of cellular signalling events 
that are subject to negative feedback control. Perturbation of the signalling pathways 
resulting from constitutive activation of hematopoietic growth factor receptor or 
downstream signalling molecules potentially results in the delivery of signals leading 
to suppression of apoptosis, stimulation of proliferation at inappropriate times, and 
possibly leukemia (Evans, et al, 1996). 
Leukemic cells are arrested at immature stages of their development. They do 
not differentiate into mature cells, but continue to multiply, so that there are too many 
immature cells. Several observations suggest that leukemogenesis requires 
abnormalities in both growth and differentiation (Sawyers, et al., 1991; Olssons, et 
al., 1996). The process involves many of the same key regulatory molecules as the 
normal pathway. 
It is essential to understand the cellular and molecular mechanism that control 
the growth and differentiation of normal blood cell. Knowing the changes and 
abnormalities in leukemia would lead novel therapeutic strategies (Sachs, 1996). If 
we have a clear understanding of the manner in which normal hematopoiesis is 
regulated, we shall have gone a long way to understanding the nature of the cellular 
abnormalities responsible for leukemic transformation. 
1.2.1 General regulation of hematopoiesis 
Hematopoiesis is a continuous process in which precursors cells proliferate 
and differentiate throughout life. However, the molecular mechanism that govem the 
process including the regulation of the processes of lineage or differentiative 
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commitment and the molecular nature of the growth to differentiation signal 
transduction cascade, is still unclear (Liebermarm, et al., 1989; Magli, et al., 1991). 
Hematopoiesis is a profound example of cell homeostasis which is regulated 
throughout life to maintain steady state levels of mature blood cells, as well as to 
stimulate the rapid production of specific cell types as needed in response to 
emergencies. The regulation of production of blood cells is highly complex. The 
complexities arise from the requirement of self-renewal of the rare population of 
undifferentiated pluripotent hematopoietic stem cells to ensure a reserve of quiescent 
multipotent stem cells throughout the life of an individual. At the same time, the 
precisely coordinated continuous generation of more developmentally restricted 
progeny, multiple lineage of the functional mature blood cells such as granulocytes, 
monocytes, erythrocytes and platelets from the pluripotent stem cell is required. The 
generation of mature blood cells from these pluripotent hematopoietic stem cells 
involves the highly regulated progression through successive stages involving 
commitment to a specific cell lineage, promotion of terminal differentiation of 
lineage-restricted progenitors, and growth arrest (Bedi, et al., 1995). 
Hematopoietic stem cells have the ability both to self-renew and to 
differentiate into multipotent progenitors. Theoretically, a balance between 
symmetrical cell divisions that results in self-renewal versus that which results in 
differentiation could maintain the stem cell pool as well as provide a constant source 
of multipotent progenitors. This balance could be regulated by a stochastic 
mechanism, environmental signals, or both, and requires the participation of many 
factors, including positive and negative regulators of growth and differentiation, 
which determine survival, growth stimulation, terminal differentiation, and 
programmed cell death (apoptosis). Evidence shown that these processes are 
probably separately regulated (Hoffman, et al., 1996). 
Different models have been proposed to explain the regulation of growth, 
lineage commitment and terminal differentiation in hematopoiesis. Two major models 
to explain lineage commitment and hematopoietic differentiation have been proposed, 
^he stochastic model and the inductive model. In inductive model, it argues that stem 
cell behaviour and lineage commitment is regulated by extemal signals such as 
hematopoietic growth factors which can be produced by multiple cell types and 
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cellular microenvironment and differentiation inducer and the integration of multiple 
signals within intracellular signal transduction pathways to the nucleus influence gene 
transcription (Williamson, et al., 1995). 
Another view of hematopoiesis is that the process of stem cell renewal, 
differentiation and maturation are random. This so-called ‘stochastic’ model 
apparently conflicts with the idea that hematopoietic cell development follows a 
deformed sequence of events (Gordon, 1994). In the stochastic model, random 
activation of a cascade of interacting transcription factors would regulate the 
transcriptional rates of the structural and regulatory genes necessary for determining a 
specific cell lineage. It is based on the premise that multipotent cells are intrinsically 
and randomly committed to lineage restriction and differentiation (Bedi, et al., 1995; 
Kehrl, et al., 1995). 
A third model that combines aspects of both these models has also been 
proposed. The generation of progeny from multipotential hematopoietic progenitors 
that are committed to a single or restricted lineages seems to be random rather than 
intrinsically determined, but extrinsic factors can enhance the probability of 
commitment to a particular lineage (Metcalf, 1989). 
Although the differentiation commitment of hematopoietic stem cells and 
progenitor cells may be intrinsically determined that cells possess a genetic control 
element that dictates whether to self renew or to generate committed progeny, it is 
apparent that a wide variety of extrinsic regulatory molecules including the 
hematopoietic growth factors, which can influence and modulate lineage commitment 
and differentiation (Metcalf, 1989). Decisions that determine the fate ofhematopoietic 
progenitors are mediated by a variety of interrelated mechanisms, including 
interaction of growth factors with cognate cell surface receptors, intracellular 
signalling pathways, and nuclear regulatory factors that coordinate gene expression 
responsible for lineage survival, commitment, proliferation, diverse mature 
phenotypes, cell cycle progression in order to achieve the correct balance between cell 
multiplication and differentiation (Weiss, et al., 1995). It was anticipated that quite 
different regulators would be necessary to control such different events as new cell 
production, release of mature cells, or functional activation of mature cells in the 
tissues. The interactions between multiple hematopoietic regulators constitute a 
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network of regulatory control. An extrinsic signal triggers an cellular event that 
stimulates transcription or production of a hematopoietic regulator, or probably 
activates an inducing signal for a regulator-producing cell. This cell type will 
simultaneously modulate the action of the hematopoietic regulator by stimulating on 
the hematopoietic target cell via other factors. Though some of these events may be 
controlled by exclusive regulatory mechanism, it has been shown that individual 
regulators can have actions on a wide range of these events, therefore, the pathway 
may be much complicated (Metcalf, 1995). 
Lineage selection implies a choice between alternate pathways. Activation of 
one pathway is suggested to be accompanied by suppression of the other. The binary 
fate decisions of hematopoietic progenitors are likely to involve cross-regulation of 
lineage-restricted factors, repression of target genes in alternative lineages, and on/off 
switches of lineage-restricted factors (Orkin, 1995). 
1.2.2 Regulation of the differentiation of myeloid 
lineage 
During myelopoiesis, multipotent progenitors differentiate into macrophages 
through successive intermediates involving monoblasts, promonocytes, and 
monocytes. The development of granulocytic progenitors involves the differentiation 
ofprogenitors into myeloblasts, promyeloblasts, and myelocytes (Simon, et al, 1996). 
It was reported that the maturation of neutrophil in both normal and leukemic cells 
involves a crucial transition from the promyelocyte to the myelocyte stage. The 
transition in normal marrow cells is found to associate with a loss of proliferative 
capacity and a loss of the capacity for maturation. Normal myelocytes are stimulated 
by terminal granulocyte maturation where promyelocytes show responsiveness to 
stimuli of both granulocyte and monocyte differentiation (Khanna-Gupta, et al., 
1996). 
The program of myeloid cell differentiation develops via multiple regulatory 
pathways, in which a hierarchy of differentiation signals and transcriptional processes 
is established for developing myeloid cells. Cooperation between tissue-specific and 
more widely expressed transcription factors in the stage-specific regulation of genes is 
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essential to myelopoiesis (Shapiro, et al., 1995; Sachs, 1982). Combined effects by 
both cytokines and specific transcription factors may couple myeloid cell growth, 
differentiation and survival and regulation of the cell cycle seems to have an essential 
role in this coupling (Olsson, et al, 1996). Various facts are essential in myeloid 
differentiation. First, the intrinsic cellular commitment to differentiation can be 
manipulated by cytokines. Second, the response of target cells to cytokines is 
determined by specific cytokine membrane receptors, the genetic program, the pattem 
of pre-existing transcriptional activity and the cytokines combination (Bedi, et al., 
1995). 
Myeloid cell differentiation has been investigated on many levels, from the 
cytokine signals required by each cell lineage to the scheduled expression of 
distinctive myeloid cell-specific genes regulation of primary response genes and 
protooncogenes and the programmed appearance ofcharacteristic cell surface markers 
(Shapiro, et al., 1995). The extrinsic and genetic mechanisms that orchestrate the 
differentiation commitment and myeloid lineage restriction of pluripotent stem cells 
are of fundamental importance in the regulation ofhematopoiesis. The elucidation of 
the control mechanisms of normal myeloid differentiation has provided conical 
insights into the ways in which disruption of the control mechanisms can contribute to 
leukemic transformation (Bedi, et al., 1995). 
1.2.2.1 Regulation of myeloid cell differentiation by 
hematopoietic regulatory protein 
Development of hematopoietic cells require a tight and complex control 
mechanism which involve a cascade of interactions between different proteins. In 
v/vo and in vitro studies have demonstrated that the hematopoietic growth factors, the 
cytokines, which are produced by a wide variety of hematopoietic and 
nonhematopoietic cells, play a central role in these processes (Touw, et al., 1996). 
The hematopoietic growth factors are glycoprotein hormones that regulate the 
proliferation and differentiation of hematopoietic progenitor cells and the function of 
mature blood cells. They may act locally at the site where they are produced or 
circulate in plasma. During differentiation of myeloid cells, genes coding for the 
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heamtopoietic growth factors are induced. The hematopoietic growth factors interact 
with hematopoietic growth factor receptor. The hematopoietic growth factor 
receptors can be subdivided into two major subgroups, members ofthe tyrosine kinase 
receptor and cytokine receptor superfamilies, based on the presence or absence of an 
intrinsic tyrosine kinase activity (Evans, et al., 1996). 
An important feature of growth factor action is that the hematopoietic 
cytokines function in a network of interactions. Two or more factors may synergies in 
stimulating a particular cell to proliferate or differentiate. Moreover, the action ofone 
growth factor on a cell may stimulate production of another growth factor or growth 
factor receptor (Woude, 1995). 
Most of these regulators can exert their action to cells of multiple lineages, 
although it appears to be redundant. It was demonstrated that six to eight regulators 
could mediate biological effects on cells of each lineage. Nevertheless, the regulators 
were found to have unique functions that cannot be completely compensated for by 
other regulators. This illustrate a highly complex, subtle controlling systems with 
considerable overlapping functions within the regulators (Metcalf, 1995). 
The cytokine action on hematopoietic survival, proliferation and 
differentiation is coupled by inducing a signal that initiates a sequential genetic 
program of transcriptional activation. The transcription factors act in a collaborative 
manner to regulate expression of lineage-specific genes in a stepwise fashion in the 
differentiation program (Olsson, et al., 1996). Cytokine signalling through 
transcription factors can also ensure the auto-regulation and trans-regulation of 
cytokine genes that occur in the network (Sachs, 1996). However, little is currently 
known regarding the mechanisms by which human cytokine and growth factor 
receptor genes are expressed and regulated during the commitment and differentiation 
ofhematopoietic progenitors to the myeloid lineages (Sun, et al, 1996). 
A number of cytokines have been shown to influence the differentiation of 
hematopoietic stem cells and their lineage-restricted progeny. These cytokines 
include the hematopoietic CSF, GM-CSF, G-CSF, macrophage colony-stimulating 
factor (M-CSF), multi-colony stimulating factor (IL-3), stem cell factor (kit ligand), 
IL-1 to IL-11，erythropoietin, leukemia inhibitory factor (LIF), transforming growth 
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factorP (TGF-P), interferons, macrophage inflammatory protein l a , and insulin-like 
growth factors. 
Four major myeloid growth factors, namely IL-3, GM-CSF, G-CSF, M-CSF 
and IL-3, referred to as colony stimulating factors, induce proliferation and coupled 
differentiation of normal myeloid precursor cells to form colonies. CSFs have the 
functions of enhancement of the survival of precursors and mature cells, irreversible 
induction of differentiation commitment, induction of cellular maturation, and 
stimulation of the functional activity of mature cells (Metcalf, 1989). The CSFs have 
considerable overlap in their proliferative actions on granulocyte-macrophage 
progenitors. IL-3 directly stimulates proliferation and development of multipotent 
stem cells, various developmentally restricted progenitor cells and precursor cells, 
leading to the formation of various types of mature myeloid cells (Dexter, 1994). IL-
3 leads to increased platelet as well as granulocyte and monocyte production. GM-
CSF is more restricted and preferentially promotes growth and development of 
neutrophil, macrophage and eosinophil progenitor and precursor cells (Dexter, 1996). 
GM-CSF and multi-CSF can stimulate the formation of both granulocytes and 
macrophages, G-CSF tends to stimulate only granulocyte formation and M-CSF only 
macrophage formation. Interleukin-6 resembles G-CSF in its actions, at least on 
murine granulocyte- macrophage cells. IL-6 also has a particular role in 
megakaryocyte formation. It was found that all four CSFs, GM-CSF, G-CSF, M-CSF 
and IL-3, can induce the formation of colonies and induce myeloid precursor cells to 
differentiate (Sachs, 1996). 
IL-5 is eosinophil-specific and plays a crucial role in regulating the 
differentiation and development of human eosinophil lineage. GM-CSF and IL-3 take 
part in the regulation but IL-5 alone is sufficient for eosinophil development to 
proceed. It follows that the expression of the high-affinity IL-5 receptor in early 
lineage-specific event is an important event in the hematopoietic. (Sun, et al., 1996). 
IL-6 influence the proliferation of multipotent myeloid progenitor cells; IL-1, 
IL-4 and IL-9 can modulate the response of myeloid progenitor cells to the CSF, and 
IL-8 can activate neutrophils. Interferons, TNF-a, TGF_P, macrophage inflammatory 
protein l a affect progenitors throughout a wide range of developmental stages and 
LIF augments proliferation of primitive human progenitors. All of the mentioned 
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biomolecules belong to the group of lineage-nonspecific factors (Ogawa, 1993). 
Interferons (type I alpha and beta, and type II gamma) are important on myeloid 
growth and differentiation. For instance, IFN-y inhibits the growth of myeloid 
progenitors and induces a differentiated monocytic phenotype. The mechanisms 
involve activation of cytoplasmic DNA-binding proteins and the subsequent inducing 
of the gene transcription that control the cell cycle and differentiation program (Bedi, 
etal., 1995). 
Many evidence have shown that cytokines work in synergy. Combination of 
GM-CSF or multi-CSF with SCF significantly increased the number of granulocytes 
progenitors and for multi-CSF, also of eosinophil progenitor cells (Metcalf, 1991). 
IL-1 and IL-6 enhance the effects of SCF, IL-3 and GM-CSF on survival and 
differentiation of the early hematopoietic cells, while TNF and TGF-pi can have both 
positive and negative regulatory effects on cells of the myeloid lineages. Induction of 
the TNF and/or TGF-Pi genes during differentiation, and the induction of 
prostaglandin Ei and IFN-p in inhibition of myeloid precursor cell proliferation, may 
proceed together for differentiation-associated properties and the switch off of cell 
multiplication (Lotem, et al., 1991). Erythropoietin, G-CSF, M-CSF and IL-5 act on 
later cells which are more committed to one cell lineage. 
Cytokines that regulate normal hematopoiesis have shown to be capable of 
controlling the abnormal growth of certain types of leukemic cells and suppressing 
malignancy by inducing terminal differentiation with inhibition of cell proliferation. 
Knowledge of the responses of leukemia cells to HGFs contributes to the design of 
new clinical protocols involving the application of growth factors for the treatment of 
leukemia patients. 
A number of cytokines, such as IL-1, IL-5, IL-6, IL-11, EPO, M-CSF, and 
tumor necrosis factor (TNF) and TNF-p, have been reported to inhibit the growth of 
various types of AML cells (Touw, et al., 1996). Interleukin-3, GM-CSF, G-CSF, M-
CSF，and IL-6 have the potential to induce differentiation commitment in myeloid 
leukemic cells (Bedi, et al., 1995). GM-CSF is a potential inducer of monocytic 
differentiation of myeloid leukemia cell although it has a growth-promoting effects on 
cells (Hozumi, 1994). TGF_p was shown to inhibit the proliferation ofmouse myeloid 
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leukemia Ml cells. Conversely, TGF_p alone and in combination with TNF induced 
monocytic differentiation of human leukemic cells (THP-1, U937, ML-1 and HL-60). 
TNF-a have shown to induce monocytic differentiation of murine myeloid leukemia 
cell line, WEHI-3B (JCS) (Fung, et al., 1997). It was also indicated that IL-6, IL-1, 
IFN"P, IFN-y, all of these compounds inhibited the growth o f M l D + cells to varying 
extents, with IL-6 exerting maximal growth inhibition. It was also reported that 
combinations of IFN_P and IFN-y synergize for the induction of a mouse myeloid 
leukemia cell line (Ml) (Cold, 1990). 
1.2.2.2 Signal transduction pathways in myeloid cell 
differentiation 
Signal transduction pathway, involves the integration of multiple intracellular 
signals in which the primary external signal is transduced through the target cell 
membrane to the nucleus, primarily by regulatory phosphorylation events, targeting 
the transcription factors required for an altered pattem of gene expression, are crucial 
in directing hematopoiesis. The first event involves the binding of the growth factor to 
its cell surface receptor. Ligand binding of the colony stimulating factor receptors for 
G-CSF, GM-CSF, the macrophage lineage-specific CSF-1, or by the IFN-y receptor, 
induces partial or complete differentiation of granulocyte-macrophage precursors, 
promyelocytes or promonocytes into mature granulocytes and macrophages. Each of 
the growth factors bind with high affinity to its corresponding receptor on the target 
cell. Most of the receptors belong to a structurally related set of membrane 
glycoproteins, the hematopoietic receptor family including IL-2-6, GM-CSF,G-CSF, 
Epo. Binding of the growth factor to these receptors cause alteration of the 
intracellular domains of the receptor protein. This initiates a cascade of 
phosphorylatory events in other signalling molecules such as cyclic AMP, cyclic 
GMP, diacylglycerol, inositol tris and tetraphosphate (IP3 and IP4) and 
phosphatidylinositol triphosphate. Although lacking kinase domain, the cytokine 
receptors coupled ligand binding to tyrosine phosphorylation, induction of 
phosphorylation requires the conserved, membrane-proximal region of the 
cytoplasmic domain. 
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A second small group of growth factor receptors have an intracellular tyrosine 
kinase domain. It contains a domain with homology to region 2 of the src 
protooncogene protein (src homology SH region 2). It includes the ligand for c-kit, 
also known as steel locus factor (SLF), flt-3 ligand, and CSF-1, a macrophage CSF. 
The further events by which the signal reaches the nucleus are being 
unravelled. The signals form complex interacting and feedback loops. A cascade of 
phosphorylation events is involved. The tyrosine kinase transmit signals in the 
cytoplasm for further transmission to the nucleus. In the nucleus, activation of 
transcription factors by phosphorylation or other mechanism is an early event before 
DNA synthesis is initiated (Hoffman, et al, 1993). 
Several different mechanisms have been identified by which a growth factor 
signal for the cell to proliferate or differentiate is transduced through the target cell 
membrane to the cell nucleus. It includes p21Ras pathway (c-myc pathway) and Jak-
STAT. The activation of the Jak-STAT signalling path in which the Jak (Janus 
kinase) family of tyrosine kinases is involved in signaling from HGF receptors has 
been demonstrated. The tyrosine kinase domain of the tyrosine kinase receptor or the 
cytoplasmic domain of the cytokinase receptors have been shown to associate with 
one or more protein tyrosine kinase (PTKs) of the Januse kinase family. The Jak 
proteins are subsequently phosphorylated on receptor activation and, in tum, activate 
members of a novel family of transcription factors termed signal transducer and 
activator of transcription (STATs). Activation of STAT molecules results in the 
formation of STAT complexes, which translocate to the nucleus and directly activate 
gene expression. 
Another signalling pathway involves activation ofp21^^® pathway. A number 
of growth factor receptors that belong to the hematopoietic receptor superfamily, e.g. 
IL-2, IL-3, IL-5, and GM-CSF, G-CSF, have been shown to activate p21^''. The 
cellular protooncogene p21^ ^® is a important mediator of a signalling pathway that 
regulates proliferation and differentiation of eukaryotic cells. The activation ofp21^^^ 
is associated with the downstream activation of a protein kinase cascade (Bashey, et 
al., 1994). 
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Undoubtedly, identification of the signalling molecules and signalling 
pathways and study of their function in normal and leukemic cells will shed more 
light on the contribution of genetic defects specifically interfering with growth factor-
induced maturation in the development of leukemia. 
1.2.2.3 Gene regulation of myeloid cell differentiation 
While much has been leamed about the extracellular signals and their 
respective receptors that trigger the proliferation and differentiation of myeloid 
progenitors, the molecular mechanisms for the differentiation of multipotential 
myeloid progenitors are largely unknown. 
The control of lineage commitment and differentiation of myeloid cells by 
normal hematopoietic regulatory proteins is associated with the interacting networks 
of lineage-restricted transcription factors that can regulate and maintain synchronous 
expression of an array of genes in the differentiation program (Shabo, et al., 1990). 
Interactions among the proteins encoded by the genes presumably are crucial to 
differentiation (Sachs, 1982). While differentiating, the cells are continuously 
reprogrammed for the expression of stage-specific genes. Specific genes must be 
tumed on and off in both a temporal and a lineage specific manner for immature 
hematopoietic cells to proliferate and properly differentiate to specific cell types. 
Each differentiation step thus requires the activation of transcription factors that cause 
progression within the lineage (Barahmand-pour, et al, 1996). Interruption of this 
orderly process may lead to aberrant gene expression and interference with normal 
differentiation. A maturation arrest or cell transformation may result (Kehrl, et al., 
1995). Therefore, it is important to gain a better understanding of the molecular 
mechanism including the transcriptional regulation of developmentally important 
myeloid genes to determine how these mechanisms in this intricate system orchestrate 
the ultimate fate of cells, e.g. proliferation, differentiation or apoptosis (Wolff, et al, 
1996). 
The genes that regulated during myeloid cell differentiation can be grouped 
into five families: 1) genes that convey growth-stimulating signals from the cell 
membrane to the nucleus; 2) genes that activate transcription; the products of these 
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two gene families bind to target DNA region and enhance the synthesis ofmRNA; 3) 
genes that involve in cellular differentiation; 4) genes that involve in programmed cell 
death; and 5) anti-oncogenes that suppress tumor development. However, this 
classification of gene families is somehow vague as the products of a gene may have 
more than one function (Cline, 1994). 
1.2.2.3.1 Transcription factors 
Activation of specific genetic programs of differentiation involves reception 
and intracellular processing of external signals. Correct temporal and spatial 
expression of myeloid specific transcription factors are required for the process to 
proceed (Olsson, et al., 1996). Recent studies of the regulation of normal myeloid 
genes, as well as the study of leukemias, indicate that chromosomal alteration is a 
common feature of acute leukemia. For instance, in the case of translocations, 
rearrangement was found from promoter/enhancer sequences on one chromosome to a 
gene encoding an oncogenic transcription factor on a separate chromosome. As a 
result, a nuclear regulatory protein was mistakenly expressed and interfered with the 
differentiation of hematopoietic progenitors (Shapiro, et al., 1995). By molecular 
cloning of genes in the regions involved in translocations, deletion and inversions of 
leukemia, a number of genes coding for DNA binding transcription factors have been 
identified, indicating that the erroneous expression of their interferes with myeloid 
differentiation. Such transcription factors which developmentally regulated showing 
stage-specific expression, are emerging as key regulators of myeloid cell 
differentiation. In order to understand the process of normal myeloid differentiation, 
it is important to identify and characterize the transcription factors which specifically 
exert positive or negative effects on gene expression in the myeloid lineage. 
Transcriptional factors are also referred as master genes, that normally control 
transcription via direct DNA binding and by diverization with other binding protein, 
controlling the expression of responder genes required for completion of myeloid cell 
differentiation progress (Dabbts, 1991). Since the expression level o f a transcription 
factor is regulated by numerous transcription factors at that particular time point in the 
cell, a complex network of regulatory genes are responsible for gene expression 
modulation (Kehrl, 1995). 
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Among the known transcription factors, the GATA, zinc finger transcription 
factors are important regulators of gene expression in hematopoietic cells (Bedi, et al., 
1995). GATA proteins participate in the transcriptional control of a broad array of 
genes expressed in several blood lineages (Weiss, 1995). GATA-1 play important 
roles in the cellular differentiation of erythrocytic and megakaryocytic lineages, the 
expression of GATA-1 decreases during myelo-monocytic differentiation (Olsson, et 
al., 1996). Over-expression of GATA-1 in a myeloid lines blocks myeloid 
differentiation (Zhang, et al, 1996), while GATA-2 is considered to maintain and 
promote the proliferation of early hematopoietic progenitors (Shimamoto, et al., 
1995). The GATA-1 and GATA-2, two related zinc finger transcription factors, that 
recognize the consensus sequence (A/T) GATA(A/G), a DNA motif first appreciated 
in the regulatory regions of erythroid-expressed genes. Although GATA-1 and 
GATA-2 act at distinctly different steps in hematopoietic differentiation, as defined 
by the phenotypes resulting from targeted disruption of their respective genes, the two 
proteins exhibit a substantial degree of overlap in function and expression and appear 
to be subject to cross-regulation (Weiss, 1995). 
The zinc finger transcription factor, Egr-1 is another member of myeloid 
differentiation primary response (MyD) genes that are activated in the absence of de 
novo protein synthesis following induction of myeloid differentiation. A recent study 
has shown that the Egr-1 gene is essential for and restricts differentiation of 
myeloblasts along the macrophage lineages. Because a consensus Egr-1 binding site 
is present in the c-myb promoter, it is possible that Egr-1 expression could, in addition 
to promoting macrophage differentiation, block granulocyte differentiation through 
trans-activation of c-myb expression. 
A gene that encodes a novel zinc finger DNA binding protein termed MZF-1 
was found in a screen of cDNA library prepared from a patient with chronic 
myelogenous leukemia. MZF-1 has two independent DNA binding domains that 
recognize two distinct but similar nucleotide sequences. Each target sequence has a 
G-rich core (Kebal, 1995). MZF-1 has been localized to the telomere of chromosome 
19q, where a large number of related zinc finger genes reside (Hromas, et al., 1996). 
MZF-1 is expressed preferentially in myeloid cells and is essential in the development 
ofgranulocyte colonies in vitro (Hromas, et al. 1996) Its consensus DNA binding site 
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has been isolated, and sites in several promoters of myeloid-specific genes, such as 
CD34, lactoferrin, and myeloperoxidase, have been defined (Hromas, et al. 1996). 
Over-expression of MZF-1 will aggressively transform 3T3 cells, and inhibit 
apoptosis and promote leukemogenesis in the IL-3 dependent myeloid leukemia line 
FDCP-1 (Hromas, et al., 1996). 
CAAT enhancer binding proteins (C/EBP) belong to a family of tanscription 
factors which are implicated in a number of developmental and growth regulatory 
processes. In the hematopoietic system, the C/EBPs have been found to be restricted 
in their expression to myeloid cells, C/EBPa, p and 6 appear to play decisive roles in 
myelopoiesis (Twamley-Stein, et al., 1996). C/EBPp (called NF-M in the chicken 
system) is particularly important in myelomonocytic cells because it is targeted by 
kinases and collaborates with the Myb oncoprotein to induce the expression of 
myeloid specific lysozymes and mim-1 genes, which are normally silent in this 
lineage (Sharino, 1995; Twamley-Stein, et al., 1996). The activity ofC/EBPp protein 
appears to be regulated by a number of factors that induce macrophage activation 
including bacterial lipopolysaccharide(LPS), cytokines, growth factor receptors and 
kinase oncogenes (Twamley-Stein, et al., 1996). The relative abundance of the 
different C/EBP proteins during myeloid differentiation, particularly C/EBPa, are 
critical for myeloid CSF receptor promoter function, and may also act via 
autoregulatory mechanisms, suggesting the major role of C/EBP in myelopoiesis 
(Zhang, et al, 1996). C/EBPa expression was found to be predominates in early 
myeloid cells, but it is downregulated in a differentiated murine myeloid cell line. 
This protein may be essential for production of early myeloid cells (Friedman, et al., 
1996). 
AML1 belongs to a gene family of heteromeric DNA-binding transcriptional 
regulatory proteins. It is a member of the core binding factor family, and is expressed 
in a variety of hematopoietic cells, with significant levels in myeloid and T cells 
(Zhang, et al., 1996). AML1 gene was first identified as the gene on chromosome 21 
which is disrupted in the (8;21)(q22;q22) translocation forming a fusion protein, 
AML1/ET0, one of the most common translocation found in AML (Tanaka, et al., 
1995). Myeloperoxidase (MPO) gene was the first identified myeloid gene regulated 
by AML1. The 5' flanking region of neutrophil elastase gene contains binding sites 
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for the AML1 protein. The core site for binding of the AML1 protein was also found 
on genes for IL-3, IL-5, GM-CSF and G-CSF. Additional unidentified factors that 
regulate the proximal regulatory regions to MPO and neutrophil elastase genes were 
necessary for activation of these genes (Olsson, et al, 1996). AML1 also regulates 
the M-CSF receptor promoter. It may play a major role in myeloid development by 
activating multiple myeloid CSF signalling pathways. The AML1 site in the M-CSF 
receptor is separated from the downstream C/EBP site by only 10 bases. Both C/EBP 
and AML1, bind to these two adjacent sites independently, and interact positively in 
activation of M-CSF receptor expression. However, mutation of either site 
dramatically decreases the promoter function. (Zhang, et al., 1996). 
The AML1 gene produces 3 forms of protein AMLla, AMLlb and AMLlc, 
by alternative splicing. AMLla can repress transcriptional activation by AMLlb and 
shows a higher DNA binding than AMLlb (Olsson, et al, 1996). Antagonistic 
interactions between AMLla and lb could be important in leukemaogenesis and/or 
myeloid cell differentiation, since more than half of the patients with myeloid 
leukemia showed an increase in the relative amount of AMLla (Twamley-Stein, et 
al, 1996). Granulocytic differentiation was suppressed but cell proliferation in 
32Dcl3 murine myeloid cells treated with granulocyte colony-stimulating factor was 
stimulated in over-expressed AMLla. Over-expression of AMLlb can obliterated the 
effects o fAMLla , which in tum, can suppress transcriptional activation by AMLlb. 
Nevertheless, AMLla alone exerts no effect as a transcriptional regulator and exhibits 
higher affinity for DNA binding (Tanaka, et al., 1995). 
The ratio between the transcriptionally inactive (AMLla) and the active form 
(AMLlb) is important for regulation of their role in myeloid differentiation and 
proliferation, as governed by the antagonistic effects. Myeloid leukemia may be 
evolved by shifting towards transcriptional inactivation of AMLlb form. Evidences 
have shown that the repression of AMLlb is likely to dismpt differentiation and 
growth in some cases of AML (Olsson, et al., 1996). 
The helix-loop-helix (HLH) proteins are a class of transcription factors 
involved in cell type-specific transcription and cell lineage commitment (Bedi, et al., 
1995). The dimerization surfaces of the proteins are characterized by two 
amphipathic a helices that are separated by a loop of variable length. bHLH, a 
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subclass of these proteins, contains a basic amino acids region which is adjacent to the 
HLH domain. Binding sites for these proteins are represented by the palindromic E-
box motif, CANNTG (Kreider, et al., 1992). 
Id is a member of the HLH protein. It suppresses several bHLH proteins that 
are involved in cell type-specific transcription and cell lineage commitment. Id is not 
able to bind DNA due to the lack of basic amino acids. The myeloid precursor cell 
line 32DC13(G) expressed Id mRNA, which was transiently decreased when cells 
were induced to terminally differentiate with G-CSF. Constitutive expression ofan Id 
cDNA in 32DC13(G) cells blocked their ability to differentiate. A recent study has 
demonstrated that constitutive expression of Id blocked the ability of a myeloid 
precursor cell line to terminal differentiation into neutrophils in response to G-CSF 
(Bedi, et al., 1995). Hence, it is likely that Id and bHLH proteins function in the 
process of myeloid differentiation. 
The PU.1 ets family member tanscription factor had previously been 
implicated as an important regulator of hematopoiesis. The transcription factor PU. 1 
is the product of the PU.l-Spil-Sfpil protooncogene (Scott, et al., 1994). PU.1 is 
expressed exclusively in the hematopoietic system; it is highly expressed in B 
lymphocytic, granulocytic, and monocytic cells and expressed to a lesser extent in 
immature erythroid cells (Simon, et al., 1996). PU.1 has been suggested to control the 
differentiation o f B lymphocytes and monocytes (Scott, et al., 1994). 
The protooncogene PU.1 regulates three myeloid CSF receptors: the M-CSF 
receptor (CSF-1 receptor, c-fms), GM-CSF receptor and the G-CSF receptor. 
Expression o fPU. l activates its own promoter, and tums on the three myeloid CSF 
receptors (M, GM, G), pushing these cells along the pathway of myeloid 
differentiation. PU.1 could advance monocytic cell development at multiple levels by 
positively regulating CSF-1 receptor transcription, making cells more sensitive to 
CSF-1, thereby upregulating CSF-l-dependent macrophage gene programs. PU.1 
may be active throughout myeloid cell differentiation. PU.1 is expressed in early 
human multipotential CD34+ cells, and specifically upregulated during commitment 
of these progenitors to the myeloid lineage (Zhang, et al., 1996). 
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PU.1 RNA transcripts have been detected via in situ hybridization primarily in 
immature myeloid cells and in macrophages, its expression declines in the more 
mature stages of granulocyte differentiation. PU.1 induces a change in chromatin 
structure that enables the binding of ubiquitous transcription factor Spl to an adjacent 
sequence element, resulting in a lineage-specific elevation of transcription levels. 
Posttranslational modification of the Spl protein in macrophage is crucial for lineage 
specificity. In PU. 1 deficient mice, there was a defect in the generation of myeloid 
and lymphoid progenitors (Shapiro, et al., 1995; Kehrl, 1995). 
Chromosomal translocations are the hallmarks of leukemias. AML 
translocations often involve transcription factor. Forming of a protein with 
transforming ability is a result of fusion of two genes. One example of a transcription 
factor fusion is the translocation t(15;17) of APL. The translocation breakpoints are 
localized in the PML gene, a zinc finger transcription factor and the a-retinoic acid 
receptor gene (RARa) localized on two separate chromosome, 15 and 17 respectively. 
The resulting PML-RARa fusion gene is transcriptionally active. Inhibition of PML 
could contribute to growth stimulation and resistance to apoptosis at a critical stage of 
APL development. The RARa receptor was suggested to transactivates either 
structural or other regulatory genes important in the final commitment to the 
neutrophil lineage (Kehrl, 1995). Other transcription factors known to be involved in 
myeloid differentiation are also affected in AML. Their genes are aberrantly activated, 
resulting in interference with differentiation by production of oncoproteins, e.g. in 
AML patients with chromosomal translocation t(8;21) and t(3;21), as well as in 
patients with inversion . Myeloid cell-restricted transcription factors are prime targets 
for chromosomal translocations in AML because disruption of these factors can give 
growth advantage due to lack of terminal development (Olsson, et al, 1996). 
Rapid transcriptional induction of specific genes is an essential part of the 
cellular response to growth factors or cytokines. Signal transducers and activators of 
transcription (STAT), a transcriptional factor, is vital in such a process. A novel 
family of cytoplasmic protein tyrosine kinase, termed the Janus kinases (Jaks), as 
receptor associated signal transducers, associate with the cytokine receptors and are 
catalytically activated by autophosphorylation on tyrosine kinase, after cytokine 
stimulation and ligand binding. The activated Jaks, phosphorylate and activate the 
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STATs transcription factor. The phosphorylation occurs at a single tyrosine residue in 
those STAT proteins. The activated STAT proteins are assembled into complexes and 
translocated to the nucleus. Most STATs then bind to a class of elements designated 
GAS-like elements in the promoter of interferon-responsive genes (Barahmand-pour, 
etal., 1995). 
Thus far, six distinct members of the STAT protein family, Stat 1, Stat 2, 
APRF-Stat 3, Stat 4, MGF-Stat 5, IL-4-Stat, have been cloned. Among the domains 
conserved between all family members are those that constitute the Src homology 
(SH) domains 2 and 3. The SH2 domain appears to mediate the dimerization or 
oligomerization of activated STAT proteins that is necessary for DNA binding 
(Barahmand-pour, et al., 1995). Because stimulation of cells with each of the 
cytokines induces broadly differing responses in myeloid progenitors, biologic 
specificity must be effected downstream of receptor/Jak interaction, in that the Jak2 
kinase associates with the IL-3, erythropoietin, and granulocyte-macrophage colony-
stimulating factor receptors and is rapidly autophosphorylated and activated in a 
response to ligand-receptor interactions. A third Jak kinase (Jak 3), expressed by both 
myeloid cells and T cells was found to be activated in response to IL-2, and IL-4 
ligand-receptor interactions. A new member of the STAT family of proteins STAT4, 
was found to be expressed by undifferentiated myeloid cells and phosphorylated and 
activated by both Jakl and Jak2, further implicating Jak-STAT pathways in early 
myeloid gene regulation and signal transduction. Additionally, the STAT3 protein, is 
activated by tyrosine phosphorylation in response to epidermal growth factor and IL-
6，but not IFN-y. These findings suggested the role for Jak-STAT signalling pathway 
in the regulation of gene transcription that are referred for the arrest of immediate 
gene expression in response to differentiation stimuli, during early myeloid cell 
differentiation (Shapiro, et al., 1995). 
A variety of other transcription factors are known to be involved in myeloid 
differentiation. Interferon regulatory factor 1 (IRF-1) is another myeloid 
differentiation primary response gene that encodes a transcription factor for the 
expression of IFN-p. Inhibition of IRF-1 partially inhibits IL-6 and LIF-induced 
myeloid differentiation and deletion of IRF-1 has recently been demonstrated in 
human acute myeloid leukemia (Bedi, et al., 1995). It is apparent that gene 
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expressions for myeloid commitment and differentiation are tightly controlled by the 
cumulative, synergistic, and antagonistic effects of multiple transcription factors, in 
tum, are themselves regulated by an enormous number of internal and external 
factors. 
WT (Wilms，tumor) 1 transcription factor is suggested to have a role in 
myeloid differentiation and AML. It is downregulated during induction of 
differentiation of myeloid leukemic HL-60 cells, suggesting that repression of WT1 
may be necessary for differentiation of some hematopoietic lineages. GATA-1 may 
play a major role in the regulation of WT1 in hematopoietic cells. The consensus 
DNA sequences to which the WT1 protein binds is also a binding target for the EGR 
transcription factor family, which can transactivate a large number of genes involved 
in regulation of growth and differentiation. A competition between the WT1 products 
and family EGR transcription factors for binding to crucial target genes may have a 
regulatory role in myeloid differentiation. A complex pattem of alternative splicing 
leads to distinct WT1 gene products, some of which can activate transcription. 
However, WT1 can also activate transcription, WT1 interacts with nuclear 
component which are required for its repressor function and the absence of tumor 
suppressor p53 appears to convert WT1 from a transcriptional repressor to a 
transcriptional activator. Therefore, it is of considerable interest that the WT1 gene is 
highly expressed in AML cells. WT1 may play a role in the differentiation block 
characteristic of AML (Olsson, et al., 1996). 
Less is known about transcription repressors and their role in regulating 
lineage-specific genes and in the commitment ofprogenitors to specific hematopoietic 
lineages. However, their importance should not be underestimated because negative 
regulatory mechanisms are extremely important for the prevention of inappropriate 
genes expression during differentiation. A transcription factor including a lineage-
specific expression of target genes could in addition regulate genes specific for other 
lineages negatively, preventing the expression of genes ofthe alternative lineage. The 
failure of these mechanisms may lead to arrested differentiation and cell 
transformation. Thus the choice of lineage for hematopoietic progenitors could be 
made by transcription factors functioning as onA)ff switches (Olsson, et al., 1996). 
Further studies of both transcriptional repressors and activators will lead a more in-
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depth understanding of the complex molecular regulation of hematopoietic lineage 
specification and will identify useful targets for the manipulation ofhematopoiesis. 
1.2.2.3.2 Myeloid specific genes 
During the process of myeloid differentiation, numerous genes are 
coordinately expressed. Genes regulated during myeloid differentiation can be 
catalyzed as those that code for ubiquitously expressed housekeeping proteins 
necessary for normal cellular proliferation and survival for proteins important for 
cellular recognition and cell-cell interactions, and for gene products important for 
specific functions of the different end-stage myeloid cells. Using predominantly 
myeloid cell lines, many cDNAs coding for genes that are specifically expressed in 
myeloid cells have recently been molecularly cloned and expression patterns of these 
genes have been determined (Lubbert, et al, 1991). 
Myeloperoxidase (MPO). MPO is an enzyme exclusively found in myeloid 
cells and synthesized in the azurophilic (primary) granules ofpromyelocytes. MPO is 
important in host defenese through the generation of microbicidal hypochlorous acid. 
The expression of MPO mRNA is detectable solely in cells of the late myeloblastic 
and promyelocytic stages differentiation. Normal granulocytes and monocytes 
express negligible amounts ofMPO mRNAs although these cells have abundant MPO 
protein, reflecting the long half-life of this protein. During granulopoiesis, certain 
myeloid genes encoding products of azurophilic granules are specifically down-
regulated. For instance, during induced differentiation of promyelocytic leukemic 
HL60 cells to granulocyte- or monocyte-like cells, myeloperoxidase RNA is 
depressed. The expression of their genes is tumed on during early myeloid 
differentiation and finally repressed in later stages of cell maturation (Meier, et al., 
1992). When HL-60 cells were induced ot differentiate into monocytic or 
granulocytic lineage, MPO mRNA rapidly decreased (Lubbert, et al., 1991). 
Neutrophil NADPH oxidase. The multicomponent enzyme neutrophil 
NADPH oxidase is activated in stimulated granulocytes and catalyzes the production 
of superoxide. It has an important function in host defense, as evidenced by the fact 
patients with defects of this electron transport system suffer from recurrent infections 
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from a variety of microorganism. This oxidase composed of four components. The 
membrane bound neutrophil cytochrome b is a heterodimeric protein of 
approximately 115Kd, composed of a glycosylated 91Kd heavy subunit and a 
nonglycosylated 22Kd light subunit (Lubbert, et al., 1991). The 91Kd heavy subunit 
is encoded by a gene also termed X-CGD (chronic granulomatous disease) gene. Its 
transcript is expressed in a tissue-specific manner; levels of expression are very low in 
promyelocytic HL-60 cells but are strongly upregulated with induction of these cells 
toward granulocyte-like or monocyte-like differentiation. The gene is also expressed 
in normal monocytes and granulocytes. Previous studies showed that mRNA 
accumulation of this gene is strongly upregulated in HL-60, U-937, THP-1, and ML-3 
after treatment of the cells with IFN-y and tumor necrosis factor a . Added together, 
these cytokines act synergistically. It is shown that the effects of each of these 
component as well as of a combined regimen of retinoic acid and dimethy formamide 
predominantly stimulate transcription of the X-CGD gene. 
The 22-Kd light subunit of membrane bound cytochrome b code for a 0.8Kb 
mRNA expressed in promyelocytic and granulocytic HL-60 cells as well as in K562 
myeloid cells. It is not restricted to cells with NADPH oxidase activity, its expression 
is constitutive and is not significantly altered by regimens that modulate expression of 
the heavy subunit. The 47 and 67 Kd proteins that are part of the cytoplasmic 
component of NADPH oxidase are expressed in normal granulocytes and monocytes. 
Levels of expression of X-CGD gene are very low in promyelocytic HL-60 cells but 
are strongly upregulated with induction of these cells toward granulocyte-like or 
monocyte-like differentiation (Lubbert, et al., 1991). 
Myeloid-specific serine esterase. Human neutrophil elastase (NE) is a serine 
protease that digests elastin and collagens as well as a variety of other human proteins 
(Lubbert, et al, 1991). NE is stored in azurophilic (primary) granules ofPMNs and 
released into the extracellular environment after activation of these cells. Analysis of 
expression of NE mRNA in human primary myeloid cells and myeloid cell lines 
shows several similarities but also subtle differences when compared with the 
regulation of expression of the MPO gene. These proteins, and their corresponding 
mRNAs, are not found in other cell lineages except myeloid lineages. MPO and NE 
are early markers of both the granulocytic and monocytic myeloid lineages 
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(Friedman, et al. 1996). mRNAs for both NE and MPO accumulate to high levels in 
promyelocytes, but both are absent in mature PMNs, macrophages, and in 
macrophage-like HL-60 cells induced with a phorbol ester for 3 days. However, 
mRNA expression of NE is upregulated in HL-60 cells treated with dimethyl 
sulfoxide, whereas rapid shut off of MPO occurs in HL-60 treated similarly. It 
suggests that peak levels of NE transcripts in HL-60 cells are reached after these cells 
have partly differentiated toward granulocytes (Lubbert, et al., 1991). It was found 
that the 5’ flanking region of NE gene harbors a 19bp pyrimidine rich sequence 
sharing 95% homology with a sequence present in the 5' franking region of the MPO 
gene. Possibly, this sequence is functionally related to the observed similarities in 
expression patterns o f N E and MPO. The human NE gene was recently shown to be 
adjacent to genes encoding two other myeloid-specific serine proteases, azurocidin 
and myeloblastin (Friedman, et al., 1996). 
Human cathepsin G. Like NE, cathepsin G is probably involved in the 
breakdown of cognitive tissue proteins. It is a serine protease of 26-Kd molecular 
weight that accumulates in the azurophilic granules of neutrophils and monocytes. 
Macrophage-like differentiation of myelomoncytic U937 cells using a phorbol ester 
decreases transcription of the gene for cathepsin G (Lubbert, et al., 1991). A factor 
governing the coordinate regulation of neutrophil secondary granule protein gene 
expression may be involved in early events in the neutrophil differentiation pathway. 
Human neutrophil gelatinase (HNG) is unique among the four major content proteins 
of the neutrophil secondary granule in that it is also expressed in the 
monocyte/macrophage lineage (Khanna-Gupta, et al., 1996). 
Lysozyme. Lysozyme, like MPO, is an enzyme primarily involved in host 
defense. It hydrolyzes the linkage between bacterial N-acetylmuramic acid and N-
acety-D-glucosamine. Several studies have shown that accumulation of lysozyme 
mRNA is high in normal monocytes on in vitro maturation to macrophages and 
myelomoncyte U937 cells induced by the macrophage inducer 1,25-dihyroxyvitamin 
D3 increase lysozyme expression (Lubbert, et al., 1991). 
Defensins. Defensins, also termed human neutrophil peptides (HNP), are a 
family of peptides of 29 to 34 amino acids that are part of the nonoxidative host 
defense apparatus ofmature granulocytes. HNP 1-2 are stored in the primary granules 
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of mature neutrophils and make up about 30% of the total granule protein of these 
cells. Defensin mRNA accumulation is highest in neutrophil precursor cells but not 
terminally differentiated normal neutrophils. Expression studies showed that defensin 
mRNA is detectable in unfractionated normal bone marrow cells, on leukemic cells 
from patients with AML, CML and CLL, but not in normal mature neutrophils, 
lymphocytes or moncytes, it implies that this gene is upregulated during progression 
of differentiating promyelocytes toward the myelocyte and metamyelocyte stages 
(Lubbert, et al, 1991). 
Lactoferrin. Lactoferrin is an approximately 80-Kd iron binding protein 
synthesized by myeloid cells as they progress through the myelocyte to late 
metamyelocyte stages of development, the protein is stored in the secondary granules 
of these cells. It may be associated with regulation of proliferation of myeloid cells. 
However, expression of this protein is not restricted to myeloid cells; lactoferrin is 
also synthesized by several secretory tissues such as the pancreas, salivary gland, and 
mammary tissue (Lubbert, et al., 1991). Northern blot analysis shows that lactoferrin-
specific transcripts can be detected in bone marrow cells from healthy donors and 
from patients in the stable phase of CML. However, less mature myeloid cells lack 
lactoferrin transcripts. 
CDllb/CD18. The adhesion molecules CDllb/CD18, also termed Moll or 
Mac-1, are members of a family of three heterodimeric cell surface glycoproteins and 
thus part of the broad gene family of integrins involved in cell-cell interactions during 
host defense and immune response. CD1 lb/CD18 is an important marker of terminal 
myeloid differentiation because of its high specificity for specific cells. The 
CDllb/CD18 surface antigen is first expressed during the myelocytic and 
monoblastic stages of maturation and is upregulated during granulocytic and 
monocytic differentiation. Functions of this molecule include binding of a 
complement component (C3b fragment) as well as promotion of homotypic 
granulocyte adhesion and adhesion of granulocytes and monocytes to endothelial 
cells. In addition, CD1 lb/CD18 molecule is associated with granulocytic oxidative 
burst, phagocytosis, and antibody-dependent cellular cytotoxicity (ADCC). 
Expression of CDl lb mRNA is sharply upregulated during induction of granulocytic 
or monocytic differentiation of HL-60. In a similar manner, expression of transcripts 
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for the P"Subunit CD18 is upregulated during chemical induction of HL-60 to 
granulocytes or moncytes (Lubbert, et al, 1991). 
Receptors for IgG. Receptors binding the Fc fragment ofIgG in complex with 
antigen target these complexes to the effector cells. Thus these receptors (FcR) 
represent a link between the humoral and cellular immune responses. Three types of 
Fc receptors for the constant region of IgG have been recognized based on the 
different affinities for IgG and their tissue specific expression pattem. FcRI (CD64) 
is a high affinity receptor expressed by monocytes. FcRII (CDW32) is a low affinity 
receptor found on various hematopoietic cells including granulocytes, monocytes, B 
cells, and platelets. FcRIII (CD16) is a low affinity receptor, its expression is 
restricted to macrophages, neutrophils, NK cells, and T-suppressor cells. Expression 
studies using a cDNA for the high-affinity receptor FcRI showed expression in 
normal monocytes, in myelomonocytic U937 cells, and in placental tissue (rich in 
monocytes/macrophages). Similarly, expression of mRNA for the low affinity 
receptor FcRIII (CD16) was demonstrated in NK cells but not in myelomonocytic 
U937 cells or in several lymphoblastoid cell lines. The low affinity receptor FcRIII is 
expressed most broadly, being found on various cells of both the myeloid and 
lymphoid lineages. 
Other differentiation antigens. These are some of the cell surface antigens 
found on hematopoietic cells and grouped as cluster determinants (CDs). The surface 
antigens expressed on myeloid cells and analyzed thus include the CD34 marker 
molecule for human hematopoietic stem cells, a marker for colony-forming units for 
granulocytes, erythocytes, monocytes, and megakaryocytes (CD33), for progenitor 
cells of the granulocytic and monocytic lineages (CD13), and for mature monocytes 
(CD14). Previous experiments studying the regulation of CD34 mRNA expression 
with induced monocytoid differentiation of KG-1 cells and showed a post-
transcriptional made of downregulation (Lubbert, et al, 1991). 
The immediate early genetic response of myeloid cells to terminal 
differentiation and growth inhibitory stimuli was complex. This complex response 
encompassed stable or transient increase in the expression of various genes, of which 
some are known and others are unknown, including ICAM-1, a gene encoding for a 
ligand to a cell surface adhesion receptor; junB an c-jun genes encoding for nuclear 
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transcription factors; terminal differentiation histone variants; and novel genes such as 
MyD88 and MyD116. Expression of all these MyD genes was highly induced in 
automatously replicating differentiation inducible MlD+ myeloblasts following 
induction of terminal differentiation and growth inhibition by IL-6. Expression of 
MyD genes except MyD88 was induced upon inhibition of MlD+ cell growth and 
induction of early, but not late, differentiation markers by IL-1 and 
lipopolysaccharide. In sharp contrast, only expression of H1° and H3.3 histone 
variants was increased following inhibition of MlD+ cell growth by IFN-P and y, 
which did not induce any differentiation associated properties (Lord, et al., 1990). 
Taken together, it is indicated that the expression of same MyD genes (junB, 
c-jun, ICAM-1, MyD88 and MyD116) is linked to the developmental program of cell 
differentiation, whereas expression of others (H1° and H3.3 histone variants) is linked 
to the inhibition of cell growth. It is also indicated that immediate early activation of 
MyD genes junB, c-jun, ICAM-1, and MyD116 is not sufficient to induce terminal 
differentiation and that the activation of MyD88 may be necessary for the regulated 
progression of myeloid differentiate toward more mature cell types. Furthermore, 
whenever combination of cytokines synergized for differentiation, there was also 
synergism for the immediate early activation of MyD88 expression, these 
observations strengthen the correlation of induction of MyD88 expression with 
terminal differentiation (Lord, et al, 1990). 
Analysis of the expression of another novel myeloid differentiation primary 
response gene, MyD 118, indicated no detectable levels of MyD 118 mRNA in 
uninduced MlD+ myeloblasts. Following stimulation with IL-6, MyD 118 mRNA 
exhibited transient expression kinetics. Accumulation of MyD118 RNA was 
observed already within 0.5h following IL-6 induced differentiation, reaching 
maximum level at lh and dropping to undetectable levels by 1 day. MyD118 
expression was also induced in MlD+ cells following simulation with LIF, IL-1 and 
the inflammatory substance LPS (Abdollahi, et al., 1990). 
In contrast to the observation that IFN-y did not induce ICAM-1 expression in 
MlD+ myelobasts, IFN-y was observed to induce ICAM-1 expression in the human 
HL-60 promyelocytic cell line. IFN-y was shown to induce early differentiation 
. Chapter 1 
^ 37 
associated properties in HL-60 cells. This is consistent with the notion that ICAM-1 
expression is an early event in the developmental program of myeloid differentiation 
(Lord, et al., 1990). 
NF-1 (neurofibromin) is a guanosine triphosphate-activating protein (GAP) 
that inhibits the Ras growth stimulatory signalling pathway by hydrolyzing RasGTP 
to RasGDP. Children with neurofibromatosis type I (NF-1) are predisposed to 
develop AML and loss of the normal parental NF1 allele is a common finding in NF-1 
patients afflicted by AML. These results suggests that loss ofNF-1 function could be 
of importance for development of AML and its differentiation block (Olsson, et al., 
1996). 
1.2.2.3.3 Protooncogenes and tumor suppressor genes 
A variety of protooncogenes and tumor-suppressor genes are involved in 
normal myeloid differentiation. The protooncogenes encode proteins enabling cell 
proliferation. If over-expressed or mutated, they can make a cell proliferate without 
normal restriction. Conversely, tumor suppressor genes normally restrain growth, 
inactivation of tumor suppressor genes, those that make it possible for a cell to 
respond with inhibition of proliferation, will have the same effects (Olsson, et al., 
1996). The proteins encoded by these genes impact on cell differentiation through 
diverse mechanisms including l)constituting growth factors or growth factor receptors 
{c-fms); 2) mediators of growth factor-signal transduction {c-ras and c-raf)-, and 3) 
transcription factors for genes involved in cell cycle regulation or differentiation (c-
myc, c-myb, c-fos, c-jun and p53) (Bedi, et al., 1995). 
The normal protooncogene c-fms encodes a tyrosine-kinase transmembrane 
receptor protein, the M-CSF receptor normally expressed in the monocyte-
macrophage lineage ofhematopoietic cell development that is dependent on its ligand 
M-CSF for activation of its kinase and growth stimulatory properties (Rohrschneider, 
etal., 1997). 
Activated ras oncogenes have been shown to induce differentiation in 
neuronal cells or human B lymphocytes and prevent skeletal myoblast on mammary 
epithelial cell differentiation. Mutations of the ras gene resulting in constitutive 
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activation are frequently observed in human acute myeloid leukemia. The induction 
of the v-Ha-ras gene in the differentiation-arrested FDC-P1 cell line has been shown 
to lead to a preferential commitment to monocytic macrophage differentiation without 
terminal growth arrest. As mentioned in section 1.2.2.2, ras and raf are important 
mediators of growth factor in signal transduction pathway, suggesting the mechanism 
by which ras expression promote terminal differentiation and myeloid cell. 
C-myc is expressed in almost all proliferating normal cell types, and is down-
regulated in many cell types when they are induced to terminally differentiate, and 
abnormal expression has been associated with many naturally occurring neoplasms, c-
myc functions as a transcriptional regulator. The c-myc protein contains three 
structural domains that are homologous to domains found in characterized 
transcription factors, including a leucine zipper, a helix-loop-helix motif, and an 
adjacent domain rich in basic amino acids (Hoffman, et al., 1996). Evidence have 
shown that c-myc binds to DNA and may activate or suppress the expression of a 
variety of genes (Liebermann, et al., 1991). 
The c-myc gene is believed to have a pivotal role in cell proliferation and 
differentiation. The c-myc mRNA is expressed during cell proliferation and is 
downregulated during the induction of differentiation in many cell types, including 
normal hematopoietic cells and myeloid cell lines. The constitutive expression of an 
exogenously introduced c-myc gene can inhibit differentiation of several cell types. 
The induction of differentiation of myeloid cell lines (U-937, HL-60, and mL-l) by 
TPA, retinoic acid, or IFN-y is associated with the decrease of c-myc expression 
(Bedi, et al, 1995). It was shown that blocking c-myc expression in HL-60 cells, in 
which the c-myc gene is amplified 8- to 30- fold and is highly expressed, results in 
growth arrest, and, in some instances, induction of monocytic differentiation. Failure 
to suppress c-myc blocks differentiation at an intermediate stage. All four major 
myeloid growth factors, IL-3, GM-CSF, G-CSF and M-CSF, suppressed c-myc and c-
myb RNA expression in normal, but not in leukemic, myeloid precursors, inducing 
differentiation and growth arrest in MlD+ leukemic myeloid precursors (Liebermann, 
et al., 1989) It was also found that c-myc is expressed in proliferating Ml myeloid 
leukemic cells, and is downregulated following induction of terminal differentiation 
by IL-6 or LIF, exhibited a unique pattem of expression, with an early transient 
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increase followed by a decrease to control level by 12 hours and there is no detectable 
c-myc mRNA or protein by 18 hours following stimulation for differentiation. In 
contrast, c-myb expression was rapidly suppressed, with no detectable c-myb mRNA 
by 12 hours (Hoffman-Liebermann, et al., 1991). De-regulated and continued 
expression of c-myc blocked terminal differentiation induced by either IL-6 or LIF at 
an intermediate stage in the progression from immature blasts to mature macrophages, 
precisely at the point in time when c-myc is normally suppressed, leading to 
intermediate stage myeloid cells which continued to proliferate in the absence of c-
myb expression (Hoffman, et al, 1996). 
c-myb has been implicated in myeloid lineage commitment. Target disruption 
of c-myb results in a marked impairment in hematopoiesis (Kehrl, 1995). High c-myc 
and c-myb RNA expression is associated with myeloid cell growth, and decreased 
expression of c-myc and c-myb was coordinated with myeloid differentiation 
(Liebermann, et al., 1989). 
Expression of the nuclear protooncogenes c-myc and c-myb is high in 
proliferating normal and Ml leukemic myeloid precursor cells and is suppressed 
following induction of terminal differentiation and growth arrest, c-myc and c-myb 
down-regulation is not intrinsic to growth suppression but is essential for terminal 
myeloid differentiation (Selvakumaran, et al., 1992). c-myb encodes a DNA-binding 
protein capable of trans-activating the c-myc promoter. Upon induction of both 
terminal differentiation and growth inhibition in myeloid leukemia cells, these proto-
oncogene was suppressed. The genetic program of myeloid differentiation can be 
disrupted at early stage by continuous expression of c-myb. Besides, transcription 
levels of both c-myb and c-myc were found to decrease at late stages in the myeloid 
cell differentiation. Hence, expression of these genes in immature cells may reflect a 
function related to the proliferative state of myeloid cells but not to the controlling 
function in the differentiation of myeloid cells (Gonda, et al., 1984). Taken together, 
it showed that c-myb plays a key regulatory role in regulation of myeloid 
differentiation and deregulated expression of c-myb can play an important role in the 
development and progression of leukemia (Selvakumaran, et al., 1992). 
The protooncogenes c-junJun B,jun D, and c-fos recently have been shown to 
encode for transcription factors with a leucine zipper that mediates dimerization to 
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constitute active transciption factors (AP-l);juns were shown to dimerize with each 
other and with c-fos, whereas fos was shown to dimerize only with juns (Lord, 1992). 
The expression of fos and juns was induced during differentiation of normal myeloid 
precursor cells (Lord, 1992). Moreover, c-jun, junB and junD were identified as 
myeloid differentiation primary response MyD genes that are stably expressed 
following induction of terminal differentiation ofmyeloblastic leukemia Ml cells. 
Induction of differentiation to macrophages in two different clones of myeloid 
leukemic Ml cells Ml by IL-6, or GM-CSF or IL-3, is shown to be associated with 
sustained accumulation of c-jun, jun-B, and c-fos mRNA (Shabo, et al., 1990). 
Enforced expression of c-fos, and to a lesser extent jun-B, in Ml cells results in both 
an increased susceptibility of these leukemia myeloblast to be induced to differentiate 
by IL-6. The expression of c-fos was also shown to be increased markedly during 
monocytic differentiation of WEHI-3B cells, c-fos may also be required for the 
expression of some macrophage-specific functions (Gonda, et al., 1984). Taken 
together, these observations show that the protooncogenes which encode for fos/jun 
transcription factors pare positive regulators in myeloid differentiation (Lord, 1992). 
Myeloid cell differentiation was shown to be correlated with increased 
expression oic-fos, c-fes, and c-fms. Myeloid cell growth was correlated with high c-
fnyc and c-myb RNA levels, decreasing to undetectable levels in terminally 
differentiated cells. RNA levels of the proto-oncogenes c-fos, c-fes and c-fms were 
undetectable in normal or Ml differentiation inducible (D+) leukemic myeloblasts， 
and were stably induced upon stimulation of the normal precursors for growth and 
differentiation, with highest levels at the time when most of the cells had undergone 
terminal differentiation. Only c-fes RNA was induced upon MlD+ differentiation. It 
was also shown to be induced upon induction of differentiation without growth in 
normal myeloid precursors followed by accumulation of c-fos and c-fms RNAs. 
Previous studies shown high levels of c-fos RNA in mature myeloid cells, including 
macrophages and granulocytes. The high levels of c-fms RNA in mature myeloid 
cells, most likely in macrophages, may be indicative of additional functions for the M-
CSF receptor in differentiated myeloid cells (Liebermann, et al., 1989). 
Recent findings suggest that the src family genes may prove to be more 
important in the regulation of differentiated functions than in growth and 
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developments, src gene family (nine members, src, fgr, lck,fyn, lyn, hck, blk, yrk) are 
protein tyrosine kinases which are organized by similarities in amino acid sequence, 
by the arrangement of functional domains, and by other modifications such as 
chemical modifications and intracellular location. Two members of the src proto-
oncogene family of intracellular tyrosine kinases, c-fgr and hck, are selectively 
expressed in differentiated myeloid cells. Expression of the c-fgr protein-tyrosine 
kinase and the c-fms gene encoding the CSF-1 receptor was not detected in 
morphologically undifferentiated leukemic myeloblasts with an HLA-DR, CD34, 
CD33, CD13 cell surface phenotype. Induction of monocytic differentiation of 
leukemic cells in vitro was synchronized by a significant increase in c-fgr and c-fms 
mRNA transcripts. Cell surface expression of CD14 was increased, and expression of 
CD13 and hck were induced when the monocytic features was acquired. In contrast, 
differentiation of leukemic cells into granulocytic lineage was accompanied with 
surface expression of CD33, CD13 and hck mRNA transcripts. The expression of hck 
is associated with granulocytic and monocytic lineages whilst c-fgr in the monocytic 
lineage. Therefore, the expression of c-fgr and c-fms is correlated with myeloid cell 
commitment. Monocyte precursor cells expressed significantly higher levels of c-fgr 
mRNA than more differentiated monocytic cells, indicating the progessive decrease in 
expression started from early stages ofdifferentiation (William, et al., 1991). 
The pathogenesis of leukemia is associated with the inactivation of at least 
twos different tumor suppressor genes, the p53 and the Rb. pRb is closely related to 
the control of the cell cycle. pRb is involved in cell proliferation by its ability to 
regulate cell cycle and tumor suppression. It was shown that downregulation of pRb 
leading to hypophosphorlated pRb in myeloid stem cells induced differentiation into 
granulocytes. Thus, blocking of pRb phosphorylation could be important for initiation 
of cellular differentiation and regulation of pRb gene seems to play a key role in 
lineage specific decisions (Olsson, et al., 1996). 
p53 tumor suppressor gene encodes a transcription factor that serves in cell 
cycle regulation and in response to DNA damage. It mediates the signal for DNA 
repair and apoptosis. It has been shown that p53 is involved in differentiation and 
differentiation induction of leukemic cells. Inactivation of p53 has been associated 
with the pathogenesis of leukemia. However, mice lacking p53 showed normal 
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hematopoietic differetiation, indicating that the gene may not be essential for normal 
hematopoiesis (Olsson, etal., 1996). 
The induction of p53 expression in a variety of cell types has had diverse 
effects including Gi arrest and apoptotic death. Deregulated expression of the tumor-
suppressor gene wild-type p53 can induce apoptosis in myeloid leukemia and other 
cancer cells. Apoptosis is a cellular self-destruction process during normal embryonic 
development and in adult life. Developmental abnormalities and cancer development 
can be the outcomes of disruption of this normal process. Certain viability factors are 
required throughout the differentiation process from immature to mature cells, without 
those factors, programmed cell death will be initiated. Previous studies showed that 
wild type p53 is involved in the normal process of apoptosis presumably by its ability 
to act as a transactivator or inhibitor of transcription of other genes. Suppression of 
apoptosis in normal cells by viability factors is associated both with downregulation 
of wild type p53 and expression. Mutant p53 suppress the enhancing effect on cell 
death of deregulated c-myc, and thus allow induction of cell proliferation and 
inhibition of differentiation (Sachs, 1993). p53 induction in certain hematopoietic cell 
lines including HL-60 promyelocyte cells induces phenotypic differentiation, arrest 
and apoptotic death, levels of the endogenous p53 protein also increase during 
myeloid maturation (Bedi, et al., 1995). Treatments that downregulate the expression 
on activity of mutant p53 in cancer cells should be useful for therapy. 
1.2.2.3.4 Homeobox genes 
A number of lines of evidence suggest that the homeobox-containing genes 
would appear to be strong candidate genes to regulate a number of developmental 
processes, including hematopoiesis. Homeobox proteins are members of the helix-
tum-helix family as one of the major classes of transcription factors that control 
cellular differentiation during development, there has been increasing interest in the 
possible role of these proteins as control factors during hematopoiesis (Lawrence, et 
al., 1992). 
The homeobox is highly conserved 183 nucleotides that encode a 61-amino 
acid domain, the homeodomain. The homeodomain is a DNA-binding domain 
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capable of recognizing specific sequences by virtue of a helix-tum-helix structural 
motif whereas the sequences flanking the homeodomain have been shown to provide 
either activating or repressing functions (Magli, et al., 1991). 
The homeobox containing genes play a major role in control of and are 
assumed to act as a selector genes determining programs of development pattem 
formation during embryogenesis of Drosophila (Blatt, et al., 1988) Each Drosophila 
homeobox gene has its own characteristic effects on the development of embryos and 
adults, in part secondary to its unique spatial and temporal patterns of expression. 
These proteins are like genetic switches used by cells to choose among different 
developmental pathways (Kehrl, et al., 1995). They are organized in clusters 
expressed in the developing embryo with a positional hierarchy (Magli, et al., 1991). 
The genes are subsequently recognized in Drosophila developmental genes that 
control body segment identity. The expression of these genes are highly precise but 
have overlapping zones from head to tail during embryonic development. Homeobox 
genes also appear to be master control genes for the development of the mammalian 
body plan (Lawrence, et al, 1992). 
Based on structural similarities, Drosophila and human homeobox genes can 
be divided into various classes. Approximately 40 human homeobox gene have been 
designated as class I genes according to their homeodomain relevant to the 
Drosophila Anterrapedia class. Homeobox genes have been highly conserved 
through evolution (Blatt, et al., 1988). In mice and humans, the class I homeobox 
genes of the HOX family are organized in four clusters referred to as H0X1, HOX2, 
HOX3 and HOX4 which are located on chromosomes 7, 17, 12 and 2 respectively. 
Human clusters of class I homeobox gene are labelled H0X1, HOX2, etc. The 
individual genes in each cluster are designated by a letter e.g. HOXlA, whereas the 
murine equivalents are referred to with decimal point designation, Hoxl.l, Hox2.1, 
etc (Lawrence, et al, 1992). The order of genes within each cluster is also highly 
conserved throughout evolution, suggesting that the physical organization of HOX 
genes may be essential for their expression. Homeobox genes are expressed at low 
levels and often as multiple, alematively spliced transcripts, and it seems that several 
homeobox genes are active with the same cell (Magli, et al., 1991; Lawrence, et al., 
1992). 
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Several reports have recently demonstrated that some homeobox genes are 
expressed within the hematopoietic system. Coordinate regulation of these genes 
rather than the expression of specific HOX genes demonstrated to play an important 
role in lineage commitment during early stages ofhematopoiesis (Magli, et al, 1991). 
Altered homeobox gene expression has been identified in certain leukemias, 
suggesting the involvement ofhomeobox genes in hematopoiesis. 
Among the abnormal homeobox genes, Hox2.4 was found to be activated in 
the murine myelomonocyte cell line WEHI-3B as a result of a DNA rearrangement 
due to insertion of a retrovirus-like intracistemal A particle. The homeobox gene 
Hox2.4, like other homeobox genes, play a role in normal development, and its 
expression is restricted spatially and temporally during the development of the 
embryo. The oncogenic action of Hox2.4 appeared related to its ability to prevent IL-
3-driven terminal differentiation of myeloid cells. Consistent with this inhibition, 
transfection of Hox2.4 into a myeloid cell line interfered with specific pathways of 
myeloid differentiation triggered by IL-6 (Kehrl, 1995). Constitutive expression of 
activated Hox2.4 in these differentiation competent myeloid cells altered the 
transcriptional regulation which disrupts specific pathways of the differentiation 
program and interferes with induction of cell differentiation (Blatt, et al., 1992). 
In other studies in murine leukemias, the partial deletions of chromosome 2 
which carry the Hox4.1 gene have been observed in a large majority of myeloid 
leukemia. It suggested that malignant transformation might be contributed by the loss 
of function of certain homeobox gene. The significance of these observations is 
unclear because expression of HOX4 genes has not been noted in hematopoietic cells 
(Lawrence, etal., 1992). 
A number of homeobox genes have been shown to have lineage-restricted and 
stage-specific patterns of expression; e.g. Hox2.3 is required for murine myelopoiesis 
and TPA-induced differentiation of HL-60 cells. Expression of Hox2.2 resulted in 
myelomonocytic differentiation in K562 cells. The sequential activation ofhomeobox 
genes by retinoic acid suggests a potential mechanism by which extrinsic regulators, 
like retinoic acid, could influence Hox mediated myeloid differentiation (Bedi, et al., 
1995). It was also shown that certain HOX family members are present in normal 
hematopoietic cells, in cell lines, and primary leukemic cells. Some HOX family 
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members have not been found in any hematopoietic cells or cells lines. Moreover, 
different HOX family members were expressed in a complex lineage restricted 
manner and are coordinately switched on or off in blocks. Members of the H0X1 
locus were expressed in myelomonocytic cell lines, but infrequently in erythrocytic 
and mature lymphocytic cell lines. The HOXlA gene was ubiquitously expressed in 
all cell lines examined (Kehrl, 1995). One transcript of the human homeobox gene 
HOX AlO, previously HOXlH, was found to be preferentially expressed in cell lines 
of the myelomonocytic lineage. Two HOXA10 mRNA transcripts were identified. 
The larger transcript was only present in myelomonocytic cell lines while the smaller 
one was detected in a variety ofhematopoietic cell lines. 
Four H0X1 genes located at the 5' end of the locus were switched-off in the 
erythroleukemia cell lines and tumed on in the myeloid-restricted cell lines, which 
suggest that commitment to the myelomonocytic lineage involves the switch on of a 
set of genes 5, of H0X1 (Magli, et al., 1991). Most members of the HOX2 locus 
were not present in cell lines with a myelomonocytoid or lymphoid phenotype with 
the exception of HOX2C. HOX2C was also expressed in non-erythroid cells 
including lymphoid cell lines and normal lymphocyte. HOX2 locus were expressed in 
the erythro-leukemia cell lines. The genes located at the 3'end of the HOX3 locus 
were ubiquitously expressed present in all cell lines. Genes located at the 5'end of the 
HOX3 locus were well expressed in the erythroleukemia cell lines and in more 
primitive cells but switched off in the myeloid cell lines. However, the HOX4 locus 
was silent in the all the cell lines examined. The undetectable expression of HOX4 
genes suggests that this locus either is not involved in hematopoiesis (Kehrl, 1995; 
Magli, et al., 1991). 
Taken together, previous studies on cell line shown that the expression of 
several HOX family member is lineage specific, which can be best demonstrated by 
several HOX family members whose expression is the erythroid specific expression of 
several members of the HOX2 locus, for example HOX2D, and the lymphoid specific 
expression ofHOX3E. Some HOX family members are widely expressed showing no 
preference for any specific lineage, for example HOXlA, and HOX3A (Kehrl, 1995). 
Besides the class I homeobox-containing genes there are a number of genes 
which encode for proteins with homeodomains that are diverged from the classical 
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Anteneapedia homeodomain. Several of these genes are expressed in hematopoietic 
cells. HB24, recently cloned homeobox gene, that is predicted to encode a protein 
with a diverged homeodomain. The HB24 gene was found to be constitutively 
expressed in hematopoietic progenitors (CD34+) but not in differentiated cells, 
suggesting a potential role for it in the regulation of gene transcription during 
hematopoiesis. HB24 downregulation is necessary for the normal differentiation of 
hematopoietic progenitors. HB24 mRNA transcripts were elevated in bone marrow 
and peripheral blood mononuclear cells isolated from patients with acute 
myelogenous leukemia compared with normal controls. Induction of HB24 
expression in the FDC-P1 myeloid cell line promoted phenotypic myeloid maturation 
(Bedi, et al., 1995). It suggested that HB24 is an important transcription factor during 
hematopoietic progenitor proliferation and that differentiation to specific cell types 
requires its downregulation. Furthermore, dysregulated expression of HB24 impairs 
the normal differentiation of hematopoietic progenitors and may contribute to 
leukemogenesis (Deguchi, et al., 1992). 
Another homeodomain-containing protein implicated in the regulation of 
myeloid specific genes is termed CCAAT displacement protein (CDP). It is 
homologous to the Drosophila melanogaster homeobox gene cut which is known to 
be important in the determinant of cell fate. The human CDP is a putative repressor 
of the myeloid specific gene, gp91-phox, the product of the X-linked chronic 
granulomatous locus. CDP bound to a region surrounding the CCAAT box in the 
gp91-phox promoter and prevented binding of a positively activating CCAAT binding 
factor, the C/EBPa to the CCAAT box. CDP is expressed ubiquitously in immature 
cells and tumed off during myeloid maturation (Kehrl, 1995). 
Taken together, it is indicated that the homeodomain protein play a role in the 
regulation of a lineage-specific gene. The HOX gene clusters display characteristic 
patterns of expression in different hematopoietic cell lineages and provide an 
indication that the coordinate regulation of HOX genes may have a fundamental role 
in myeloid lineage determination and differentiation commitment (Magli, et al., 1991) 
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1.2.2.3.5 Cell cycle control in myeloid growth and 
differentiation 
The induction of terminal differentiation is strictly associated with cell cycle 
arrest. The cell cycle is coordinated and driven from one stage to another by cyclin 
dependent kinases (CDKs) and inhibitors of CDKs stop the cell cycle progression. 
Checkpoints prevent division of cells with too many DNA lesions. The Gi/S 
checkpoint is a crucial phase ofthe cell cycle that involves the decision to either begin 
DNA replication or commit the cell to terminal differentiation. A G\/S checkpoint 
can arrest cell cycle progression by activation of CDK inhibitors. It leads to 
prolongation of the Gi phase and allows for the repair of damaged DNA. Loss of a 
Gi/S checkpoint would lead could play a part in malignant transformation. 
Furthermore, the duration of the Gi phase has a bearing on differentiation since the 
first two-thirds of it, before a restriction point, appears to function as a window for 
differentiation decisions, apoptosis and quiescence. Other work indicated that 
commitment to terminal differentiation occurs in late Gi (Weinberg, 1996). 
A variety of proteins that govem G]/S transition have been demonstrated to 
modulate differentiation. Proteins that promote Gi/S transition, including c-myc, Gi 
cyclins D2/D3, cdk2 inhibit terminal differentiation, whereas inhibition of S-phase 
entry by the tumor suppressor genes, pRB and p53 is associated with facilitated 
differentiation. Several lines of evidence shown that a group of genes, gadd genes, 
that are co-ordinately induced by DNA damage and growth arrest, are closely related 
to the myeloid differentiation primary response genes, MyD. This indicates that the 
induction ofDNA damage potentiates the terminal differentiation of cells. Despite the 
undeniable importance of cell cycle regulation in the commitment to differentiation, 
the precise mechanism that couples this inverse relationship has yet to be defmed 
(Bedi, et al, 1995). 
A review of the regulators controlling the process of commitment to myeloid 
differentiation revels a real complex picture. It involves a stochastic program that is 
influenced by numerous signals, including external and internal, in series and in 
parallel, synergistic and antagonistic, that are in tum constitutes a network of 
regulatory pathways. 
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1.3 Induction of differentiation in myeloid 
leukemia cell 
As review in the previous sections, it is commonly proposed that lineage 
commitment of myeloid cell differentiation is regulated by a combination matrix of 
factors. Our knowledge of the regulation of myeloid cell differentiation has increased 
remarkably in the past decade, nevertheless, the information on certain key function 
on the control mechanism of regulation of myeloid cell differentiation remains 
incomplete. To enhance our understanding of the regulators and molecular 
mechanism involved in the regulation of normal terminal differentiation of myeloid 
lineage and alterations in these regulatory processes that block differentiation, leading 
to leukemogenicity and its progression. Different biological systems are employed in 
studies owning to dissect the control mechanism that regulate the myeloid 
differentiation. The availability of a wide array of myeloid leukemic cell lines arrest 
at different stages of myeloid differentiation which can be induced for differentiation 
and loss of leukemogenicity by several factors provide an excellent biological system 
which aided in the study of, the general and molecular biology of normal myeloid 
growth to differentiation developmental cascade as well as the lesions that affect it in 
leukemia (Cold, 1993). 
1.3.1 Induced myeloid leukemia cell 
differentiation 
Normal myeloid precursor cells can be induced in vitro for proliferation 
coupled to terminal differentiation, using a variety of hematopoietic growth and 
differentiation inducers (Selvakumaran, et al., 1992). As mentioned in section 
1.1.2.2, tumor cell can also be induced to terminal differentiate and loss its 
tumorgenicity by certain inducers and it suggests an alternative approach in cancer 
therapy, the differentiation therapy. 
There is accumulating evidence that various tumor cells including leukemia 
cells can be induced by various compounds to differentiate terminally both in vitro 
and in vivo into mature cells. Myeloid leukemic cells can be induced to differentiate 
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to mature macrophages or granulocytes through normal sequence of gene expression 
by incubation with a normal myeloid differentiation-inducing protein (Sachs, 1987). 
These results were obtained with various mouse and human myeloid leukemia cell 
lines that can be induced to partially differentiate along one or several pathways to 
become more mature cells. The most broadly studied human myeloid cell line, 
promyelocytic HL-60, was established from cells of a patient with AML type M2, 
was the first human cell line with distinct myeloid features. These cells can be 
induced to differentiate along the granulocytic or the monocytic pathway when 
incubated with certain physiological or non-physiologic inducers (Lubbert, et al., 
1991). 
Other myeloid cell lines established from bone marrow cells of a patient with 
myeloblastic leukemia KG-1 cell line, derived from bone marrow cells of a patient 
with acute myelogenous leukemia. KG-1 cells are at the myeloblast and 
promyelocyte stages of differentiation. These cells can differentiate toward 
macrophages when incubated with certain inducing agents. The human myeloid 
leukemia cell line ML-1 were established from a patient with acute myelogenous 
leukemia (Hozumi ). The human early myeloblast or erythroblast cell line K562 was 
established from a patient with CML. These cells are arrested at a very early 
myeloblast/erythroblast stage. They are capable of differentiating along the erythroid 
myeloid or mekaryocytic lineages with certain inducer. The monocytic cell line U937 
can be induced to differentiate along monocyte pathway. Many more human myeloid 
cell lines have been developed and are listed in Table 1.1 (Lubbert, et al., 1991). 
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Table 1.1 (opposite page) Human Myeloid Cell Lines Arrested at Different 
Stages of Myeloid Differentiation. (Reproduced from Lubbert, et al., 1991) Abbreviations: 
ALL, acute lymphocytic leukemia; AMegL, acute megakaryoblastic leukemia; AML, acute 
myeloblastic leukemia; AMML, acute myelomonocytic leukemia; AMoL, acute monocytic 
leukemia; APL, acute promyelocytic leukemia; B, basophil differentiation; BDA, Blackfan-
Diamond anemia; CML-bc, chronic myelogenous leukemia in blast crisis; CMML, chronic 
myelomonocytic leukemia; EL, erythroleukemia; Eo, eosinophilic differentiation; EoL, 
eosinophil leukemia; Er, erythroid differentiation; G, granulocytic differentiation; HL, 
histiocytic lymphoma; M, monocyte-macrophage differentiation; Mk, megakaryocytic 
differentiation; MM, multiple myeloma; T-ALL, acute T-lymphoblastic leukemia. 
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[Cell Line Stage ofMaturation Source Differentiation 
pU.528 — Multipotential T-ALL M 一 
BV173 Pre-B,pre-T cell/myeloblastic CML-bc  
RS4; 11 Pre-B cell/monoblastic ALL 
LB84-1 Myeloma/myelomonoblastic MM  
MR-87 Early B cell/myeloblastic CML-bc — 
KG-la Early myeloblastic AML  
KG-1 _Myeloblastic AML M 
KCI:22 "Myeloblastic CML-bc “ 
EM-2, EM-3 ~Myeloblastic CML-bc "(M) 一 
RDFD-2 —Myeloblastic AML M  
KYO-1 "Myeloblastic CML-bc “ — 
M26 —Myeloblastic AMML — 
KBM-7 —Myeloblastic CML-bc 一 
TMM Myeloblastic AML G 
HL-60 Promyelocytic AML G, M，Eo, B — 
PL-21 Promyelocytic APL G, M 
K562 Myeloblastic/erythroblastic CML-bc Er, M, Mk 
HEL Myeloblastic/erythroblastic EL Er, M, Mk 
ML-1,-2,-3 Myelomonoblastic AML M 
RC-2A Myelomonoblastic AMML “ 
GDM-1 Myelomonoblastic AMML 
HL-92 Myelomonoblastic AMML 
M2Q Myelomonoblastic AML M 
M24 Myelomonoblastic AMML “ M 
KOPM-28 Myelomonoblastic CML-bc (M) 
TK-1 Myelomonoblastic Lymphoma M 
PLB-985 Myelomonoblastic AML G，M 
AML-193 Myelomonoblastic AMoL 
MV4-11 Myelomonoblastic AMML ~ 
CTV-1 Early monoblastic AMoL (M)  
U937 Monoblastic HL M  
THP-1 Monoblastic AMoL M 
JOSK-I Monoblastic AMML M “ 
JOSK- Monoblastic AMoL M 
S,JOSK-K  
JOSK-M Monoblastic 一 CML-bc — M 
YK-M2 Monoblastic AMoL M 
CM-S Promonocytic BDA 'M 
Mono Mac 6 Monocyte-like AMoL M 
KU812 Basophil precursor cell CML-bc B, Er, M 
EoL-l, EoL-3 Eosinophil precursorcell EoL Eo_  
CHRF-288 “ Megakaryoblastic AMegL “ “ 
MEG-01 Megakaryoblastic CML-bc 
T-33 Megakaryoblastic CML-bc Mk 
CMK Megakaryoblastic AMegL ^ 
Dami Megakaryocytic AMegL Mk 
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Apart from human myeloid cell lines, many studies using the animal model 
also demonstrated that there are several murine myeloid leukemia cell lines that can 
be induced to differentiate. A myeloid leukemia cell line, Ml, was established from a 
spontaneous myeloid leukemia in an SL mouse. WEHI-3B myelomonocytic leukemia 
was induced in BALB/C mouse ingested with mineral oil. The Ml, 32DC13, FDC-
P1, and WEHI-3B mouse myeloid leukemia cell line which would be described in 
detail in section 1.3.4, can all be induced to partial or terminal differentiation upon 
induction by various agents (Bedi, et al.,l 1995; Fung, et al., 1992; Kreider, et al., 
1992; Selvakumam, et al, 1992). 
The establishment of those myeloid leukemic cell lines arrested at different 
and distinct stages of myeloid differentiation and its ability to be induce to 
differentiate along one or several lineage to become mature cells provide an excellent 
system for the study of those interacting regulator controlling the developmental 
pathway of myeloid cell maturation. Different differentiating agents act by different 
mechanisms in inducing differentiating of leukemic cells along different lineages. 
The myeloid leukemia cell lines can serve as model to study the regulation of genes 
that are specifically expressed in certain stages during the myeloid cell differentiation 
along particular lineage, and therefore reflecting the abnormalities in the 
hematopoiesis as observed in leukemia (Olsson, et al, 1996). 
1.3.2 Inducers of myeloid cell differentiation 
A search for differentiation agents have been performed by use of myeloid 
leukemic cell lines, and a number of differentiation agents have been demonstrated to 
induce the myeloid leukemia cell differentiation, including cytokines, hormones, 
vitamins, tumor promotors and cancer chemotherapeutic agents (Koeffler, et al., 
1985). 
Cytokines, individually or synergistically, have shown to induce 
differentiation in certain types of myeloid leukemia cell. Mouse myeloid leukemia 
Ml cells can be induced both in vitro and in vivo into macrophages and granulocytes 
by several cytokines including IL-1, which is mediated by induction of IL-6, LIF and * 
G-CSF (Abdollahi, et al., 1991; Hozumi, 1994; Lord, et al., 1990; Mak, et al., 1993). 
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Ml cells can be induced to differentiated in response to TNF-a only in the presence 
of exogenous IL-1 (Mak, et al., 1993). TNF-a play a crucial role in the induction and 
regulation of macrophage differentiation. TNF-a has previously been shown to 
induce macrophage differentiation of the human promyelocytic HL-60 cell line (Mak, 
et al., 1994). Also, TNF-a is known to induce monocytic differentiation in a number 
ofhuman myeloid leukemic cell lines such as HL-60, ML-1 and THP-1. 
It was found that all form CSFs, GM-CSF, G-CSF, M-CSF, and IL-3 can 
induce the production of IL-6 that induce myeloid precursor cells and myeloid 
leukemia cells to differentiate (Sachs, 1996). G-CSF promotes the differentiation of 
the murine myelomonocytic leukemia cell line WEHI-3B (D+). In addition, WEHI-
3B (D+) cells differentiate in response to G-CSF and IL-6 (Mak, 1993), TNF-a can 
induce murine myeloid leukemia cells WEHI-3B (JCS) to differentiate along 
monocytic lineage, the differentiation inducing effect can be enhanced by IL-4. 
TNF-a has been shown to act synergistically with TGF-p to induce 
differentiation of the human myeloid leukemic cell line HL-60. Proliferation of the 
murine leukemic cell line Ml could be inhibited by TNF-a but differentiation into the 
mature macrophages phenotype required the additional presence of IL-1 (Mak, et al., 
1993). Synergy between TNF-a and IFN-y has previously been shown in the 
induction of differentiation ofHL-60 cells. 
Previous studies found that TGF-p induced monocytic differentiation of 
human leukemic cell line HEL/S cells, on the other hand, it could inhibit the 
proliferation of mouse myeloid leukemia Ml cells and cause dose-dependent 
inhibition of their monocytic differentiation induced by several differentiation 
inducer. Conversely, another studies reported that TGF-P alone and in combination 
with TNF induced monocytic differentiation of human leukemic cells (THP-1, U937, 
ML-1 and HL-60). Thus the effects of TGF-P on monocytic differentiation differed 
markedly in different lines of leukemia cells (Hozumi, 1994). 
In addition to cytokines, some vitamins including retinoids and active 
metabolites of vitamin D3 have been found to control growth and differentiation of 
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myeloid leukemia cells. As mentioned in section 1.2.2.3.1, acute promyelocytic 
leukemia is characterized by the translocation t(15:17) which fuse two genes, the 
RARA transcription factor gene and PML, thus blocking differentiation in APL cells. 
The PML/RARA disrupt differentiation in APL as it interferes with the normal 
signaling pathway of RARA or disrupt the normal functioning of PML or both. 
Retinoic acid receptors bind to the retinoic acid and then bind to specific DNA-
responsive elements of the promotor region of target genes and modulate 
transcription. Results shown that high dose of retinoic acid switch the PML/RAR-
induced differentiation block in APL cells to stimulation of differentiation (Olsson, et 
al., 1996.). 
Retinoic acid, a metabolite of vitamin A, plays a significant role in human 
myeloid differentiation through its activation of RAR-a. Retinoic acid has been 
shown to inhibit proliferation and to induce terminal neutrophilic differentiation of the 
human myeloblastic cell line HL-60. Retinoic acid also stimulate granulocyte 
production while inhibiting monocyte and erythroid differentiation in in vitro 
differentiation assays using purified CD34+ progenitors. All trans-RA (ATRA) can 
induce leukemic cells from patients with acute promyelocytic leukemia to 
differentiate into mature neutrophils both in vivo and in vitro (Bum, et al., 1994). 
Only leukemias with the PML/RARA fusion gene have so far been found to be 
sensitive to ATRA. 
1,25 dihydroxyvitamin D3 (VD3) has been demonstrated to induce the 
maturation of both normal and leukemic immature myeloid cells along 
monocyte/macrophage pathway in vitro and in vivo. VD3 has been recently found to 
induce differentiation of Ml cells into macrophages and induce the HL-60 cells to 
acquire a monocytic cell type (Collart, et al., 1996). 
In examining the effects of several cytokines in combination with, either 
retinoic acid (RA) or VD3 on growth and differentiation of myeloid leukemia cells, 
GM-CSF was found to stimulate differentiation of U937 cells induced by VD3 
(Hozumi, 1994). APL cells especially were stimulated to proliferate by G-CSF, and 
were then also induced to differentiate into mature granulocytes by G-CSF in 
cooperation with RA. G-CSF also stimulates RA-induced morphological and 
functional differentiation of HL-60 cells. GM-CSF was also reported to be partly 
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responsible for induction of monocytic differentiate of HL-60 cells in the presence of 
RA. It was also found the VD3 and IFN-y synergistically induced the differentiation 
ofHL-60 cells. GM-CSF significantly enhanced differentiate ofHL-60 cells induced 
by VD3 and also enhanced monocytic differentiation in the presence of IFN-y and 
VD3. On the other hand, combinations of TGF_p and VD3 inhibited synergistically 
cell proliferation and induced monocytic differentiation of HEL/S and HL-60 cells 
(Hozumi, 1994). 
Studies with various compounds, other than normal hematopoietic regulatory 
cytokines, have shown that certain stages of differentiation can be induced in 
appropriate clones of myeloid leukemic cells by steroid hormones such as 
dexamethasone, which induce differentiation of murine myeloid leukemia cell Ml, 
estradiol, chemical such as adriamycin, methotrexate, and by presumably surface 
acting agents such as the plant lectins Con A, phytohaemagglutinin, pokeweed 
mitogen, bacterial lipopolysaccharide, lipid A and dimethyl sulphoxide (DMSO), 
which induce HL-60 cell to differentiate into granulocyte. Differentiation is also 
induced by actinomycin D and other compounds that can interact with DNA; for 
example, cytosine arabinoside (ara-c), which is one of the most effective single agent 
for the treatment of myeloid leukemia and is acted by incorporation in DNA and 
inhibition of DNA replication, mitomycin C, 5-bromodeoxyuridine nitrosoguanidine 
and X-irradiation, some polycyclic hydrocarbons and the tumor promoter phorbol 
ester, 12-0-tetradecanoylphorbol- 13-acetate (TPA). The induction of some stages of 
differentiation by low concentrations of actinomycin D may be explained by 
inhibition of the formation of repressor of the differentiation process (Sachs, 1978). 
The chemotherapeutic agent such as mitomycin, adriamycin, cytosine arabinoside, 
methotrexate have been shown to induce Ml and HL-60 leukemic cell differentiation 
(Gabrilove, 1986). The phorbol esters are potent inducers of differentiation of human 
leukemia cells inducing HL-60 into macrophage-like cells and U937 cells. The TPA 
induces monocytic differentiation of K562, HEL and KU812 cells, induce 
differentiation of KGT and ML-1 cells into macrophage-like cells, and 
megakaryocytic differentiation of K562, HEL cells (Hozumi, 1994) DMSO can 
induce ML1 cells to differentiate into granulocytic cells and induce differentiation in 
HL-60 cell (Koeffler, et al., 1985). 
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It seems that not all of these compounds are equally active on the same 
leukemic clone. Different types of differentiation inducer may induce the myeloid 
leukemia cells to differentiate along various lineages. The differentiation of myeloid 
leukemia cells induced by certain inducers along a particular lineages may suppress 
the cellular regulatory mechanisms of differentiation along another lineage of 
leukemic cells. Therefore, combinations of cytotoxic agents and differentiation 
inducers with various mechanisms of action and biological effects have been proposed 
in treating cancer. Trial with these combinations were found to enhance the 
therapeutic effects of both conventional cytotoxic anticancer agents and 
differentiation inducers (Hozumi, 1994). 
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1.3.3 Chemical inducers 一 Flavonoids 
Flavonoids, a large group of plant polyphenols, are naturally occurring benzo-
y-pyrone derivatives which are ubiquitous in vascular plants. Flavonoids are found in 
the thylakoid membrane. Flavonoids have important effects in plant biochemistry and 
physiology, acting as antioxidants by acting as free radical scavengers and/or as metal 
ion chelators, enzyme inhibitors, precursors of toxic substances, and pigments and 
light screens. These compounds are involved in photosensitization and energy 
transfer which probably participate in the light phase ofphotosynthesis as catalysts of 
the electron transport and/or as regulators of ion channels involved in 
photophosphorylation, the actions of plant growth hormones and growth regulators, 
control of respiration and photosynthesis, morphogenesis and sex determination, and 
defence against infection indicate that plant flavonoids activate bacterial nodulation 
genes involved in control of nitrogen fixation (Das, et al., 1992; Havsteen, et al., 
1983). 
Over 4000 chemically unique flavonoids have been identified in plant sources 
(Middleton, et al., 1993). Flavonoids are regular components of the human diet. 
Edible plants such as fruits or vegetables contain significant amounts of flavonoids, 
and their concentrations are consistently and significantly greater in the leaves, skin 
and peel than in their deeper tissues (Stavric, et al, 1992). Apples, prunes, citrus 
fruits, cabbage, lettuce, potatoes, nuts, cereals, seeds, stems, flowers as well as tea and 
wine are a few example of fruits and vegetables in which flavonoids are found in 
substantial amounts (Middleton, et al., 1993). 
At present, flavonoids are considered to be secondary, have little nutritional 
value, non-essential dietary factors, without any documented relevance to human 
health and/or disease although they provide certain benefit to plant (Starvic, 1992). 
Nevertheless, flavonoids have been reported to have a number of biological activities 
in humans and pharmacological potencies with many therapeutic application. 
Flavonoids can maintain or restore normal integrity of the blood vessel wall 
and therefore they are used for the treatment of decreasing capillary fragility. While 
other flavonoids are found to be effective in the treatment of arteriosclerosis, 
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hyperlipidemia and atherosclerosis. Additionally, flavonoids have been recognized to 
possess a number of beneficial pharmacological effects, such as anti-allergic, anti-
inflammatory, antibacterial, antifungal, antiviral, antiproliferative and 
anticarcinogenic activities. Flavonoids are known to modulate the immune and 
inflammatory cell functions. Flavonoids have been demonstrated to affect the activity 
of many mammalian enzyme systems in vitro such as inhibiting the activity of a 
variety of critical enzymes including lipases, hydrolases, phosphatases, and kinases 
that are vital to the function of mammalian cells (Mace, et al., 1990). Further, they 
posess free-radical scavenging activity, chelate certain metal cations and have 
antioxidant properties and, importantly, to affect cellular protein phosphorylation. 
Certain flavonoids have been found to inhibit protein phosphorylation by 
protein kinases in human neutrophils and platelets. Protein phosphorylation is 
involved in the activation of these cells during inflammations. Flavonoids have also 
been shown, in both in vitro and in vivo, to inhibit platelet aggregation, and to modify 
the activity of enzymes involved in arachidonic acid metabolism, thereby mediate the 
anti-inflammatory activity. Furthermore, they have been found to inhibit histamine 
release from basophilic leukocytes and other mediators of allergic hypersensitivity 
reactions. Flavonoids inhibit the activities of hyaluronidases, enzymes that are 
involved in a number of processes, including allergic reaction, inflammation, 
migration of cancer cells and malignant cell proliferation. Therefore, preparation 
which contain flavonoids as the principal physiologically active constituents have 
been used to treat a variety ofhuman diseases (Starvic, et al., 1992). 
Still, it was found in animal test, that several flavonoids exhibited some 
antitumorigenic and antimutagenic acitivity which might be useful as new 
chemopreventive agents in human carcinogenicity and a number of other potentially 
beneficial effects for human health. As a result, there is considerable interest and 
effort in research on the therapeutic potential of flavonoids as drugs for the prevention 
or treatment ofcertain human diseases (Gambhir, et al., 1992; Stavric, et al, 1992). 
Epidemiological studies have clearly revealed an association between dietary 
factors and the incidence of human cancer. There is well documented evidence 
shown that flavonoids which are commonly found in edible plants are natural anti-
tumor compounds. Isofavonoids are a large distinctive subclass of flavonoids. 
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Isoflavones constitute the largest group of natural isoflavonoids. Isoflavones are 
known to have various biological activities. An isoflavone, genistein, have shown to 
induce in vitro differentiation of mouse erythroleukemia cells K562 and human 
myeloid leukemia cells HL-60 (Constantinou, et al., 1990). Furthermore, previous 
studies shown that, genistein and another isoflavone, biochanin A, strongly inhibit the 
in vitro growth of stomach, breast and prostate tumor cells through inactivation of 
signal transduction pathway for apoptosis. In addition, they reduce in vitro mutagenic 
activities of chemical mutagens, and suppress in vivo tumor development and tumor 
promotion in mice (Fung, et al., 1997; Yanagihara, et al., 1993). 
Biochanin A (Figure 1.2), an isoflavone, isolated from the red clover, 
Trifolium pratense L, was identified in the search for potential chemopreventive 
agents from higher plants based upon alteration of the carcinogenic hydrocarbon 
benzo[a]pyrene (B[a]P) metabolism in cell cultures. B[a]P requires metabolic 
activation in cells to form reactive intermediates capable of binding to DNA, RNA 
and protein in order to exert its biological effects. Biochanin A greatly reduced the 
mutagenic activity of B[a]P in a mammalian cell-mediated mutation assay. 
Biochanin A inhibited the metabolism of B[a]P and B[a]P-DNA binding in hamster 
embryo cells in culture. It inhibited the metabolic activation of B[a]P through 
inhibition of oxidation of B[a]P as well as inhibition of glucuronidation of B[a]P 
metabolites. Furthermore, biochanin A is an effective inhibitor of the mutagenicity of 
2-aminoanthracene and aflatoin Bi , and of a direct-acting carcinogen, N-methyl-N'-
nitro-N-nitrosoguanidine. Thus biochanin A may potentially serve as a blocking 
agent for several class of chemical carcinogens (Chae, et al, 1991). Biochanin A has 
been shown to mediate multiple biological effects including anti-mutagenic activity in 
mammalian cells, anti-tumor activity and modulation of intracellular signal 
transduction. The anti-tumor effect of biochanin A has been correlated with its 
cytotoxic and cytostatic properties. Recent studies shown that biochanin A capable of 
inducing the monocytic differentiation ofmyeloid leukemia cell line WEHI 3B (JCS) 
cells, which may be mediated by the regulation of cytokine expression (Fung, et al., 
1997). 
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Figure 1.2 Chemical structure of biochanin A 
Therefore, the flavanoids, including the isoflavone, which can be identified in 
most edible plants, possess the anti-tumor activity, may act as a potent inducer in 
inducing differentiation of tumor cells that may be developed as a differentiating 
agents used in the differentiation therapy. Further studies are needed to gain more 
insight in the possible application of flavonoid as anti-onocogenic agent and the anti-
tumor and differentiation-inducing mechansim in different biological system so as to 
elucidate its potential therapeutic value. 
1.3.4 Murine myeloid leukemia cell - WEHI-3B 
JCS 
The myelomonocytic leukemia cell line WEHI 3B was established in 1972 by 
Dr. C. Wyss as a cloned continuous cell line in liquid culture (Hozumi, 1983). WEHI 
3B myelomonocytic leukemia was induced in a BALB/c mouse injected with mineral 
oil (Hozumi, 1983). Several subclones ofWEHI 3B have been established, WEHI 3B 
(D+) and WEHI 3B (D"). One of the subclones of the D" line was designated WEHI 
3B (JCS). The WEHI 3B myelomonocytic leukemia cell line was previously 
subdivided into D+ and D" sublines based on responsiveness of the cells to G-CSF. In 
response to G-CSF, the D+ subclone produced macrophage and macrophage-
granulocyte differentiated colonies, while the D' and JCS subclones produced 
compact colonies containing undifferentiated cells in the presence of G-CSF (Mak, et 
al, 1993). Although JCS cells was unresponsive to G-CSF, previous studies 
demonstrated that the JCS cell line has a multipotentiality to differentiate into 
different cell lineages by different differentiating agents such as TNF-a, IL-1, 12-
myristate 13-acetate (PMA), biochanin-A and midazolam (Chan, et al., 1995; Fung, et 
al., 1997; Mak, et al., 1993; Mak, et al., 1997) 
‘ Chapter 2 
今 6 1 
D+ cells did not differentiate in response to TNF-a but exogenous TNF-a 
inhibited proliferation and induced the monocytic differentiation of JCS cells. 
Maturation of the cells was associated with increased expression of the macrophage 
specific markers Mac-1 and FcR, increased phagocytic activity and decreased 
expression of J l l D antigen. The clonogenicity of TNF-a treated JCS cells was 
reduced (Mak, et al., 1993). Another studies shown that ILl-a and ILl-p are 
endogenously produced in the TNF-a induced monocytic differentiation of JCS cells. 
In addition, IL-la and ILl-p were found to inhibit the growth as well as induce the 
differentiation of JCS cells, indicating that IL-1 alone may directly trigger myeloid 
leukemic cell differentiation (S.C.Chan) It was also found that the antiproliferative 
effect of TNF-a on JCS cells was markedly increased in the presence of IFN-y with 
increased level of Mac-1 antigen. PMA is also a differentiation-inducing agent for 
JCS cells. TNF-a was transiently expressed during the PMA induced differentiation 
into mature macrophages. It suggested that the PMA-induced differentiation of JCS 
cells may be mediated by TNF-a (Mak, et al., 1993). 
The effect of TNF-a in inducing monocytic differentiation of JCS can be 
enhanced by Pertussis toxin, which is a complex bacterial exotoxin isolated from the 
gram-negative bacteria Bordetella pertussis, with enhanced expression of the specific 
macrophage differentiation marker Mac-1, increased phagocytic activity of the cells, 
decreased proliferative potential and reduced tumorigenic capacity of the treated JCS 
cells. Pertussis toxin alone did not induce morphological changes in JCS cells (Mak, 
et al., 1994). Also, in another studies, it was demonstrated that TNF-a and IL-4 acted 
in synergy in the inhibition of JCS cell proliferation and induced monocytic 
differentiation of the JCS cells, as shown by increased expression of the macrophage 
differentiation antigens, F4/80 and Mac-1, stimulation of phagocytic activity, reduced 
clonogenieity in vitro and also decreased the tumorigenicity in vivo. IL-4 alone did 
not indue JCS cells to differentiate but can augment the differentiation activity of 
TNF-a in JCS cells (Leung, et al，1994). 
JCS cells was also found to be differentiated into macrophages and 
granulocyte induced by the plant extracts from the pericarpium of citurs fruits Citrus 
reticulata. Evidence shown the active components of the plant extracts are 
methoxylated flavones (Mak, et al., 1996). Recent studies shown biochanin A, an 
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isoflavone, was found to inhibit the growth of JCS cells and also induce monocytic 
differentiation of JCS cells to macrophage. It was suggested that endogenous 
produced cytokines such as IL-la, ILl-p, IL-4 and TNF-a but not LIF, appear to be 
involved in the later stages of biochanin A induced monocytic differentiation of JCS 
cells (Fung, et al., 1997). 
In another studies, it was also shown that midazolam can induce both 
monocytic and granulocytic differentiation of the JCS cells. Midazolam (MID) ’ a 
water-soluble benzodiazepines (BDZs) derivative, is one of the widely used drugs in 
anesthetic induction and postoperative longterm sedation for intensive care patients. 
MID has been demonstrated to inhibit the proliferation of JCS and Ml cells in a dose 
dependent manner but cannot induce Ml cells differentiation. Induction of 
morphological differentiation of the JCS cells was associated with the enchanced 
expression of the differentiation antigens Mac-1, F4/80, and Gr-1 for the cells. The 
expression of TNF-a and neutrophil-specific J l l D differentiation marker was 
significantly upregulated in MID-treated JCS cells. The phagocytic activity of MID 
treated JCS cells was increased. The result suggested that TNF-a is one of the 
mediator involved in MID-induced differentiation. It agrees with the previous 
observation that TNF-a play a positive role in induction of differentiation of the JCS 
cells (Mak, et al., 1997). 
Taken together, the result indicated that murine myeloid leukemia cell line 
WEHI 3B (JCS) can be induced to differentiate to monocytic and/or granulocytic 
lineages by various inducers. Certain cytokines, TNF-a, IL-1 and IL-4 shown to play 
a role in the JCS cells differentiation. However, the mechanism whereby those 
cytokines that shown to be involved in JCS cells differentiation can exert their effect 
on JCS cells differentiation is still unknown. Studies are currently in progress to 
examine the role of other cytokines and cytokine receptors in JCS cells differentiation 
and define the molecular mechanisms underlying the JCS cells differentiation induced 
by different differentiating agents so as to work out the signalling pathway that might 
be involved in the process. 
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1A Aim of study 
Hematopoiesis is an important process for the survival of an individual. As 
review in the previous sections, our current knowledge on the regulation of 
hematopoiesis and the commitment of terminal differentiation of myeloid lineage is 
incompleted. The understanding of the control of hematopoietic development would 
advance the identification of novel treatment of the disease. The ultimate aim of the 
present study is to dissect the gene regulation of the terminal differentiation of 
myeloid cells, identify the critical molecular regulators that control the process and 
pursuit of genes aberrantly activated in leukemia, which would be a fruitful approach 
to hematopoietic development. 
Induction of myeloid leukemia cell differentiation has long been used as a 
model to study the mechanism underlying the myeloid cell differentiation. Genes 
encoding for a network of positive and negative hematopoietic regulatory proteins are 
swithched on/off during differentiation of the myeloid leukemic cells and that there 
are leukemic clones with specific defects in this network (Lotem, et al., 1991). 
Isolation of genes through the study of leukemic cell lines would add to our 
understanding not only the multiple steps in leukemogensis but also ultimately 
provide us a much clearer picture of factors controlling normal hematopoietic 
developmental pathway (Varmus, et al., 1994). 
The murine myeloid leukemia cell line WEHI 3B(JCS) have long been studied 
in our laboratory and- used as a model to study the mechanism of myeloid cell 
differentiation. Previous studies demonstrated that the plant extracts from the 
pericarpium of citrus fruits Citrus reticulata induced WEHI 3B (JCS) cells to 
differentiate into macrophages and granulocytes (Mak, et al, 1996). Later it was 
found the active components of the plant extracts are methoxylated flavones. In an 
recent study in our laboratory, an isoflavone, biochanin A, have shown to induce the 
JCS cells to differentiate along monocytic lineage, which is mediated by the 
coordinated regulation of the expression of certain cytokines genes. However, the 
molecular mechanism whereby the biochanin A exert their effects on the 
differentiation of JCS cells along monocytic lineage is still unclear. To better 
understand the mechanism underlying biochanin A-induced macrophage 
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differentiation, in the present study we have used the recently described RNA 
fingerprinting by arbitrary primed-polymerase chain reaction (RAP-PCR) technique 
to identify and characterize genes that are differentially regulated during the 
monocytic differentiation of JCS cells induced by biochanin A and evaluate the 
pattem of gene expression. By comparing the RNA fingerprints generated from 
different patterns of transcript expression in response to biochanin A induction of JCS 
cells for a different intervals, it is possible to identify cDNA that are differentially 
expressed between samples. The differentially amplified PCR products were isolated, 
reamplified, subcloned and characterized by sequencing and homology search with 
the GenBank. Their expression during the biochanin A induction of JCS cells 
differentiation were examined by reverse transcription polymerase chain reaction 
(RT-PCR). Thereafter, the study of the role of the cloned differentially expressed 
genes in myeloid cell differentiation help our clearer understanding on the mechanism 
controlling the differentiation process of myeloid cell. Hopefully, the current study 
would lead to advance in diagnosis and treatment of myeloid leukemia. 
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CHAPTER T W O … 
Isolation Of Genes That Are Differentially 
Expressed During Biochanin A Induced WEHI-
3B (JCS) Myeloid Leukemia Cell Differentiation 
2.1 Introduction 
2.1.1 Strategy for searching differentially 
expressed genes - RNA fingerprinting by 
arbitrarily primed polymerase chain 
reaction (RAP-PCR) 
Changes in gene expression are the hallmark of many cellular and 
developmental processes. The identification of the differentially expressed genes 
would definitely help understand the underlying molecular mechanism of a particular 
biological process. Several methods have been developed for the detection of 
differential gene expression, including differential screening of cDNA libraries and 
construction of subtracted cDNA libraries (subtractive hybridization). Though these 
approaches have widely and successfully been used in many studies for the detection 
of differentially expressed genes, both of these techniques are technically difficult, 
time consuming, laborious and require large amount of RNA. Both approaches 
require the construction of high-quality, representative cDNA libraries from the cells 
under investigation. Moreover, when using these approaches in detecting differential 
gene expression, only substantial changes in transcription are able to be detected. 
Also, only two RNA samples can be compared at one time (Welsh, et a/.,1995). 
RNA fingerprinting by arbitrarily primed polymerase chain reaction (RAP-
PCR) (Welsh, et al, 1992) and differential display (Liang, et al., 1992) are 
polymerase chain reaction-based methods introduced recently for detecting 
differentially expressed genes. The methods have been successfully applied in the 
isolation of differentially expressed genes in cancer, heart disease, diabetes, 
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embryogenesis as well as other situations. The principles of the two approaches are 
essentially the same. In RAP-PCR, first strand cDNA was synthesized from total 
RNA using an arbitrarily selected primer at low stringency. The arbitrary primer has 
a specific sequence but is arbitrarily chosen. While in the differential display 
protocol, oligo dT with an anchor of two bases at the 5'end was used as primer in the 
first strand cDNA synthesis, which is selective for the polyadenlyated RNA and 3'end 
ofthe mRNA. After the reverse transcription, the same or a different arbitrary primer 
was used to synthesize the second strand cDNA from the resulting first strand cDNA 
at two low stringency cycles PCR amplification and conventional PCR amplification 
at high stringency cycles were then followed. The rationale of using the arbitrarily 
primed PCR or differential display techniques to identify the differentially expressed 
genes is that, under the low stringency conditions and using the arbitrary chosen 
primer with specific sequence, the arbitrarily selected primer could anneal to the best 
match in the template though it only matches imperfectly. After two low stringency 
cycles of PCR, the arbitrary primer flanks a number of anonymous sequences. These 
sequences are then further amplified by conventional PCR at high stringency and a 
fingerprint is then generated when the amplified products are resolved by gel 
electrophoresis. The fingerprints generated from different cells or tissues could then 
be compared. Any differences between the pattem of the fingerprints reveals the 
variation in the abundance of the corresponding RNA transcripts and therefore 
reflecting differential gene expression. 
The RNA fingerprinting by arbitrarily primed PCR and differential display are 
semiquantitative, the intensities of the amplified bands are proportional to the 
abundance of the corresponding target sequences in the RNA preparation. The 
advantages of using these PCR-based methods for detecting differentially expressed 
genes in compared with the classical methods, i.e. differential screening and 
subtractive hybridization, are easier and faster. It only requires minimal amounts of 
RNA and allows simultaneous comparison of many samples. Therefore, the overall 
pattem of gene expression in different cell types and in specific cellular and 
physiological condition of the same cell type could be examined (Perucho, et al, 
1995). 
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In the present study, RAP-PCR was used to identify transcriptionally regulated 
genes that are potentially involved in the biochanin A induced JCS cells monocytic 
differentiation. RAP-PCR can help in identifying the candidate genes that are being 
regulated for further anlaysis. Methodological modification on RNA fingerprinting 
by arbitrarily primed PCR have been introduced to streamline the techniques. In our 
study, the protocol ofRAP-PCR was modified. The first strand cDNA is synthesized 
using the oligo dT to selected for the mRNA. After the reverse transcription, PCR 
was performed on the resulting first strand cDNA using a single arbitrary primer. 5 
low stringency cycles were followed by 45 high stringency cycles PCR. In order to 
increase the chance of primer annealing, the number of low stringency cycles was 
increase to 5 rather than 2 as described in the original protocol. The fingerprints were 
resolved on an agarose gel. The differentially amplified fragments were then isolated, 
reamplified and subcloned for further analysis. 
2.1.2 Reamplification of PCR products by 
Touchdown PCR 
In using RAP-PCR to identify the differentially expressed genes, confirmation 
of differential expression of the recovered differentially amplified bands is needed, 
since false positive is an avoidable problem of the technique. The differentially 
amplified fragments should be first reamplifled with the same primer used in the 
RAP-PCR. It is generally reported that the differentially amplified bands purified 
from the gel were in many cases heterogeneous in sequence and contaminated with 
the comigrated overlapping or neighbouring bands. Further, the generation of 
spurious smaller bands in the product due to mispriming of the primer is a frequently 
encountered problem in PCR amplification of specific gene. The shorter misprimed 
products have advantage over the longer specific product in amplification. After 
several numbers of amplification cycles, the non-specific PCR products may 
dorminate over the target template. It poses a serious problem in the subsequent 
anlaysis ofthe differentially amplified bands. 
To solve the problem, a number of parameters can influence the kinetic of 
PCR amplification, such as, the concentrations of Mg�+, H, dNTP, primer, template 
and annealing temperature. Careful adjustments of these variables may reduce the 
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chance of mispriming and increase the specificity of the PCR amplification. 
However, such empirical determinations of the parameters are time consuming. 
Here we employ the touchdown PCR (Don, 1991) to optimise the 
reamplification efficiency of the differentially amplified bands. The optimization is 
achieved by a single variable, the annealing temperature. The annealing temperature 
of the initial cycles is well above the estimated melting temperature of the primer-
template complexes. The annealing temperature then decreases progressively in the 
subsequent cycles, l°C less than the preceding cycle, until the estimated melting 
temperature is reached. In the initial cycles, high annealing temperature well above 
the empirically annealing temperature allows specific priming and generated 
homogeneous products. When the annealing temperature drops to the level where 
mispriming would occur, the amplification of homogeneous and specific product 
generated in the initial high stringency cycles would outcompete that of the non-
specific product. The touchdown PCR protocol, focus on determining a single 
variable, the annealing temperature, therefore improving the efficiency of specific 
amplification of target sequence without lengthy optimization of a number of 
amplification parameters. 
2.1.3 Methods for eliminating false positives : Dot 
blot hybridization screening 
The frequently encountered problem in adapting RAP-PCR technique to 
identify the differentially expressed genes is the need of elimination of false positive 
and confirmation of differential expression. Several approaches have been developed 
to circumvent this problem. One of them is the use of northern blot for affinity 
capturing of cDNA. In this approach, the differentially amplified fragment was used 
as probe to hybridize specific RNA in northern blots. The fragment bound to the 
northern blot showing differential expression can be eluted and cloned (Li, et 
al.,X99A). This method is rapid and effective, but require a large amount o fRNA to 
prepare the blots and not suitable when a large number of differentially amplified 
bands have to be examined. Another approach uses the differentially amplified 
fragments as probe to screen the cloned differentially amplified fragments. The 
differentially amplified fragments are split into two fractions, half is cloned and the 
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recombinants are dot-blotted and hybridized with the remaining half of the mixture. 
The plasmid clone inserted with the corresponding differentially expressed fragments 
would hybridize to the probe. Although the method is simple but the result may not 
be conclusive because of the heterogeneity of the probe derived from the differentially 
amplified fragment. Furthermore, only one differentially expressed cDNA can be 
analyzed at one time (Callard, et al., 1994) 
Dot blot hybridization screening is an alternative method in the elimination of 
false positives among the isolated differentially amplified fragments. In the dot blot 
hybridization method, cDNA probes are generated from RNA samples and hybridized 
to the reamplified differentially amplified fragments dot-blotted on duplicate 
membranes. Using this method, a large number of differentially amplified fragments 
can be screened simultaneously and no more total RNA sample that required in the 
original RNA fingerprinting is required. In our study, two rounds of dot bot 
hybridization screening were adapted to eliminate the false positives of the isolated 
differentially amplified fragment. Those fragments showing differential expression in 
the first round screening were then cloned and subjected to second round dot blot 
hybridization screening. 
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2.2 Materials 
2.2.1 Cell line，Bacterial strain and Vector 
1. WEHI-3B JCS murine myeloid leukemia cell line 
The murine myeloid leukemia cell line WEHI 3B (JCS) was maintained by 
Dr. N.K. Mak at the Department ofBiology, Hong Kong Baptist University. The JCS 
cells was cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS, 
Gibco), 2 mM glutamine, and 50 U/ml penicillin, 50p,g/ml streptomycin, and 10 
fig/ml neomycin. The cultures were maintained under a humidified atmosphere of 
9 5 % a i r / 5 % C O 2 a t 3 7 X . 
2. Escherichia coli (DH5a) 
3. pBluescript SK-
4. Competent cell, prepared from Escherichia coli (DH5a), kindly prepared by 
Miss S.C. Chan. 
2.2.2 Chemicals 
(3- [N-Morpholino]propanesuifonic acid QVIOPS) Sigma M8899 
p-mercaptoethanol Sigma M7154 
p P ] d C f P Amersham A0005 
5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-gal) Amresco 7240-90-6 
Agar, bacteriological grade . 繊 „ ^ 辦 : _ _ 警 二 - i i ^ f i Diagnolab 711655 
Agarose type I : Low EEO Sigma A6013 
:•  i.iw|ip3^ a^atj^y:.,:,;>: :•. :.;<.:.:?灘5«^««»1?4«5«8«^»^;? ^ 
Ammoniumacetate , 漆 .你⑶产逊镇〜' ,SigraaA1542 
Ampicillin Sigma A9518 
、脚 ‘»>^ ^p*^^-i^ <»v ‘ s iyj<t^<j>A 狐权紅“^'- *<ti *<»«:<S¥flS^J»v f；^ 
Biochanin^A (5，7-dihydroxy-4 ’ - Sigma D2016 
methyoxyisoflavone) 
Cesium chloride Sigma C4036 
Ghloroform - … _ 嫩 Ajax 152 
Diethyl pyrocarbonate, DEPC Sigma D5758 
Ethanol, absolute Merck 2500 
Ethidium bromide Sigma E8751 
Guanidine thiocyaaate * Fluka 50990 “ 
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Hydrochloric acid, 36 % Ajax 1364 
Iso-amyl alcohol Ajax 64 
Isopropyl-p-D-thiogalactopyranoside (IPTG) Sigma 16758 
Lauroyl sulfate . � � , � SigmaL5750 
N-Lauroylsarcosine Sigma L5125 
Phenol � � � . i,v-^- SigmaP1037 
Potassium acetate Sigma P1147 
Ready-Safe scintillation fluid Beckman 158735 
Sodium acetate, anhydrous Sigma S8750 
Sodiumchloride : ‘ Sigma S9625 
Sodium citrate, trisodium salt Sigma S4641 
Sodiumhydroxide SigmaS5881 
Synergel Diversified Biotech SYN1000 
TAE bufifer, 25X Amresco 0796 
Tris base Boeringer Mannheim 604205 
Triton X-100 Fluka93426 ‘ 
Tryptone Difco0123-17-3 
Yeast extract 醫 “ Difco 0127-17-9 
2.2.3 Reagents and nucleic acids 
1 kb DNA ladder Gibco BRL15615-024 
Adenosine 5'-triphosphate Pharmacia 27-2056 
M-MLV reverse transcriptase; Gibco BRL 28025-013 
5X reverse transcriptase buffer: 250 mM Tris- � 
HC1, pH 8.3, 375 mM KC1,15 mM MgCb； 
Dithiothreitol (DTT) 
pd(T)i2-i8 Pharmacia 27-7858-01 
RNaseONE™ ribonuclease 、， Promega M4261 
rRNasin ribonuclease inhibitor Promega N2511 
Sma I, 10X buffer J “ PromegaR6221 
T4 DNA ligase, One-Phor-All buffer Pharmacia 27-0870 
T47DNA pol35aerase " ~ " — Pharmacia 27-0718-02 
ThermoprimePius DNA polymerase; Advanced Biotechnologies #AB_ 
10X reaction buffer : 200 mM (NH4)SO4, 750mM 0301 
Tris-HCl, pH 9.0, 0.1% Tween; 
25 mM MgCl2 
Ultrapure dNTP set (2'-deoxynucleoside 5’- Pharmacia 27-2035-01 
triphosphate) 
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2.2.4 Kits (See Appendix A2) 
Megaprime DNA labelling system Amersham RPN 1606 
QIAGEN plasmid midi kit Qiagen 12145 
2.2.5 Solutions 
20X SSC Dissolve l75.3g of NaCl and 88.2g ofsodium citrate in 1 liter 
d d H 2 O . Sterilize by autoclaving. 
LB(Luria Bertani) 10 g tryptone, 5 g yeast extract, 10 g NaCl and 20 g bactoagar 
+Ampi00piate in 1 liter d d H 2 O . Sterilize by autoclaving. 100 ^g/ml of 
ampicillin was then added to the medium at 50°C. 
LB(Luria-Bertani) :¾ 10 g tryptone, 5 g yeast extract and 10g NaCl in 1 L ddH20. 
+Amp broth �: Sterilize by autoclaving. A final concentration 100 ^ig/ml of 
ampicillin was then added to the medium at 50°C. 
P1 Dissolve 6.06 g Tris base，3.72 g EDTA.2H2O in 800 ml 
d d H 2 O . Adjust the pH to 8.0 with HC1. Adjust the volume to 
1 liter w i t h d d H 2 O . 
P2 Dissolve 8.0 g NaOH pellets in 950 ml d d H 2 O , 50 ml 20 % 
SDS solution. The final volume should be 1 litre. 
P3 Dissolve 294.5 g potassium acetate in 500 ml d d H 2 O . Adjust 
the pH to 5.5 with glacial acetic acid ( � 1 1 0 ml). Adjust the 
volume to 1 liter with d d H 2 O . 
QBT Dissolve 43.83 g NaCl, 10.46 g MOPS (free acid) in 800 ml 
d d H 2 O . Adjust the pH to 7.0. Add 150 ml pure ethanol and 15 
輪 ml lO % Triton X-100 solution. Adjust the volume to 1 liter 
w i t h d d H 2 O . 
QC Dissolve 58.44 g NaCl and 10.46 g MOPS (free acid) in 800 ml 
d d H 2 O . Adjust the pH 7.0. Add 150 ml pure ethanol. Adjust 
the volume to 1 liter with d d H 2 O . 
QF Dissolve 73.05 g NaCl and 6.06 g Tris base in 800 ml d d H 2 O 
and adjust the pH to 8.5 with HC1. Add 150 ml pure ethanol. 




STE Dissolve 5.84 g NaCl, 1.21 g Tris base and 0.37 g EDTA.2H2O 
in 800 ml d d H 2 O . Adjust the pH to 8.0 with HC1. Adjust the 
volume to 1 liter with d d H 2 O . 
2.2.6 Equipments 
Bench-top microcentriftige Eppendorf5415C 
Bio-dot microfiltration apparatus Bio-Rad 170-6545 
Centrifiige Beckman J2-M1 
Easi-Ecastmini&midielectrophoresisgel systems Hybaid HB-BlA>HB-B2 
FilmCassette Polaroid 
Gel documentation system & imaging densitometer Bio-Rad GS-670 
GeneQuant, RNA/DNA calculator Phartnacia 80-2103-68 
Horizon ™ 20.25 Gel electrophoresis apparatus and Gibco 1069BD 
power supply 
Hybridization oven Robbins scientific 
Liquid scintillation counter Beckman LS 5801 
Liquid scintillationcounterLS5801 Beckman 015-246318 
Nick column Pharmacia 52-2076-00 
Nylon membrane, positivelycharged BoeringerMannheim 1209299 
Polaroid 667 film Polaroid 
SpeedVac concentrator Savant SC110 
Thermal cycler MJ research PTC-100™ 
Ultracentrifuge Beckman XL-80 
Whatman 3MM chromatography paper Whatman 3030917 
Scientificimaging film Kodak8715187 
X-Omatic intensifying screen and cassette Kodak 
‘ Chapter 1 
今74 
2.3 Methods 
2.3.1 Induction of murine myeloid leukemia cell 
line -WEHI-3B (JCS) cells by biochanin-A 
The induction of murine myeloid leukemia cell line with biochanin A and 
preparation of cell lysate were kindly performed by the colleagues in Dr. N.K. Mak's 
research laboratory in the Department of Biology, Hong Kong Baptist University. 
The murine myeloid leukemia WEHI 3B (JCS) cells were incubated with 50 ^M 
biochanin A for 1，5, 18 hours. The untreated JCS cells and the biochanin A induced 
JCS cells were harvested by centrifugation at 200 g for 5 minutes at room 
temperature. The supernatant was decanted and the cells were washed once in RPMI 
1640. The cells were resuspended in 200 i^l ofRPMI 1640 and the suspension was 
added drop by drop to 4 ml (per lO^cells) 4M guanidium thiocyanate solution with 
vortex. The resulting cell lysate was stored at -70°C until use. 
2.3.2 Isolation of total RNA by guanidium 
thiocyanate cesium chloride 
ultracentrifugation 
Total RNAs of the biochanin A- induced JCS cells were isolated using a 
modification of the guanidium thiocyanate cesium chloride method (Chirgwin, et al, 
1979). The frozen cell lysate was thawed by incubating in a 70°c water bath with 
constant vortexing aiming to shear the DNA molecules. This shearing of DNA 
prevented the formation of impenetrable DNA mat which would otherwise block the 
sedimentation of the RNA molecules and thereby facilitating the purification of RNA 
(Herrmann, et al, 1987). The thawed cell lysate was then chilled on ice immediately. 
Approximately 2 ml of the thrawed cell lysate was layered on 1 ml 5.7 M cesium 
chloride cushion in a DEPC treated ultra-centrifuge polyallomer tube (Beckman). 
Before layering on the cesium chloride cushion, the cell lysate was passed through a 
15g syringe needle in order to further shear the DNA molecules in the cell lysate. The 
‘ Chapter 1 
^ 75 
gradient was then centrifuged in a SW60 Ti rotor in a ultracentrifuge (Beckman) at 
32000 rpm for 18 hours at 18°c. 
After centrifugation, the supernatant was removed by aspiration under 
vacuum. The tube was inverted quickly and drained for a while to remove excess 
supernatant and allow the RNA pellet to dry. Afterwards, the bottom 0.5 cm of the 
tube containing the clear RNA pellet was cut off with a new sterile scalpel blade. The 
RNA pellet was then rinsed out and resuspended very carefully to a new eppendorf 
tube with a total of400ul DEPC treated d d H 2 O . 
The RNA molecules was precipitated by 1 ml absolute ethanol and 45 ul of 
3M sodium acetate (pH 4.8). After mixing, the solution was spun at maximum speed 
for 30 minutes to obtain the RNA pellet. The RNA pellet was washed with 70 % 
ethanol to remove any residual salts. The vacuum dried RNA pellets were 
resuspended in 50 ul of DEPC treated d d H 2 O and stored at -70^c until synthesis of 
first strand cDNA (Wallace, 1987). 
The yield ofRNA was measured by absorbance at 260 nm. An optical density 
of 1 unit corresponds to approximately 40 ug / ml for single stranded RNA. The ratio 
of the absorbance at 260 nm to 280 nm is a useful indication of purity. Pure 
preparation of RNA should give an O.D.26o 丨 O.D.28o value of 2.0 (Maniatis, et al., 
1982). 
2.3.3 RNA fingerprinting by arbitrarily primed 
PCR 
2.3.3.1 Synthesis of first strand cDNA 
A modified protocol of the described RAP-PCR (Welsh, et al., 1992) was 
performed. First strand cDNA was synthesized using oligo d(T)12-i8 as primer. For 
better pipetting accuracy, the total RNA sample was diluted to O.lug/ul before reverse 
transcription so that 10 ul could be added to the RT reaction. A volume of 10 ul 
containing 1 ug of total RNA in DEPC d d H 2 O was incubated at 65°c water bath for 5 
minutes to denature the RNA, and then immediately chilled on ice. The reverse 
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transcription is initiated by the addition of a mixture of a total volume of 10 ul 
containing 200 U of Moloney murine leukemia virus (M-MLV) reverse transcriptase, 
0.2 mM of each dNTP, 0.1 ug oligo (dT)12-i8, IX MMLV reverse transcriptase buffer, 
10 mM dithiothreitol and 40 U RNasin. The reaction mixture with final volume of 20 
ul was incubated for 1 hour at 37°C. The reaction mixture was then 5-fold diluted. 
2.3.3.2 Normalization of RNA samples 
As RNA extraction and reverse transcription often have rather variable yields, 
to compensate for the possible occurrence of differentially amplified products that 
reflect the concentration or quality difference among the RNA samples, the amount of 
various RNA samples were normalized by measuring the housekeeping gene 
transcript, GAPDH. Housekeeping genes are assumed to be equally transcribed in 
various samples and their transcripts are reverse transcribed with comparable 
efficiencies. A total volume of 10 ul of the diluted cDNA derived from 0.1 p,g total 
RNA was boiled for 10 minutes to denature the first strand cDNA and chill on ice 
immediately for 2 minutes. 20 cycles of PCR was performed in a 50 i^l reaction 
containing 0.1 i^g boiled cDNA template, IX reaction buffer, 0.2 mM of each dNTP, 
1.25 mM M g C l 2 , 0.25U ThermoprimeP'"' DNA polymerase, and 1 pmole of each of 
the two specific primers for amplifying the GAPDH gene. The reaction mixture was 
incubated at 94°C for 5 minutes and the PCR performed at 94°C for 1 minutes of 
denaturation, 1 minute of primer annealing at 56°C for the GAPDH primers, and 1 
minutes of extension at 72°C. The PCR products were electrophoresed in a 2% 
agarose gel stained with 0.5 |ig /ml ethidium bromide and visualized under UV 
irradiation. The relative amounts of the GADPH transcript in various RNA samples 
were compared by examining the intensity of the bands. 
2.3.3.3 RAP-PCR 
RAP-PCR was performed in a 50 \x\ reaction. 10 i^l containing normalized 
first strand cDNA sample derived from 0.1 |ig total RNA was boiled for 10 minutes 
and chilled on ice immediately for approximately 2 minutes. This 10 ^1 boiled first 
strand cDNA sample was combined with 40 i^l master mix containing IX reaction 
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buffer, 0.2 mM of each dNTP, 1.25 mM M g C l 2 , 0.25U ThermoprimeP'"' DNA 
polymerase, and 1 pmole of an arbitrarily chosen primer of 20-25 mer that are 
previously designed to specifically amplify several cytokine gene transcripts. The 
modified RAP-PCR adapted in this study was composed of 5 low stringency cycles 
followed by 45 high stringency cycles. During the low stringency cycle, the reaction 
mixture was allowed to go through a denaturation step at 94°C for 1 minutes, primer 
annealing at 46°C ( 20°C below Tm) for 1 minute and extension at 72°C for 1 minute. 
In high stringency cycle, the denaturation step was 94°C for 1 minute, primer 
annealing at 56°C (10°C below Tm), and then extended at 72°C for 1 minute. 15 ^1 
of the RAP-PCR product was then separated in 1.5% synergel. Bands that were 
differentially expressed PCR products were excised from the gel and placed in an 
eppendorf tube containing 450 p,l TioEo.i buffer (pH 7.5). The suspension was boiled 
for 10 minutes and stored at -20°C for further reamplification. 
2.3.3.4 Reamplification of differentially amplified 
fragment 
The excised differentially expressed PCR products were reamplified by 
touchdown PCR for further analysis. 2 p,l of the suspension of the differentially 
expressed PCR product was mixed with 48 p.1 master mix containing IX reaction 
buffer, 0.2 mM of each dNTP, 1.25 mM M g C l 2 , 0.25U ThermoprimeP'"' DNA 
polymerase, and 1 pmole of arbitrary primer which have been used to amplify the 
differential expressed bands. The reaction mixture was incubated at 94°c for 5 
minutes for template denaturation. The touchdown PCR profile started at 94°c for 1 
minute for denaturation; 65°c for 1 minute, reduced l%ycle for primer annealing; 
72°c for 1 minute for primer extension for the first 5 cycles. Then the PCR 
amplification continued to carried out with annealing temperature at 60°C for 30 
cycles. Two PCR reactions was prepared for each isolated fragment. 
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2.3.4 First round dot blot hybridization screening 
2.3.4.1 Dot blot 
Dot blot hybridization screening was adapted to eliminate the false positives 
among the differentially amplified bands generated in the RNA fingerprinting 
arbitrarily primed PCR. 15 i^l of the reamplified differentially amplified PCR 
products and GAPDH were denatured in 0.2 M NaOH in a total volume of 200 ^1 for 
15 minutes at room temperature. The denatured PCR products were then applied on a 
nylon membrane pre-wetted with ddH2O assembled in the dot blot apparatus (Figure 
2.1) under vacuum. Still under vacuum, 400 i^l of 20X SSC was applied to each dot 
of samples for neutralization. The membrane was then removed and baked for 30 
minutes at 120°C in an oven. Four identical blots were prepared. 
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Figure 2.1 Assembly of dot blot apparatus (Adapted from manufacturer's 
manual, Bio Dot apparatus, BioRad SF). 
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2.3.4.2 Preparation of cDNA probe 
5 |ig of total RNA ofbiochanin A induced JCS cells for 0, 1，5, 18 hours were 
used as template in the synthesis of the first strand cDNA as described in section 
2.3.3.1. The cDNA was purified by phenol chloroform extraction and ethanol 
precipitation. Equal volume of phenol: chloroform : isoamyl alcohol (25: 24 :1) was 
added to 100 i^l of the cDNA sample, mixed well and centrifuged at 14000 rpm in a 
benchtop microcentrifuge for 10 minutes. The upper aqueous layer containing the 
cDNA was recovered and mixed with 0.5 volume of7.5 M ammonium acetate and 2.5 
volume of absolute ethanol. The pellet was then washed with 70% ethanol and 
centrifuged for further 10 minutes. The DNA pellet was vacuum dried and 
resuspended in 45 i^l T]oEo.i buffer (pH 7.5). The amount of various cDNA samples 
were normalized by detection of expression of GADPH gene transcript by RT-PCR as 
described in section 2.3.3.2 using 2 p,l of the purified cDNA as template. 
2.3.4.3 ^^P-labelling of cDNA probe 
The cDNA probes were radioactively labelled of ^^ P by Megaprime™ DNA 
labelling system. Random sequence nonamers were used to prime DNA synthesis on 
denatured template DNA at numerous sites along its length. The primer-template 
complex is a substrate for the 'Klenow' fragment of DNA polymerase I. By 
substituting a radiolabelled nucleotide for a non-radioactive equivalent in the reaction 
mixture newly synthesized DNA is made radioactive. Two probe labelling reaction 
were prepared for each cDNA probe. 20 ^1 of purified cDNA prepared as described 
in section 2.3.4.2, 5 fil of primers and 7 i^l ddH2O were mixed and the mixture was 
boiled for 5 minutes in a boiling water bath to denature the double strand cDNA 
template. The tube was spun for a few seconds to collect the solution to the bottom of 
the tube. Keeping the tube at room temperature, 10 i^l of labelling buffer and 2 i^l of 
DNA polymerase I Klenow fragment was added followed by 5 i^l of the 17 pmole 
[32p]dCTP, specific activity ~ 3000 Ci/mmol, making up the total reaction volume to 
50 p,l. The reaction mixture was mixed gently by pipetting up and down and spun for 
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a few seconds. The solution was incubated at 37°C for 10 minutes. The reaction was 
then stopped by adding 2 i^l of0.5M EDTA (pH 8.0). 
2.3.4.4 Removal of unincorporated probe by NICK^^ 
column 
The probe unincorporated with [^^P]dCTP was removed by the NICK™ 
column to reduce the background in hybridization. The NICK columns are prepacked 
disposable columns containing Sephadex G-50 DNA grade for rapid and convenient 
separations of nick-translated DNA from unincorporated ^^P-labelled nucleotides. 
Probe reactions were passed through the NICK columns, which retained the free 
nucleotides within the column matrix. The top and bottom caps of the NICK column 
was removed and the excess liquid was poured off. The NICK column was rinsed 
with 3 ml equilibration bufferTioEo.i buffer (pH 7.5). The equilibration buffer was 
allowed to completely enter the gel bed. Two 50 i^l reaction of cDNA probe labelling 
as described in section 2.3.4.3 were pooled and added to the column. After the 
sample has entered into the gel bed, 400 i^l ofTioEo.i buffer (pH 7.5) was added and 
allowed to run in the gel bed. The eluted fraction was collected in an eppendorf tube. 
This fraction contained the unincorporated probe. 400 ^1 of TioEo.i buffer (pH 7.5) 
was further added to the column to elute the ^^ P incorporated probe and was collected 
in an eppendorf tube. The labelled DNA was boiled for 5 minutes and chill on ice 
immediately to denature for use in the hybridization. 
2.3.4.5 Estimation of ^^ P labelling efficiency by 
scintillation counting 
2 p,l of first eluted fraction as described in section 2.3.4.4 was 50-fold diluted 
with 98 ^1 ddH2O and 10 ^1 of the diluted fraction was mixed with 10 ml scintillation 
fluid. 10 i^l of the second eluted fraction was mixed with another 10 ml scintillation 
fluid. The activities of the two eluted fractions were measured by the liquid 
scintillation counter (Beckman). 
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2.3.4.6 Prehybridization and hybridization 
The membranes prepared in section 2.3.4.1 were prehybridized with 20 ml 
hybridization buffer at 68°C for at least 4 hours. The hybridization buffer was then 
replaced with 10 ml hybridization buffer containing 400 i^l of the ^^ P labelled probe 
prepared in section 2.3.4.4. The membrane was hybridized with the appropriate probe 
at 68°C for at 18 hours. The membrane was washed twice with 2X SSC; 0.1% SDS at 
68°C for 15 minutes. Then the membrane was further washed twice with 0.5X SSC; 
0.1% SDS at 68°C for 15 minutes. The membrane was exposed to X-ray film in an 
X-ray film cassette for 12 hours at room temperature. The film was fixed and 
developed to obtain an autoradiography. 
2.3.4.7 Quantitation of hybridization signal by scanning 
densitometry 
The hybridization signal of the dots developed on the X-ray film were 
quantitized by the Molecular Analyst™ System (Bio-Rad). The image on the film 
was scanned by a GS-670 densitometer (Bio-Rad) in transmittance mode. Each dot 
was individually selected and the intensity of the signal of each dot was quantitized 
using the volume integration function in the Molecular A n a l y s t ™ software. The 
signal of the dot was presented as the integrated volume = [OD * area (mm^)]. The 
intensity of the signal of each dot was adjusted by the local background subtraction 
function to exclude the background signal and normalized with the GAPDH control 
dot. 
2.3.5 Second round dot blot hybridization 
screening 
Those fragments with more than two-fold difference in intensity of the 
hybridization signal among the samples of various time point in the first round dot 
blot hybridization screening were subcloned into plasmid and subjected to second 
round dot blot hybridization screening. 
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2.3.5.1 Subcloning of differentially amplified fragments 
2.3.5.1.1 Preparation of vector DNA 
The putative differentially expressed fragments screened by first round dot 
blot hybridization were subcloned into a plasmid vector pBluescript SK- (Figure 2.2). 
� . ‘ , 
,...The plasmid DNA was prepared by QIAGEN plasmid midi kit. The kit allow rapid 
purification of ultrapure supercoiled plasmid DNA with high yields. The purified 
plasmid DNA is suitable for use in such demanding procedures as transfection, 
automated or manual sequencing, and enzymatic modification. The QIAGEN 
plasmid purification protocols are based on a modified alkaline lysis procedure, 
followed by binding of plasmid DNA to anion-exchange resin under appropriate low 
salt and pH conditions. RNA, proteins, dyes, and low molecular weight impurities are 
removed by medium salt wash. Plasmid DNA is eluted in a high salt buffer, and 
concentrated and desalted by isopropanol precipitation. A single preparation of high-
copy plasmid DNA by QIAGEN plasmid midi kit from 25 ml culture can yield 75-
100 i^g plasmid DNA. 
me 1131 
^ " ^ ^ ^ \ Sspl442 
Ssp 1 2850 Ssp I 19 X ^ ^ 
Xmn I 2645^^^_^^^^^^^^^_^__-"^^^^^^^ji-"^"•""^v^^^ 5^^ x^^  Nae I 330 
Scal2526 / X ^ ^ ^ ^ ^ ^ % ^ 
^7 / \ \ fVt> 1500 
P * ^ y . ( N^^Pv^ | | 529 
]m 1 ^ _ _ 
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^SS_^Lo?^*"^^ 
Anm 1153 
Figure 2.2 pBluescript SK-
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A single colony of the bacterial culture transformed with the plasmid 
subcloned with the fragment was inoculated in 25 ml LB medium containing 100 
^g/ml ampicillin and grown for 16 hours. The bacterial cells was harvested by 
centrifugation at 7000 rpm in Beckman JA-20 rotor by Beckman J2M1 high speed 
centrifuge for 15 minutes at 4°C. All traces of supernatant was removed by inverting 
the open centrifuge tube until all medium has been drained. The bacterial pellet was 
completely resuspended in 4 ml buffer P1 containing 100 |ag/ml RNase A. 4 ml 
buffer P2 was then added and the solution was mixed gently but thoroughly by 
inverting the tube 4-6 times and the solution was incubated at room temperature for 5 
minutes. 4 ml of prechilled buffer P3 was added to the solution and mixed 
immediately but gently again by inverting the tube several times. The solution of cell 
lysate was then poured into the barrel of a 10 ml syringe which is connected to a filter 
unit with large pore filter (Millipore Ap 1002500) with a stopper. The solution was 
incubated for 10 minutes at room temperature and the precipitate floated and a layer 
was formed on top of the solution. This ensures convenient filtration without clogging 
in the following step. Meanwhile, a QIAGEN-tiplOO was equilibrated by applying 4 
ml buffer QBT and the column was allowed to empty by gravity flow. After all, the 
plunger was inserted gently into the syringe and the cell lysate was filtered into the 
previously equilibrated QIAGEN-tip. The lysate was allowed to enter the resin of the 
column under gravitational force. The QIAGEN tip was washed twice with 10 ml 
buffer QC. The plasmid DNA was then eluted with 5 ml buffer QF, precipitated with 
3.5 ml room temperature isopropanol. The DNA pellet was collected by 
centrifugation at 11,000 rpm at 4°C for 30 minutes in a JA 20 rotor. The supernatant 
was removed carefully. The DNA pellet was washed with 2 ml 70% ethanol and 
centrifuged at 11,000 rpm at 4°C for 10 minutes. The supernatant was removed, the 
DNA pellet was vacuum-dried for approximately 5 minutes and resuspended in 50 i^l 
H2O. The yield and purity of the plasmid DNA was measured by spectrophometry at 
wavelength 260 nm and 280 nm UV light. 
The plasmid was then blunt end digested by Sma I prepared for blunt end 
ligation with the putative differentially expressed fragments generated from PCR. A 
50 p,l reaction mixture containing 10 U Sma I, IX reaction buffer and 10 p,g plasmid 
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DNA were incubated at 25°C for 1 hour. The Sma I digested plasmid DNA was 
purified by the protocol used to purified the cDNA described in section 2.3.4.2. The 
purified plasmid DNA was resuspended in 25 ^1 ddH2O making up the final 
concentration of 0.2 ^ig/^il of plasmid DNA. 
2.3.5.1.2 Synthesis of blunt end PCR product 
Fragments showing more than two-fold difference in intensity ofhybridization 
signal among samples of different time point in first round dot blot hybridization 
screening were reamplified as described in section 2.3.3.4 using 2 i^l ofPCR product 
as template. Again two 50 p,l PCR reaction were prepared for each fragment. The 
PCR products were purified by phenol chloroform extraction as the protocol 
described in section 2.3.4.2 which was used to purify the cDNA. The DNA pellet was 
resuspended in 50 ^1 d d H 2 O . Afterwards, 10 i^l of the purified PCR product was 
mixed with 6 i^l of5X One-phor-All buffer, 2 i^l of 10000 U/ml T4 DNA polymerase 
and 6 p,l d d H 2 O . The reaction mixture was incubated at 37°C for 30 second and 6 |o_l 
of 10 mM of each dNTP was then added to the reaction mixture immediately, making 
the total reaction volume to 30 \xl The reaction mixture was incubated at 37°C for 30 
minutes and chilled on ice immediately. The synthesized blunt end PCR product was 
again purified by the protocol used to purify the cDNA described in section 2.3.4.2. 
The purified PCR products were resuspended in 10 p,l d d H 2 O . 
2.3.5.1.3 Blunt end ligation 
A 20 \x\ of ligation reaction containing 10 p,l of blunt end reamplified 
fragment prepared in section 2.3.5.1.2, 0.2 ^g of Sma I digested pBluescript SK-
plasmid DNA prepared in section 2.3.5.1.1, IX ligation buffer, 1 mM ATP and 
17000 U T4 DNA ligase was incubated at 16°C for 16 hours. The ligation product 
was purified by phenol chloroform extraction and ethanol precipitation as the protocol 
described in section 2.3.4.2 which used to purify the cDNA. The DNA pellet was 
resuspended in 10 ^1 ddH2O. 
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2.3.5.1.4 Transformation 
An aliquot of 150 i^l competent cells was thawed in ice. 10 p,l of ligation 
product prepared in section 2.3.5.1.3 was added to 150 i^l competent cell, mixed by 
pipetting up and down and incubated at 4°C for 1 hour. The solution was incubated 
at 42°C for 2 minutes and chilled on ice immediately for approximately 2 minutes. 
800 ^1 LB medium was added to the solution and was shaked at 37°C for 1 hour. The 
culture was then plated out on LB plates containing 100 ^ig/ml ampicillin spread with 
8 i^l of0.5 M IPTG and 4 ^1 of250 mg/ml X-gal. The plates were incubated at 37°C 
ovemight. 
2.3.5.1.5 Selection and confirmation by polymerase chain 
reaction 
10 white colonies were picked randomly from the plates. Each colony picked 
was subcultured on a master plate and at the same time resuspended in 100 p.1 d d H 2 O . 
The master plate was incubated at 37°C ovemight and kept at 4°C until further use. 
The suspension was boiled for 10 minutes. The plasmid subcloned with the 
differentially amplified fragment was confirmed by 50 cycles of touchdown PCR as 
described in section 2.3.3.4 using 10 p,l of the suspension as template. 
2.3.5.2 Dot blot hybridization screening 
The subcloned fragments were subjected to second round dot blot 
hybridization screening to eliminate the false positives. The fragments subcloned in 
the plasmid was reamplified by touchdown PCR protocol as described in section 
2.3.3.4 using the 10 i^l of the bacterial lysate as template and amplified for 50 cycles. 
Also, the fragments showing two-fold difference or more in intensity of the 
hybridization signal in first round dot blot hybridization screening and selected for 
further studies were reamplified as described in section 2.3.3.4 using 2 p,l of the 
reamplified PCR products generated in section 2.3.3.4. The reamplified fragments 
generated from both the plasmid and reamplified PCR products were dot botted on a 
nylon membrane, hybridized with the cDNA probes and the hybridization signal was 
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analyzed by the densitometry as described in section 2.3.4. Likewise, those subcloned 
fragments showing two-fold or more difference in intensity of hybridization signal 
among various samples of different time point were selected for further 
characterization. 
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2.4 Results 
2.4.1 Spectrophotometric analysis of total RNA 
Total RNAs ofWEHI 3B (JCS) cells at various time points after biochanin A 
exposure were isolated by the guanidium thiocyanate cesium chloride method 
(Chirgwin, et al., 1979). Absorbance of UV light at 260 nm and 280 nm were 
measured to analyze the yield and purity of the RNA samples (Table 2.1). The ratio 
of absorbance at 260 nm to absorbance at 280 nm among the samples were roughly 
around 1.5. The amount o f R N A obtained was measured by absorbance at 260 nm. 
An optical density of 1 unit corresponds to approximately 40 ug / ml for single 
stranded RNA. About 130 - 165 [ig total RNA were obtained among the samples 
from approximately 2 x 10^ cells. 
JCS cells incubated with Biochanin A (50 ^M) for 
JCS cells — 
1 hours 5 hours 18 hours 
^ 2 6 0 0.642 _ 0.68 " ^ 9 0.813 一 
OP280 0.429 一 0.453 0.455 ^ 3 8 “ 
OD260/OD280 "l-497 — 1.499 1.539 1.510 “ 
Conc. (^ig/^il) 2.568 2.7 2.8 ~33 
T i e l d ( ; g V 128.4 135 140 — 165 
Table 2.1 Spectrophotometric analysis of RNA samples isolated from JCS 
cells at various time points after biochanin A induction. The yields ofRNA samples were 
calculated : OD260 x dilution factor x 40 i^g/ml x 50 ^1 as the RNAs were resuspended in 50 
p.1 ddH2O, where the dilution factor was 100. 
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2.4.2 Normalization of RNA samples 
The amount of total RNA among various samples were normalized by 
detecting the expression level of the housekeeping gene GAPDH transcript in each 
RNA sample analyzed by RT-PCR. GADPH gene transcripts were amplified in each 
RNA sample for 20 cycles while the PCR was still in exponential phase, as described 
in section 2.3.3.2. The PCR products were electrophoresed in a 2% agarose gel 
stained with ethidium bromide. The level of gene expression of GAPDH was 
constant among the RNA samples of JCS cells at different time point after biochanin 
A induction. 
M Oh lh 5h 18h 
— 
^ ^ ^ ^ ^ ^ ^ ^ ^ y <-452 bp 
Figure 2.3 Normalization of the amount of RNA samples by the detection of 
the gene expression of GADPH analyzed by RT-PCR. The GAPDH gene transcripts were 
amplified for 20 cycles in equal volume of cDNAs derived from 0.1 i^g total RNAs of JCS 
cells (Oh), JCS induced with biochanin A for 1 hour (lh), 5 hours (5h) and 18 hours (18h). 15 
^1 of PCR products were loaded on a 2% agarose gel and electrophoresed. The size of the 
PCR product of GAPDH gene transcript was 452 bp. M = 1 kb DNA size marker. 
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2.4.3 RNA fingerprinting by arbitrarily primed 
PCR 
To identify the transcriptionally regulated genes that are potentially involved 
in biochanin A induced JCS cells differentiation process, a modified RAP-PCR 
protocol as described in section 2.3.3.3 was performed using total RNA derived from 
JCS cells treated with or without 50 i^M biochanin A for various time points. By 
comparing the RNA from different time points of biochanin A treatment, we could 
identify a number of differentially expressed genes during the biochanin A induced 
JCS cells differentiation. The RAP-PCR products were separated on a 1.5% synergel. 
Examples of the RNA fingerprinting generated with the RNA of JCS cells at different 
time points after biochanin A induction and arbitrarily chosen primer were shown in 
Figure 2.4. The fingerprints generated among the RNA samples of JCS at different 
time points after biochanin A induction shared similar patterns with a few bands 
different in intensity. 2 — 21 PCR products were generated and resolved from each 
single arbitrarily chosen primer in which 1 - 20 bands showed differences in 
intensities among the four RNA samples indicating there were difference in the level 
of mRNA expression of these amplified cDNAs. The size of the amplified cDNA 
was ranged from 200-1036 bp. Those amplified bands with two-fold difference or 
more in intensities, or showing ‘all or none’ in the level of expression among the 
RNA samples of JCS cells of different time point after biochanin A treatment were 
revealed as differentially expressed cDNAs. Using 53 different single primers in 
RAP-PCR, 184 differentially expressed cDNAs were identified. 
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MFl77 MFl78 MF179 MFl42 MFI4S MFI44 
M Oh 1h 5h1$h Oh 1h 5h1$h Oh 1h 5h1$h Oh 1h 5hUh Oh 1h 5h1$h Oh 1h 5h1$h M 
^ 3 H H B i ^ K S ^ | ^ 
flH ^ i ^ ^ g 
_ i _ 
' � l ^ ^ 3 # f e ^ M 
Figure 2.4 RNA fingerprinting by arbitrarily primed PCR of JCS cells at 
various time points after biochanin A treatment. Total RNAs of uninduced JCS cells (Oh) 
and JCS cells induced for 1 hour (lh), 5 hours (5h) and 18 hours (18h) were reversed 
transcribed with oligo dT12-i8 primer. The resulting cDNAs were PCR amplified using single 
arbritrary primer for 5 low stringency cycles followed by 45 high stringency cycles as 
described in section 2.3.3. 15 p.1 of RAP-PCR products were electrophoresed on a 1.5% 
synergel. M : 1 kb DNA size marker. 
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2.4.4 Reamplification of isolated RAP-PCR 
products 
To further analyze the identified differentially amplified cDNAs, the 184 
differentially amplified bands generated from RAP-PCR were excised from the gel 
and reamplified by touchdown PCR with the arbitrary primers used for RAP-PCR. 
Examples of reamplified PCR products were shown in Figure 2.5. After 
reamplification, most of the differentially amplified fragments yielded a single PCR 
product (Figure 2.5，lane 1, 6, 9, 11, 12, 14) while some of the others yielded 2 or 3 
PCR products of heterogeneous sizes in addition to one dominant PCR product, 
indicating that the differentially amplified PCR products isolated from RAP-PCR 
were heterogeneous. In another case, a few of the isolated differentially amplified 
bands were not capable of reamplification (data not shown). 
b£ M1A1B 2A g g 3B : f 5ft 5B^ 6B 7A7B y 8B 9A 9B1 OA 10B11A11B12A1 ¾^,!¾!¾^  
,^|j^ g^ g^^ yywp||g^ j|jj^ |l^ ^^ l^^ , '.¾^ *^^ ^^¾¾^¾¾^ ¾^¾^^ .'A" *;/SjiB^ 8^fflBM8MBBSMHWH*-l^ l^^ ^^ ^^  
paOff*.*^ 4« 11:jpgj|[^jj^jf^ ,^ 'nft j^.Ww^^vSx ^'*K* jii_'.oi:iiirtf?TiKi^BjBiMi^HlMSBBIiBSiP^mi^i*MWMMi 
W^%i"S'l^^^^l^^w^^'^l .:rv- 'j^^^^'%^^^IKsSBil^^^^SBBSSHISBIi 
l 3 ^ ^ ^ ^ H | f f l 
^^^H^MmM^^Kmm 
Figure 2.5 Reamplification of isolated RAP-PCR fragments. 2 i^l of the 
isolated differentially amplified fragment resuspended in 450 .^1 ofTioEo.i, pH 7.5 buffer was 
reamplified with the arbitrary primers used in RAP-PCR by touchdown PCR profile for 35 
cycles as described in section 2.3.3.4. Two 50 i^l PCR reactions were prepared for each 
fragments. 15 ,^1 of each of the reamplified PCR products were electrophoresed in 2% 
agarose gel. Lane A and B are PCR products reamplified from the same fragments. M : lkb 
DNA size marker. 
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2.4.5 First round of dot blot hybridization 
screening 
Two rounds of dot blot hybridization screening were adapted to eliminate the 
false positives. In the first round screening, it was aimed to eliminate the false 
positives generated in the RAP-PCR. ^^ P labelled-cDNAs generated from the RNA 
samples of JCS cells at different time point after biochanin A treatment were used as 
probes to screen for the differentially expressed fragments. The cDNAs synthesized 
after reverse transcription were purified by phenol chloroform extraction and ethanol 
precipitation as described in section 2.3.4.2. As the efficiency of reverse transcription 
among various RNA samples might be variable and led to quantitative and qualitative 
differences in the different cDNA samples, the amounts of cDNA of JCS cells at 
various time points after biochanin A induction were normalized by the detection of 
gene expression of GAPDH by RT-PCR. 2 i^l of the purified cDNA was used as 
template to amplify the GAPDH gene transcript for 25 cycles as described in section 
2.3.3.2. The PCR products were electrophoresed in 2% agarose gel and visualized 
under UV light (Figure 2.6). The levels of expression of the GAPDH among the 
various samples were nearly the same. 
The cDNAs were labeled with ^^ P by random labelling using the 
MegaprimeTM labelling system. The labelling efficiency was estimated by 
scintillation counting. The labelling efficiencies among the four cDNA probes were 
about 30% (Table 2.2). 
The reamplified differentially amplified fragments identified by RAP-PCR 
were dot-blotted on four membranes identically with equal amounts. A total of 184 
reamplified fragments were dot-blotted on two sets of membranes, four membranes 
blotted with identical fragments of each set, and a GAPDH PCR fragments was 
included in each blot as a control. The membranes were hybridized with the ^^ P 
labelled cDNA of biochanin A-induced JCS cells at 0 hour, 1 hour, 5 hours and 18 
hours respectively (Figure 2.7). The relative level of mRNA expression of those 
fragments in JCS cells at various time points after biochanin A induction were 
compared by the quantified hybridization signals of each dot determined by 
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densitometry scanning and each value was normalized with that of GAPDH (Table 
2.3). 41 out o f l 8 4 fragments showed more than two-fold differences in intensities of 
the hybridization signal among the membranes hybridized with the cDNA of JCS 
cells at various time points after biochanin A treatment were revealed as putative 
differentially expressed and subjected to second round of dot blot hybridization 
screening. Among the putative differentially expressed fragments, several types of 
expression pattem were observed. 2 fragments were found to be steadily up-regulated 
whereas 2 fragments were steadily down-regulated. 12 fragments were up-regulated at 
18 hours after biochanin A induction while 7 fragments were up-regulated from 5 
hours after biochanin A induction. One of the fragments was down-regulated from 5 
hours after biochanin A induction. 2 fragments were steadily up-regulated but down-
regulated at 18 hours after biochanin A induction while 9 fragments were up-
regulated from 1 hour after biochanin A induction. Six fragments were shown to be 
transiently up-regulated at 1 hour after biochanin A induction. Table 2.4 listed the 
origins of the fragments in RNA fingerprint generated by RAP-PCR. 
M Oh lh 5h 18h 
H H B H ^ S 9 B P ^ E ^ ^ ! ^ 1 ^ ^ 
E S ^ S ^ ^ ^ ^ ^ ^ P ^ % 
^ m ^ ^ j j ^ ^ ^ - 452 bp 
Figure 2.6 Normalization of amount of cDNA probes used in first round of 
dot bot hybridization screening by the detection of the gene expression of GADPH 
analyzed by RT-PCR. The GAPDH gene transcripts were amplified for 25 cycles using 2 ^1 
of the purified cDNAs of JCS cells (Oh), JCS induced with biochanm A for 1 hour (lh), 5 
hours (5h) and 18 hours (18h) as template, as described in section 2.3.3.2. 15 p,l of PCR 
products were loaded on a 2% agarose gel and electrophoresed. The size ofthe PCR product 
of GAPDH gene transcript was 452 bp. M = 1 kb DNA size marker. 
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JCS cells incubated First eluted fractionV Second eluted fraction / % of 
with biochanin A for cpm cpm incorporation 
Ohour 466,816.66 1,473,319.94 25.25 
1 hour 一 532,153.31 2,114,176.50 31.78 
5 hours ~383,496.66 1,556,813.31 32.48 一 
18 hours 548,409.97 2,070,429.88 30.20 
Table 2.2 Efficiency of labelling cDNA with "P in the first round of dot 
blot hybridization estimated by scintillation counting. The cDNA was labelled with ^¥ by 
random labelling and the unincorporated cDNA was removed by the NICK column as 
described in method 2.3.4.4. The activities of the fractions collected from the NICK column 
were then measured by the liquid scintillation counter (Beckman) as described in method 
2.3.4.5. a : fraction eluted contained both unincorporated and incorporated cDNA with ^^ P. 
b: fraction eluted contained cDNA incorporated with ^¥. % of incorporation = (b/10 ^1 x 400 
^il)/(a/10 i^l X dilution factor x 100 i^l) x 100%. 
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Figure 2.7 First round of dot blot hybridization screening of RAP-PCR 
isolated differentially amplified fragments. 15 p,l of the each of the 184 reamplified RAP-
PCR identified differentially amplified fragments were dot blotted on two sets of membranes, 
each set have four membranes blotted with identical fragments in equal amount. The 
membranes were hybridized with one of the ^^ P labelled cDNA of JCS cells at 0 hour, 1 hour, 
5 hours and 18 hours after biochanin A induction at 68°C for 18 hours. The membranes were 
then exposed to X-ray film for 12 hours at room temperature. The film was developed and 
fixed to obtain the autoradiography. The circled dots are the controls 'GAPDH'. 
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Table 2.3 (opposite page) Densitometric analysis of the autoradiography 
hybridization signals of the first round of dot blot hybridization screening. The 
autoradiography of the dot blot hybridization was scanned by the GS-670 densitometer 
(BioRad) in transittance mode. The hybridization signals of each dot were quantified by 
Molecular A n a l y s t ™ software in terms of integrated volume [OD x area (mm^)]. The 
hybridization signal of each dot was adjusted by excluding the background signal and 
normalized with the control GAPDH. GAPDH(1) and GAPDH(2) correspond to the control 
dots on two different sets of membrane. Only those fragments showing more than two-fold 
difference in intensity of hybridization signal among the four membranes and selected for 
further analysis were presented. 
# : Normalization of hybridization signal with GAPDH : The normalized data was 
calculated by multiplying the raw data (7.59) to the ratio of quantified hybridization signal of 
GAPDH at 0 hour to that of 1 hour (21.14/28.19). 
* : Expression pattem : (A) Steadily up-regulated. (B) Steadily down-regulated. (C) 
up-regulated at 18 hours after biochanin A induction. (D) up-regulated from 5 hours after 
biochanin A induction. (E) downregulated from 5 hours after biochanin A induction. (F) 
Steadily up-regulated but down-regulated at 18 hours after biochanin A induction. (G) Up-
regulated from 1 hour after biochanin A induction. (H) Transiently up-regulated at 1 hour 
after biochanin A induction. 
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Fragment OD x area ( m m � p 
raw data normalized data  
Oh |lh |5h |l8h 0iT" |lh |5h |l8h  
lA ~7.12 27.82—26.68 26.88 17.12 20.86 27.83 4 5 . 4 6 ~ C ~ 
lB — 1 1 . 4 9 19.68 v f M ~ 1 5 . 1 8 11.49 M ^ ~ ~ 1 8 . 0 9 25.68 ^ ~ ^ 
16A 3.46 ^ 5.70 _5.79 3^46 4.67 ~ 5 . 9 5 9.79 D ~ ^ 
16C -1.03 —3.67 4.13 3 M -1.03 2.75 4.31 6 . 1 0 ^ ^ ^ ^ 
16E -0.24 "5.57 U.16 5.77 -0.24 4.17 13.31 9.76 A ~ 
16F 一2.45 5.21 3 ^ 4.23 2.45 3.91 3.78 7.15 — ^ ^ 
20 — 5 . 9 6 10.55 ^ 8.39 5.96 W \ 6.69 1 4 . 1 9 — C _ 
64A 14.58 "l9.58 W.96 19.72 —14.58 14.68 21.87 —33.35 C ~ ~ 
64C 1.20 "4.11 ^ 8 2.22 —1.20 3.08 3.53 —3.76 G ~ ~ 
74B 4.10 "7.85 ^ 6 6.81 —4.10 5.89 8.20 —11.52 D 
74C — 3 . 8 7 7.29 5 M 5.06 3.87 5 ^ 5.65 8.56 C ~ ~ 
82 一9.72 12.40 ^ 9.59 9.72 ^ 7.25 16.22 C 
85C 4.43 ~6.21 ^ 2 8 0.16 —4.43 4.66 -0.29 —0.28 E 
87B 19.68 27.00 3 ^ " ~ 3 1 . 2 2 19.68 20 .24~34 .99 52.82 D 
89 24.39 26.74 23.84 28.57 2 4 ^ ~ 2 0 . 0 5 24.86 48.33—C 
107C 22.79 26.51 33.53 —31.95 ^ . 7 9 19.87 34.97 ^ 4 C 
lQ7D 17.13 25.09 2 ^ ~ 2 3 . 7 4 17.13 18.81~~29.68 40.16 C 
107E 22.48 29.20 2 ^ ~ 2 7 . 6 0 22.48 21.89~~25.48 46.69 C 
1071 5.30 11.02 1 ^ ~ 6 . 5 5 5.30 8.26 — 1 1 . 3 6 11.08 D 
1070 10.90 14.16 2Q.86~18 .16 T0.90 10.61 21.76 ^ 2 D 
107P 8.24 11.53 19.79 "l8.66 ^ ^ ^ ^ ^ g ^ g ^ _ ^ ^ ^ ^ ^ ^ ^ ^ ^ j _ J ^ ^ 
2JA 14.05 19.02 13.73 17.15 14.05—14.26 — ^ j ^ ^ ^ g g j j Q _ ^ ^ 
130F 2.57 2.37 1.38 0.61 Z57 _ M g _ ^ L ^ j L _ M ! g _ _ ^ Z I 
130J 6.39 9.95 12.18 _9.18 _ ^ ^ ^ ^ 7 ^ j g _ ^ ^ ^ j ^ 2 ^ ^ j _ ] ^ ; ^ 
130K 0.89 2.12 1.57 1.38 0.89 L59 1.64 2.33 ^ G  
131B 2.43 T^~~4A]__2.62 — 2 . 4 3 5^~4.60 4 . 4 3 一 G ^ Z 
GAPDH(l)21.14# ^ .19# 20.26 12.50 2 U 4 ~ 2 1 . 1 4 2 U 4 ~ 2 1 . 1 4 
139D 2.66 7.92 5.64 7.59 Z66 7.01 "s.62 7 3 2 _ G ^ 
178E 1.12 3.17 1.57 1.80 U 2 2.80 —1.57 — L 7 ^ _ H ^ 
178Q 2.37 6.73 2.57 3A5 2.37 5.96 2.56 — 3 . 3 2 一 H ^ 
178R 1.56 3.55 2.59 1.89 1.56 ^ 4 2.58 — L 8 2 _ _ ^ ^ 
178S 0.79 1.90 YJb 1.26 0.79 lM 1.30 1.22 G ^ 
178T 0.89 i l 5 1.37 —1.22 � 8 9 1.90 " l .36 U 8 _ _ H _ 
179A 2.06 5.76 3.95 3.45 Y.06 5.10 _ 3 . 9 4 _ _ 3 3 2 _ H ^ 
179B 1.90 8724 5.71 "4.33 L ^ ~ 7 . 2 8 5.69 i T g ^ ^ ^ 
179C 2.57 7.45 5.24 4.04 2.57 ~ 6 . 5 9 5.22 3 . 9 0 ^ ~ F ~ ~ 
179D — 2 . 7 0 7.93 6.46 —4.53 2.10 7.02 —6.43 — 4 3 6 _ _ G _ 
179G 1.07 2.45 1.63 L40 1.07 2.17 L ^ 1.35 — H ~ 
179H Z51 6.01 —4.02 144 2.57 5.32 ^ 2.35 — F " ^ 
179J 1.20 Z45 1.85 —2.91 L20 2.17 " l . 8 5 2.81 G 
142D 21.81 18.28 8.30 —9.39 ^1.81 16.17 ~8.27 9.05 B 
143C 2.75 r 0 2 4.73 "5.26 ^ ~ 6 . 2 1 4.71 S m ~ G ~ 
GAPDH(2)|l9.29 |2i.8l |l9.36 |20.01 |l9.29 |l9.29 |l9.29 |l9.29 
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Table 2.4 (opposite page) Origins of the gene fragments obtained in the 
RNA fingerprint generated by RAP-PCR. Only the fragments listed in Table 2.3 were 
presented. * : The nomenclatures of the fragments are given by the primer no. followed by 
the order of fragment in the fingerprint (from top to bottom and left to right). 
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Fragment* Arbitrary primer used Time point from which the fragments obtained 
(hours after biochanin A induction of JCS cells) 
lA 1 0  
lB 1 0 
f6A — 16 5 
l6C 一 16 0 
l6E 16 5 
l6F 16 一 18 
20 — 20 18 
^ A 64 0 
64C 64 一 0 
74B — 74 18 
74C 74 18 
^2 82 18 
85C — 85 18 
87B 一 87 18 
%9 一 89 1 
l07C — 107 18 “ 
lQ7D — 107 18 
T07E 一 107 1 
l07I 一 107 18 
T070 一 107 18 
T07P 一 107 1 
274 — 274 1 “ 
nOF — 130 5 
noj 一 130 0 
l3QK 一 130 5 
l31B — 131 5 “ 
T39D — 139 5 -
l78E 一 178 1 
l78Q 一 178 5 
178R — 178 18 
l78S — 178 5 
l78T 178 18 
l79A — 179 1 -
p79B 179 18 
� 7 9 C 179 0 
l79D — 179 5 
179G 179 — 1 
l79H 179 0 
I"79J 179 18 
f42D 一 142 18 
f43C 143 0 
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2.4.6 Subcloning of differentially amplified 
fragments 
41 fragments selected in the first round of dot blot hybridization screening 
showing putative differential expression in JCS cells at different time points after 
biochanin A induction were reamplified and subcloned into pBluescript SK-. 10 
white colonies were randomly selected from the LB plate containing ampicillin, IPTG 
and X-gal for each fragment and confirmed to have the differentially amplified 
fragments inserted by PCR as described in section 2.3.5.1.5. Examples of 
confirmation by PCR were shown in Figure 2.8. The clones with differentially 
amplified fragments subcloned were verified by the size of the PCR products. 5 of 
the 41 fragments, namely 16C, 87B, 89, 1071，1070, were not subcloned successfully. 
As some of fragments reamplified from the RAP-PCR isolated fragments isolated 
from RAP-PCR were found to be heterogeneous, as shown in section 2.4.4, 
subcloning of all of the differentially amplified fragments resulted in various plasmids 
cloned with insert of different sizes. Clones with insert sizes the same as that of the 
differentially amplified fragment were selected for further analysis. Some of the 
clones with size of insert different from that of the differentially amplified fragments 
were also selected. Finally, 43 plasmid subcloned with the differentially amplified 
fragments were recovered and subjected to second round of dot blot hybridization 
screening. 
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Figure 2.8 Subcloning of differentially amplified fragments and 
confirmation of plasmid clones with inserts by PCR. For each differentially amplified 
fragment subcloned and transformed, 10 white colonies were randomly picked from the 
selective plate (LB containing 100 i^g /ml ampicillin, IPTG and X-gal) and resuspended in 
100 ^1 ddH2O. 10 i^l ofthe bacterial lysate was used as template in a 50 i^l PCR reaction as 
described in section 2.3.5.1.5. 15 i^l of the PCR products were electrophoresed in 2% 
agarose gel. M : 1 kb DNA size marker. 
» 
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2.4.7 Second round of dot blot hybridization 
screening 
43 subcloned fragments were subjected to second round of dot blot 
hybridization screening to eliminate false positive arouse from the heterogeneous 
nature of the differentially amplified fragments isolated from RAP-PCR. The second 
round of dot blot hybridization screening was performed as same as the first round dot 
blot hybridization screening. The amount of the cDNAs of JCS cells at different time 
points after biochanin A induction were normalized by detecting the gene expression 
level of GAPDH by RT-PCR for 25 and 30 cycles, as shown in Figure 2.9. The 
expression level of GAPDH among the various cDNA samples were constant. The 
efficiency of labelling cDNA with ^^ P estimated by scintillation counting were about 
53%-74% (Table 2.5). The subcloned fragments, and also, the differentially 
amplified fragments, were reamplified by touchdown PCR and dot-blotted on four 
• 32 
membranes identically. The membranes were then hybridized with the P labelled 
cDNA of JCS cells at 0 hour, 1 hour, 5 hours and 18 hours respectively (Figure 2.10). 
The hybridization signals of each dot were quantified and then normalized by the 
control GAPDH (Table 2.6) 15 subcloned fragments showed more than two-fold 
difference in intensities ofhybridization signal among the membranes hybridized with 
cDNA probes of JCS cells at different time point after biochanin A induction were 
selected for further characterization. Several types of expression patterns were 
observed. 8 of fragments were steadily upregulated. 2 fragments was constitutively 
expressed but upregulated at 18 hours after biochanin A induction while 2 of the 
fragment were steadily upregulated but downregulated at 18 hours after biochanin A 
induction. 2 of the fragments were transiently upregulated at 1 hour and 18 hours 
while one of the fragments was downregulated at 5 hours after biochanin A induction. 
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Figure 2.9 Normalization of the amount of cDNA probes used in the second 
round of dot blot hybridization screening by the detection of the gene expression of 
GADPH analyzed by RT-PCR. The cDNA probes were normalized as in the first round of 
dot blot hybridization screening. The GAPDH gene transcripts were amplified for 25 cycles 
using equal volume of the purified cDNA derived from the total RNA of JCS cells induced 
with biochanin A for 0 hour (Oh), 1 hour (lh), 5 hours (5h) and 18 hours (18h) as template. 
15 ]A of PCR products were loaded on a 2% agarose gel and electrophoresed. The size of the 
PCR product of GAPDH gene transcript was 452 bp. M = 1 kb DNA size marker. 
JCS cells incubated First eluted Second eluted % of 
with biochanin A for fraction/ fraction/ incorporation* 
cpm^ cpm^  
Ohour 451,609.97 4,177,761.50 74.01 
Thour 452,256.62 —3,003,850.00 53.14 
Thours 530,663.31 —3，924,110.00 59.16 
18 hours 479,890.00 4,064，935.00 67.76 
Table 2.5 Efficiency of labelling cDNA with ^^ P in the second round of dot 
blot hybridization estimated by scintillation counting. As same as that in first round dot 
blot hybridization screening, the cDNA was labelled with ^^ P by random labelling and the 
unincorporated cDNA was removed by the NICK column. The labelling efficiency of cDNA 
with 32p was estimated by scintillation counting, a : fraction eluted contained both 
unincorporated and incorporated cDNA with ^¥. b: fraction eluted contained cDNA 
incorporated with ^^ P. * % of incorporation = (b/10 i^l x 400 pJ)/(aAO ^1 x dilution factor x 
100 i^l) X 100%. 
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Figure 2.10 Second round of dot blot hybridization screening of subcloned 
differentially amplified fragments. 43 subcloned differentially amplified fragments and 36 
of the corresponding differentially amplified fragments were reamplified and dot blotted on 
four nylon membrane identically with equal amounts and each membrane was hybridized 
with one of the cDNA derived from total RNA of JCS cells at 0 hour, 1 hour, 5 hours, 18 
hours after biochanin A induction, as that performed in the first round dot blot hybridization 
screening. The autoradiography was obtained after exposure of the membrane to a X-ray film 
for 12 hours. The circled dots are the control 'GAPDH'. 
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\ —^~^~~^~~~p^^~^~~i 
Fragment OD x area (mm ) * 
# raw data normalized data 
Oh | lh |5h |l8h Oh |lh |5h |l8h 
201 0.70 0.88 0.25 [ 5 9 0.70 0.97 0.30 0.90 ~ E 
64C2 0.31 0.56 "o.85 0 .28—0.31 0.61 0.99 0.42 C 
74B6 1.61 3.74 6.35 5 ^ ~ " 1.61 4.12 7.40 8.11 A 
74C1 T?73 2.83 3.30 2.76 1.73 3.12 3.84 4.21 A 
822 1.59 —2.29 2.23 3.26 " l . 59 2 . 5 2 ~ 2 . 6 0 4.97 A 
T07C10 11.31 13.75 73.57 17.55 11.31 15.lT~15.8Q 26.76 B 
107D7 0.94 1.02 "2.43 L53~~0.94 1.12 2.84 2.33 A 
T^7E10 15.76 18.55 ^ 5 9 21.40 "l5.76 20.43 25.15 32.63 A “ 
T07P5 0.23 —0.30 0.18 0.99 0.23 ^ ~ ~ 0 . 2 1 1.50 B 
130F8 0.24 0.81 0.26 ^ 0 0.24 "0.90 0.30 ^ D 
13QJ3 0 ^ 2 0.83 1.33 0 ^ 0.42 0.91 1.55 ^ ~ ~ C 
131B2 ^ ~ ~ 1 . 5 1 1.61 1.26 —0.83 1.67 1.87 1.93 A 
139D1 ^ 7 0.56 0.60 0.80 0.27 0.61 0.70 一T^ ~~~ A 
178E3 2.72~~3.91 3.77 3.64 2.12 430 4.40 ^ 5 5 " ^ A 
178S1 0.87 1.77 0.90 1.87 0.87 1.94 1.04 — 2 M ~ ~ D 
GAPDH 14.09 12.79 '12.10 9.24 14.09 R 0 9 14.09 " T ^ 
Table 2.6 Densitometric analysis of hybridization signals of the second 
round of dot blot hybridization screening. The hybridization signals of each dot were 
quantified by densitometry and normalized with the control GAPDH as in the first round of 
dot blot hybridization screening. Only those subcloned fragments showing more than two-
fold differences in intensities of hybridization signal among the four membranes were 
presented. * Expression pattems : (A) Steadily upregulated. (B) Constitutively expressed but 
upregulated at 18 hours after biochanin A induction. (C) Steadily upregulated but 
downregulated at 18 hours after biochanin A induction. (D) Transiently upregulated at 1 hour 
and 18 hours. (E) Downregulated at 5 hours after biochanin A induction. # : The 
nomenclatures of the fragments are given by the primer no. followed by the order the 
fragment in the fingerprint and then the clone no. 
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2.4.8 Comparison ofthe first and second round 
of dot blot hybridization screening 
In comparing the expression pattem of the putative differentially expressed 
fragments as revealed in the first round and second round of dot blot hybridization 
screening (see Table 2.7), the expression pattem of some of the subcloned fragments 
as revealed in second round screening was the same as that of their corresponding 
differentially amplified fragment in the first round screening while others have similar 
trends of change in expression (up-regulated or downregulated) but varied in time 
point of change in both round of screening. However, there were subcloned 
fragments appeared to have completely different expression pattem as shown in 
second round of screening in compared with that of their corresponding differentially 
amplified fragment as revealed in first round screening. In addition, some of the 
expression pattem of the differentially amplified fragment as revealed in second 
round screening were different from that predicted in first round screening. 
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Fragment ” �r o u n d screening Subcloned fragment 2"^ round screening 
20 Transient upregulation at 201 Transient down at 5 
18 hours hours 
64C Upregulation starting 64C2 Biphasic upregulation at 
from 1 hour 1 hour and 5 hours 
74B Steady upregulation 74B6 Steady upregulation 
74C Steady upregulation 74C1 Upregulation start from 
1 hour 
82 Upregulation at 18 hours 822 Upregulation at 18 hours 
107C Steady upregulation 107C10 Upregulation at 18 hours 
starting from 5 hours 
107D Steady upregulation 107D7 Upregulation from 5 
starting from 5 hours hours 
107E Upregulation at 18 hours 107E10 Steady upregulation 
107P Steady upregulation 107P5 Upregulation at 18 hours 
starting from 5 hours 
130F Steady downregulation 130F8 Biphasic upregulation at 
1 hour and 18 hours 
130J Steady upregulation 130J3 Biphasic upregulation at 
1 hour and 5 hours 
131B Upregulation starting 131B2 Upregulation starting 
from 1 hour from 1 hour 
139D Upregulation starting 139D1 Steady upregulation 
from 1 hour 
178E Transient upregulation at 178E3 Upregulation starting 
1 hour from 1 hour 
178S Upregulation starting 178S1 Biphasic upregulation at 
from 1 hour 1 hour and 18 hours 
Table 2.7 Comparison of the expression patterns of the selected fragments 
in the first and second round of dot bot hybridization screening 
‘ Chapter 2 
+ 108 
2.5 Discussion 
2.5.1 RNA fingerprinting by arbitrarily primed 
PCR 
With the use of the modified RAP-PCR method, 184 differentially amplified 
fragments were isolated in the original fingerprint. After two rounds of dot blot 
hybridization screening to eliminate the false positive, 15 fragments were shown to be 
differentially expressed during the biochanin A induction of JCS cells. 
The reproducibility of the RNA fingerprinting by arbitrarily primed PCR has 
been the main concem of those using the method. The number, reproducibility and 
intensity of amplified band in a fingerprint are affected by several factors, including 
the efficiency of the interaction of the cDNA sequence with the primer during the 
initial step, the efficiency of amplification once the primer has been incorporated into 
the sequence, which are functions of several parameters of the specific conditions of 
the reaction, including the concentration of salts, annealing temperature, template 
concentration, primer length and primer sequence (McClelland, et al., 1994). In order 
to get a reproducible fingerprint, the conditions of the amplification shoould be 
optimized and highly standardized and intemal control should be included (Welsh, et 
al., 1995; Ellsworth, et al., 1993). Duplicate reactions could also ensure that bands 
are reproducible. This reproducible improves the chance that differences observed in 
the amplified band pattem are more likely to reveal the differentially expressed genes, 
thus reducing the number of false positive. Besides, the relative intensities of bands 
amplified in a single arbitrarily primed PCR fingerprinting correlate with the initial 
template concentration. Therefore, when performing RAP-PCR, careful adjustment 
should be made to normalize the quality and concentration difference in RNA. 
Otherwise, the intensities of the differentially amplified products are likely to reflect 
concentration or quality differences rather than alterations in abundance. One of the 
method to control for the difference in RNA concnetration in RAP-PCR reaction is 
that the RNA template can be fingerprinted at several concentrations. Only those 
differentially amplified products that were present or absent at all concentrations were 
considered to be differentially expressed genes (McClelland, et al., 1994; Welsh, et 
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al., 1995). In our RAP-PCR experiment, the amount of various RNAs isolated from 
induced JCS cells at different time points were normalized by detecting the expression 
of the housekeeping gene, GAPDH. 
Many variations of the basic RNA fingerprinting strategy have been proposed 
for their own purposes. In our modified RAP-PCR protocol, oligo dT was used in the 
reverse transcription for the first strand cDNA synthesis. The first strand cDNA was 
then fingerprinted using a single arbitrarily chosen primer and five initial low 
stringency PCR cycles, incorporating the arbitrary primer at both ends for subsequent 
PCR amplification at high stringency. The number of low stringency cycles in the 
first strand cDNA synthesis was increased to five rather than one low stringency cycle 
in the original RAP-PCR protocol to increase the chance of primer annealing. It was 
reported that using oligo dT in the reverse transcription followed by the use of an 
arbitrary primer in the subsequent low stringency PCR amplification on average 
generated products that are larger in size than those generated by using an arbitrary 
primer in both reverse transcription and the subsequent low stringency PCR 
amplification steps (Welsh, et al., 1992). Using oligo dT for the first strand cDNA 
synthesis allow selection of the polyadenylated mRNA molecules, which favors the 
fingerprinting of the mRNA rather than the structural RNAs. However, the amplified 
products generated using oligo dT in the reverse transcription and single arbitrary 
primer in the initial low stringency cycle would mainly derive from the 3，end of the 
transcripts. The 3'end often contain noncoding regions, moreover, their sequences are 
poorly conserved between species and gene families. It poses the hurdle in 
identifying the corresponding gene from the sequence databases. Hence it becomes 
necessary to screen cDNA libraries to identify the corresponding gene. In the original 
RAP-PCR protocol, arbitrary primer is used for both first and second strand cDNA 
synthesis, though the reverse transcription is not selective for mRNAs, the products 
are not derived from the 3'end of the RNA transcripts but the coding regions (Welsh, 
etal., 1995). 
According to the original RAP-PCR protocol, the resolution of the RAP-PCR 
products is achieved by means of polyacrylamide gel electrophoresis and visualized 
by autoradiography as the products are radioactive labelled during the RAP-PCR 
reaction. About ten to twenty products were detected by each primer. While 1.5% 
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synergel and ethidium bromide staining were employed in our protocol to resolve the 
RAP-PCR products, we could still observe up to twenty bands, of sizes between 
approximately 200 bp to 2000 bp, detected by each primer, that the resolving power is 
comparable to the original protocol using polyacrylamide gel and radioactive 
labelling. Using 1.5% synergel and ethidium bromide staining provide a much easier 
and faster way to resolve the amplification products and avoid using radioactive 
labelling, though the resolving power may be somewhat lower than that of 
polyacrylamide gel. Those amplification products corresponding to low abundance 
transcripts may be missed in view of the comparatively low sensitivity of the ethidium 
bromide staining. On the other hand, fragments much larger than those resolved on 
polyacrylamide gel can also be detected. 
2.5.2 Limitation of RAP-PCR 
Despite the versatility and simplicity of the strategy, it is generally 
acknowledged that one of the limitation of RNA fingerprinting is the under-
representation of rare transcripts. Each mRNA species represents in an arbitrarily 
primed PCR fingerprint is a function of the efficiency of the interaction with the 
primer and the abundance of the message. In most cases, when the efficiencies of 
interaction of two sequences of the mRNAs with the primers are equal, more 
abundant RNA may be predorminately amplified. On the other hand, those mRNA 
with more complex sequence have better matches with the primer and are 
preferentially amplified. Therefore, the abundance of the mRNA species and 
complexity of the sequence have opposing effect on the efficiency of the 
amplification in an arbitrarily primed PCR. In fact, even when a rare mRNA species 
have a perfect match with the primer, its resulting amplified products would not 
dorminate over other products amplified from more abundant mRNA that have poorer 
matches. In this sense, the RNA transcripts in low abundance are under-represented 
in the fingerprint generated by RAP-PCR. This limitation of RAP-PCR would be a 
problem in the detection of differentially expressed genes as many differentially 
expressed genes of interest are in low abundance. At the moment, it is not clear how 
efficiently we were sampling the low abundance transcripts (Welsh, et al., 1992). 
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2.5.3 Two rounds of dot blot hybridization 
screening 
As with any technique of RNA fingerprinting, there is a significant rate of 
false positives generated by the PCR step. Also, no part of the gel is entirely free 
from PCR products unrelated to the differentially amplified product of interest and 
contamination of the recovered fragments by unrelated products is a frequent 
problem. Therefore, efficient screening procedure to eliminate the false positives is a 
must. Two rounds of dot blot hybridization screening adopted in our study allow 
quick examination of false positives and confirmation of differential expression of 
many differentially amplified samples simultaneously. Though the procedures of the 
two rounds of dot blot hybridization screening was the same, they are not redundant, 
because the first round of dot blot hybridization screening was aimed to first eliminate 
the false positives generated during the RAP-PCR, while the second round screening 
was aimed at identifying the right clone but not the co-migrated PCR products 
unrelated to the recovered differentially amplified product. The dot blot screening 
strategy was also termed 'reverse northern blotting’，as the procedure was just the 
reverse of that of northern blotting, in which the amplified products were dot blotted 
on a nylon membrane and probed with the radioactive labelled cDNA. The strategy 
could then establish that the cDNA isolated corresponds to a differentially expressed 
gene and confirm differential expression. In the dot blot hybridization screening, as 
the amount of the amplified products dot blotted was in excess and the amount of 
various cDNA probes at different time points were normalized, any difference in 
intensities of the hybridization signal among the dot of amplified products at different 
time points was due to the variation of the amount of the gene transcripts. After the 
first round of dot blot hybridization screening, among 184 isolated differentially 
amplified fragment only 41 shown differential expression, demonstrating the 
occurrence of false positive among the recovered differentially amplified products. 
After subcloning of the differentially amplified fragments, only 15 were revealed as 
differentially expressed upon second round of dot blot screening. The expression 
pattem of some of the subcloned differential amplified products showing differential 
expression upon second round of dot blot hybridization screening was different from 
that of the original differentially amplified fragment revealed by first round of dot blot 
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hybridization screening (Table 2.7). Furthermore, the expression pattem of some of 
the differentially amplified products as revealed in the first round and second round of 
screening were also different. The differentially amplified products recovered from 
the original fingerprint were heterogeneous while the subcloned differentially 
amplified products are pure fragment, which therefore may have different expression 
patterns of individual amplified products revealed in the two rounds of screening. 
Moreover, with regard to the second round of dot blot hybridization screening, not all 
species of the plasmid clone subcloned with the same differentially amplified 
fragment were examined, only those plasmid clones with insert size corresponding to 
that of the original recovered differentially amplified fragment were included in the 
second round screening. Some of the positive differentially expressed genes may be 
missed upon the subcloning procedure and the second round of screening. 
Furthermore, the kinetics of the hybridization of the two rounds of screening, 
including the hybridization condition, the quality of the various cDNA probe at 
various time points, were varied among individual experiment and affect the final 
hybridization signal, though effort has been made to carefully control every variable 
that may affect the conditions of the hybridization. Also, the duration of the exposure 
of the X-ray film, the densitometric processing of the raw data of the hybridization 
signal and the normalization of the hybridization signal of each differentially 
amplified product with that of the control GAPDH would varied among the two 
rounds of screening. All together, these variation may cause the difference in 
presentation of the hybridization signal of each differentially amplified products and 
that their expression pattem revealed in the two rounds of screening. Therefore, the 
differential expression and expression pattem of those differentially amplified 
fragments screened by two rounds of dot blot hybridization screening remained to be 
further confirmed. To facilitate the study of the expression of the fragments, further 
characterization of the isolated differentially amplified fragments by sequencing is 
then subsequently needed. 
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CHAPTER T H R E E . . • 
Characterization of the isolated gene fragments 
3.1 Introduction 
3.1.1 Automated DNA sequencing and analysis 
The isolated differentially amplified gene fragments screened after two rounds 
of dot blot hybridization were further characterized by sequencing and homology 
search with the GenBank to determine whether they correspond to known genes and 
eluicidate their putative function. 
Two approaches can be used for the rapid sequencing of DNA. Fisrt, the 
Maxam and Gilbert procedure, uses four different chemical reactions to cleave the 
radioactive-labelled DNA chains specifically at As, Gs, Cs, or Cs + Ts. Second, the 
Sanger procedure, uses an enzymatic procedure. Four population of fragments that 
terminate at As, Gs, Cs, and Ts are generated with labelled primer and specific chain 
terminators, the 2‘,3 ‘-dideoxyriboucleoside triphosphates. In both procedures, four 
separate parallel reactions are carried out, each of which generates a set of fragments 
terminating at one of the four bases (A, G, C, or T) in DNA. Based on the length of 
the generated fragments, these fragments are then separated by polyacrylamide gel 
electrophoresis (Garden, et al, 1991). Within the last few years, the two rate-limiting 
steps in the DNA sequencing process, that are the detection of DNA fragments and 
the translation of the fragment pattem into sequence information, can be automated. 
This automation not only can boost up the sequencing process, but also lessen the 
labor required and increases the number of clones that can be analyzed simultaneously 
(Watson, et al., 1992). 
The automated DNA sequencing system we used is the ALF DNA analysis 
system (ALF DNA sequencer), which is designed for high-volume sequencing 
projects and fragment analysis. The principle of the ALF DNA sequencer is based on 
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an adaptation of Sanger dideoxy methodology and on the device developed at the 
European Molecular Biology Laboratory in Heidelberg Germany by Dr. Wilhelm 
Ansorge and Dr. Brian Sproat (Figure 3.1). In the system, a primer labelled with 
fluorescein at its 5'-terminus is annealed to the template. Combining this non-
radioactive approach, and the standard one label, four tracks Sanger sequencing 
methodology, the system also make use of advanced features, like continuous on-line 
detection and direct storage of data in computer readable data. Four separate 
populations of fluorescently labelled chain-terminated fragments are generated by 
extending the fluorescent primer with T7 DNA polymerase using standard dideoxy 
sequencing method. The reactions are then loaded into four adjacent lanes on a 
sequencing gel and electrophoresed. Upon electrophoresis, each DNA fragment 
migrates and passes a fixed laser beam, fluorescent signals are then detected and 
t 
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Figure 3.1 ALF DNA sequencer. An electrophoresis system, a power system, 
and a computer system constitutes the ALF DNA sequencer. A laser beam is projected across 
the entire width of the sequencing gel at a fixed distance. Fluorescently labelled fragments 
separated by the gel become excited and emit fluorescence light when entering the beam, the 
signals from each single lane are continuously detected by an optical detector. The sequence 




3.1.2 GenBank and the BLAST homology search 
The availablity of DNA and protein sequence databases has made a great 
contribution to sequence analysis, that by comparing novel sequence data with 
sequence of known genes showing significant homology, researchers are able to 
elucidate the putative funtion of a uncharacterized gene. 
There are several nucleotide sequence databases maintained by various 
institutions, EMBL (the European Molecular Biology Laboratory in Heidelberg, 
Germany), GenBank (the US National Institutes of Health genetic sequence 
databases, maintained by the US National Center for Biotechnology Information, 
NCBI) and DDBJ (the DNA database of Japan). Another database, database for 
'expressed sequence tags' (dbest), is also available at NCBI. Expressed sequence tags 
are partial cDNA sequences. The average length of an EST is about 300-400 
nucleotides. The sequences of these fragments are not well characterized. 
Nevertheless, ESTs is the most rapidly expanding source of new human sequences. 
EST data can be applied in the identification of previously unknown gene products for 
genetic mapping purposes and the development of profiles of sequence that are 
differentially expressed in particular cell types or developmental stages for the study 
of the mechanisms of tissue differentiation and ontogeny (Boguski, 1993). 
Homology between sequence of known gene in databases and the query 
sequence are identified by using software that compares the query sequence with 
every sequence in the database. A variety of servers is provided for homology 
searching, including Basic Local Alignment Search Tool (BLAST)(Altschul, et al., 
1990)，provided by the US National Center for Biotechnology Information (NCBI), 
FASTA and BLITZ, provided by the European Bioinformatics Institute (EBI) 
database searches. FASTA and BLAST may be used to search both nucleotide and 
protein sequence databases, while BLITZ can only be used for protein sequence 
searches. Five different versions of BLAST are available : BLASTP (protein query 
searching a protein database), BLASTX (all six ORFs of a nucleotide query searching 
a protein databases), BLASTN (nucleotide query searching a nucleotide database), 
TBLASTN (protein query searching all six ORFs of a nucleotide database) and 
TBLASTX (all six ORFs of a nucleotide query searching all six ORFs of a nucleotide 
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databases) (Paterson, et al., 1996). Here, the homology search of the nucleotide 
sequences and the deduced amino acid sequences was performed with the NCBI's 
entrez browser, which are capable of searching a variety of databases. It uses a non-
redundant data set generated from the principal sequence databases, namely EMBL, 
GenBank, DDBJ, and the protein sequence databases, SWISS-PROT, PIR and the 
Protein Data Bank. The BLASTN and BLASTX servers were used in sequence 
similarity searching. The dbEST database was also attempted with BLASTN for 
homology search. 
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3.2 Materials 
3.2.1 Selected recombinant plasmids 
15 plasmid-subcloned RAP-PCR amplified fragments were selected for further 
studies, namely, 201，64C2, 74B6, 74C1, 822, 107C10, 107D7, 107E10, 107P5, 
130F8, 130J3, 131B2, 139D1, 178E3 and 178S1. 
3.2.2 Chemicals 
Acetic acid, glacial Ajax 1 
Acrylamide, ALF grade Pharmacia 17-1300-01 
Ammonium persulfate� Pharmacia 17-1311-01 
Bis-acrylamide, ALF grade Phamacia 17-1304-01 
Boric acid, ALF grade Pharmacia 17-1322-01 
EDTA, disodium salt, ALF, grade Pharmacia 17-1324-01 
Isopropanol 二， ,^  Ajax 424 
Sodium acetate — S i ^ a S8750 
T E M | D (tetramethy! ethylenedianune) ¥harmacia 17-1312-01 
Tris, ALF grade Pharmacia 17-1321 -01 
Urea, ALF grade Pharmacia 17-0889-01 
3.2.3 Reagents 
Ba^iH i : r、饮'^Pharmacia 27-0868-03 
Pst I Pharmacia 27-0886-03 
One-phor-all buffer Pharmacia 
JL ..-..::�,:*>.... . . ... 
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3.2.4 Kits (See Appendix A2) 
Autoread sequencing kit Pharmacia XY-056-00-02 
3.2.5 Solutions 
0.6X TBE buffer 120 ml pfthe 10X TBE stock solution was taken 
and made up to 2 litres with distilled water. 
� � \ ' ' , - -
‘ 7 , �� -, s,,. tW�41 • 
、、* ？ \.‘、 > 
10X Tris Borate Acetate(TBE) 121.14 g ofTris, 51.32 g ofboric acid and 3.72 g 
(lM Tris, 0.83 M Boric acid, EDTA, disodium salt were dissolved in 1 litre 
10 mM EDTA) distilled water and filtered through a 0.45 |im filter. 
Filtering helps to ensure that this stock solution 
remains in solution with minimal precipitation. 
6% acrylamidegd with 7M 24 ml acrylamideA)is-acrylamide solution, 33.6 g 
urea . � \v - urea, ALF grade and 4.8 ml 10X TBE were mixed 
� —, ,^  and dissolved in 80 ml distilled water with stirring. 
;:».rw,- ^ The gel solution was filtered through a 0.22 |am pore 
..，.[“ •, size membrane. 
Acrylamide/bisacrylamide 95 g acrylamide and 5 g bis-acrylamide were 
solution at a ratio 19 :1 in a dissolved in 500 ml distilled water. 
20% solution 
Ammonium persulfate — 10%) 10% (w/v) ammonium persulfate solution was made 
(w/v) solution . � �1 . up in distilled water and stored in aliquots at -20°C. 
.ii::F... •.:、^麵纏纖讓籠！藝藝觀謹二. .： •："•••. 
••"'ffeii.； :::::½¾!¾¾¾¾¾!!¾¾¾¾¾:. ,#h-:-.. .,:::_5.. 
^ ‘、二 ; � “ A * ， r ; � r � ” 
Sodium acetate, 3M, pH 4.8 3M sodium acetate solution with pH adjusted by 
glacial acetic acid. 
3.2.6 Equipment 
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3.3 Methods 
3.3.1 Preparation of selected recombinant 
plasmid DNA 
The recombinant plasmid DNA subcloned with fragments isolated from RNA 
fingerprinting by arbitrarily primed PCR and screened by two rounds of dot blot 
hybridization was prepared by QIAGEN plasmid kit as described in section 2.3.5.1.1. 
3.3.2 Restriction digestion of recombinant 
plasmid DNA 
The size of the insert of the subcloned plasmid was verified by restriction 
digestion with Bam HI and Pst I. BamH I and Pst I restriction are the sites closest to 
the cloning site. A 20 i^l reaction mixture containing 5000 U BamH I，5000 U Pst I, 
IX one-phor-all buffer and 1.5 [ig plasmid DNA was incubated at 37° for 1 hour. The 
plasmid DNA was then electrophoresed with a 1 kb DNA size marker on a 1% 
agarose gel containing IX TAE buffer and 0.5 p-g/ml ethidium bromide and visualized 
under UV irradiation. 
3.3.3 Automated DNA sequencing 
3.3.3.1 Primer annealing to template 
Each plasmid clone was sequenced by both M13 universal primer and M13 
reverse primer. A 40 i^l reaction was set up containing 32 ^1 of 5 i^g plasmid DNA 
and 8 p,l of 2 M NaOH and incubated at room temperature for 10 minutes. 7 i^l of 
3M sodium acetate (pH 4.8)，4 i^l of distilled water and 120 i^l of 100% ethanol was 
then added to the reaction mixture and incubated on ice for 15 minutes. The 
precipitated DNA was collected by centrifugation at 14,000 rpm for 15 minutes at 
4°C. The DNA pellet was rinsed with 70% ethanol, recentrifuged for 10 minutes and 
the supernatant was carefully removed. The DNA pellet was vacuum dried by 
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speedVac for approximately 5 minutes. The pellet was resuspended in 10 i^l of 
distilled water. 2 i^l of 2.1 fiM fluorescent M13 universal or M13 reverse primer and 
2 i^l annealing buffer was added to the resuspended template. The reaction mixture 
was preheated at 65°C for 10 minutes and placed the reaction mixture at room 
temperature for at least 10 minutes. 1 |Lil of extension buffer and 3 i^l ofDMSO were 
added to the reaction mixture. Then proceed immediately to the sequencing reaction 
described below. 
3.3.3.2 Sequencing reactions 
2.5 ^1 of the 'A Mix', 'C Mix', 'G Mix，and 'T Mix’ was prewarmed in four 
separate microcentrifuge tubes at 37°C for at least one minute. The four sequencing 
mixes are maintained at 37°C during the manipulations which follow. T7 DNA 
polymerase was 2-fold diluted with the enzyme dilution buffer. 2 ^1 of 4U/^il diluted 
T7 DNA polymerase was added to the annealing reaction and mixed thoroughly. 4.5 
t^l of this reaction mixture was then immediately added into each of the prewarmed 
sequencing mixes and incubated for 5 minutes at 37°C. 5 fj_l of stop solution was 
added to each reaction and mixed gently. The reactions were heated at 90°C for 2 — 3 
minutes and immediately chilled on ice until loading into the sequencing gel. 
3.3.3.3 Polyacrylamide gel electrophoresis 
The gel cassette was assembled according to the manufacturer's manual. 80 
ml of 6% polyacrylamide gel solution with 70 ^1 TEMED and 280 i^l 10% 
ammonium persulfate was casted in the gel cassette. The gel was then left to 
polymerize at room temperature. 
After polymerization, 5 - 10 |il of each of the samples were then loaded into 
the wells sequentially in the following order : A, C, G and T. The electrophoresis 
started with the conditions : voltage = 1500V, current = 38 mA, power = 34 W, 
temperature at 40°C and laser power = 3 mW. The sampling interval was 2 second 
and the running time was 8 hours. 
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3.3.3.4 Data analysis by ALF manager and DNAsis 
During electrophoresis, each fluorescently labelled fragment was excited by 
the fixed laser beam and was detected immediately by the photodetectors. The signals 
from each lane are converted into digital data and are manipulated by the computer. 
The base sequences of each lane can be detemined after processing the data 
automatically by ALF Manager ver 2.6 software. Each base in the sequence can be 
identified by a corresponding intensity peak. This serial orders of the peaks constitute 
the base sequence of the clone. The sequencing results of each clone were then 
analyzed by DNAsis (Hitachi). 
The sequences of the plasmid clone extended from the M13 universal primer 
and the reverse primer were connected by the contig manager function in the DNAsis 
program with the overlapping sequence merged and generated a consensus sequence. 
The partial sequence of plasmid vector, that is the sequence between the sequencing 
primer and the cloning site, was then removed from the consensus sequence. The 
resulting sequence was the sequence of the subcloned differentially amplified 
fragment and was ready for further analysis. 
3.3.4 Sequence homology search with databases 
Homology search with the nucleotide sequence of the putative differentially 
expressed fragments isolated from RNA fingerprinting by arbitrarily primed PCR 
subcloned in the plasmids against the nucleotide sequence databases was done by 
searching a variety of databases using the Entrez Browser provided by the US 
National Center for Biotechnology Information, NCBI with the BLASTN and 
BLASTX servers. The NCBI's Entrez Browser uses a non-redundant data set 
generated from the principal sequence databases, namely EMBL, GenBank, DDBJ, 
SWISS PROT,，PIR and the Protein Data Bank. BLASTN was also attempted with 
the dbEST database at the NCBI. The sequence homology search can be done on the 




3.4.1 Spectrophotometric analysis of selected 
recombinant plasmid DNAs subcloned with 
differentially amplified fragments 
15 plasmid DNAs subcloned with the differentially amplified fragments 
selected in second round dot blot hybridization screening were prepared by QIAGEN 
plasmid kit. Absorbance of UV light at 260 nm and 280 nm were measured to 
analyze the yield and purity of the DNA samples (Table 3.1). The ratio of absorbance 
at 260 nm to absorbance at 280 nm among the samples were mainly around 1.7. The 
amount o fDNA obtained was measured by absorbance at 260 nm. An optical density 
of 1 unit corresponds to approximately 50 ug / ml for double stranded DNA. The yield 
of plasmid DNA prepared from 25 ml culture among the samples was varied from 10 
-135 ^ig. 
Clone OP260 OD280 OD260/OD280 | Yidd (pig)* 
201 — 0.319 0.188 T ^ 79.75 
64C2 0.304 0.19 1.60 T6.00 “ 
^ 6 0.539 — 0.343 1.57 134.75 
74C1 0.375 0.220 L70 93.75 一 
822 0.348 0.203 1.71 ^ 7 . 0 0 “ 
1^7C10 0.285 — 0.168 1.70 71.25 
1Q7D7 — 0.279 0.165 1.69 — 69.75 
1^7E10 "0.323 — 0.192 1.68 80.75 
107P5 0.062 0.037 1.68 — 15.50 
l ^ F 8 0.229 0.134 — 1.71 57.25 
130J3 0.088 0.052 \ _ ^ 22.00 一 
131B2 0.041 0.025 1.64 To.25 “ 
~[39D\ 0.07 0.042 1.67 l 7 . 5 0 “ 
~mE3 0.121 — 0.07 1.73 30.25 
178S1 0.104 I 0.183 1.76 26 
Table 3.1 Spectrophotometric analysis of plasmid DNA subcloned with 
differentially amplified fragments. The yields ofthe plasmid DNA samples were calculated 
:OD260 X 50 ^g/ml X dilution factor x total volume where the dilution factor was 100. 
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3.4.2 Restriction digestion of selected 
recombinant plasmid DNA 
The prepared plasmid DNAs subcloned with differentially amplified 
fragments were digested by restriction enzyme BamH I and Pst I to verify the sizes of 
the subcloned fragments. BamH I and Pst I were the restriction sites closest to the 
cloning site Sma I, therefore digestion of the plasmid DNA by the two restriction 
enzymes would give an excised fragments with approximate size of the subcloned 
fragments. 1.5 ^g of the digested plasmid DNA were loaded on 1% agarose gel 
(Figure 3.2). Some of the recombinant plasmid yielded two excised fragments after 
restriction digestion. The sizes of the subcloned fragments were estimated by the 
migrating distance of the fragment, by comparing the standard curve Logio (base pair) 
against the migrating distance of the fragment constructed by the lkb DNA size 
marker loaded in parallel. The sizes of the subcloned differentially amplified 
fragment were summarized in Table 3.2. 
F r a g m e n t M 301 64C2 74B6 74C1 822 107CK) 107D7 107E10 107P5 130F8 BOB 131B2 139D1 178E3 178S1 
r m m m ^ 
-L^HHHDI 
1018^  ^ r ^ ^ ^ ^ H ^ H V I ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B I ^ ^ H 
^ | | | ^ ^ ^ ^ ^ 9 P I ^ | p f 
. i f i ^ ^ ^ ^ ^ H ^ 3 | ^ ^ 2 
201 二 ^^^^^H|^^^^^^^^^^^^^^^^^^^^^^^^^^H 
Figure 3.2 Restriction digestion of selected plasmid DNA subcloned with 
differentially amplified fragments. 1.5 ^g of the recombinant plasmid DNA was digested 
by BamH I and Pst I for 1 hour at 37°C and fractionated on a 1% agarose gel. 
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Fragment Size (bp), estimated by BamH I & Pst I digestion 
201 ^  
"64C2 305 
74B6 "807 
74C1 - 684 一 
822 724 
107C1Q ^ 0 7 
"l07D7 584 
lQ7ElQ "684 
107P5 Undetermined  
130F8 '470 





Table 3.2 Summary of the sizes of the subcloned differentially amplified 
fragments estimated by restriction digestion. 1.5 p,g ofthe recombinant plasmid DNA was 
digested by BamH I and Pst I and electrophoresed on a 1% agarose gel. The size of the 
differentially amplified fragment was estimated by comparing the standard curve Logio(base 
pair) against migrated distance of the fragment constructed by the 1 kb DNA size marker 
loaded parallel on the gel. 
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3.4.3 Sequences ofthe subcloned differentially 
amplified fragments 
15 of the recombinant plasmids subcloned with differentially amplified 
fragment showing putative differential expression in second round of dot blot 
hybridization screening were sequenced by the automated DNA sequencer, the ALF 
DNA analysis system, following the standard dideoxy sequencing protocol using the 
autoread sequencing kit (Pharmacia). Each of the recombinant plasmid was 
sequenced in both direction, using either the M13 primer or reverse primer provided 
by the sequencing kit. About 300-500 nucleotide can be sequenced in each reaction 
with a few ambiguity bases. The sequences of the recombinant plasmid extended 
from the M13 universal primer and the reverse primer were connected by the contig 
manager function of DNAsis software with the overlapping region merged and 
generated a consensus sequence of the subcloned differentially amplified fragment as 
described in section 3.3.3.4. The sequences of the 15 subcloned differentially 
amplified fragment were shown in Figure 3.3. Most of the sequence of the 
differentially amplified fragment could only be partially determined because of their 
large size and the limitation of the sequencing system, the sequence of the two ends of 
the fragments read by the sequencing reaction using M13 universal and reverse primer 
did not contain overlapping bases and could not be merged together. The sequence of 
the two ends of these differentially amplified fragment were then connected in the 
same orientation with a gap in between. Upon analysis of the sequences by the contig 
manager function in DNAsis, the sequence of fragment 107P5 was found to be 
resulted from recombination, in which the sequence extended from the M13 universal 
primer was the same as a part of that extended from the reverse primer. 
Chapter 2 
今 1 2 7 
Figure 3.3 (following 16 pages) Nucleotide sequence of the subcloned 
differentially amplified fragment. 15 of the subcloned differentially amplified fragments 
were sequenced by the ALF DNA system following the standard dideoxy sequencing 
protocol. Each of the plasmid clone was sequenced by both M13 universal primer and 
reverse primer. The two ends of the sequences of the plasmid clone extended from the M13 
universal and reverse primer were connected by the contig manager function in the DNAsis 
software. The consensus sequences of the differentially amplified fragments were presented. 
************ indicates the arbitrary primer used to generate the fragment in the RAP-PCR. 
> indicates the specific upper primer and <— indicates the lower primer used in 
RT-PCR for confirmation of differential expression as described in section 4.3.4. gap-
indicates the undetermined sequence of unknown size in between the fragment. For 
ambiguity code see appendix A1. 
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Fragment 107C10 
Estimated length of the fragment ： 422 bp (Table 3 . 2 ) 
Arb itrary primer ： GAA CAG AGG TGC GTC TGG TGC 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * > 
GAACAGAGGT GCGTCTGGTG CCGGGAAGTG CAGAGCCAAA TGATCAGTTG GAGTGACCAC 
CTTGTCTCCA CGCAGACCAC GGCCCTTCAC GTCTCGGTTT ACTAGTCAAC CTCACTGGTG 
70 80 90 100 110 120 
AGTGCCTRGA GTGAGTCCAC ATTTTGGGGA ATATGATACC AGATCAGTAT AGGAGTGAGG 
TCACGGAYCT CACTCAGGTG TAAAACCCCT TATACTATGG TCTAGTCATA TCCTCACTCC 
130 140 150 160 170 180 
GAGTGGCTGG AGTCCAGCTC ATGGCATGAT GCCGCCCACA TTTGGAGTGA ACCTTTCCTC 
CTCACCGACC TCAGGTCGAG TACCGTACTA CGGCGGGTGT AAACCTCACT TGGAAAGGAG 
190 200 210 220 230 240 
CTCAGCCAAA TCTCTATGGA AACACCCTCA CAGACACATC CAGAAGTGTG CTTTCTAGAT 
GAGTCGGTTT AGAGATACCT TTGTGGGAGT GTCTGTGTAG GTCTTCACAC GAAAGATCTA 
250 260 270 280 290 300 
AACTGGAAGG GCAGTCAAGT TGACAATCAA GATTTAGCTC TCATCCCACC CAGCCCATCT 
TTGACCTTCC CGTCAGTTCA ACTGTTAGTT CTAAATCGAG AGTAGGGTGG GTCGGGTAGA 
<r  
310 320 330 340 350 360 
GGGGTCAGGC YCCARACATC CYGCATGGAA CCCAGACTCC TWGGGAGAAG SACAGCCATK 
CCCCAGTCCG RGGTYTGTAG GRCGTACCTT GGGTCTGAGG AWCCCTCTTC STGTCGGTAM 
370 380 390 400 410 420 
AAACAATKGC TAGAATCCAC ACACGGTKAG GGCTGCCAGC TGCTCCARAT TTCCATGATC 
TTTGTTAMCG ATCTTAGGTG TGTGCCAMTC CCGACGGTCG ACGAGGTYTA AAGGTACTAG 
430 440 450 460 470 480 
ATGCACCAGA CGCACCTCTG TTC  
TACGTGGTCT GCGTGGAGAC AAG  
* * * * * * * * * * * * * * * * * * * * * * * 
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Fragment 107C10 
Estimated length of the fragment :305 bp (Table 3 . 2 ) 
Arb itrary primer : AGG ATA AGA AGC AAG TGA GGT TG 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * " ^ 
AGGATAAGAA GCAAGTGAGG TTGACTAGAG CAAATCCTGG ACATTGTTCT AATGAGATGG 
TCCTATTCTT CGTTCACTCC AACTGATCTC GTTTAGGACC TGTAACAAGA TTACTCTACC 
70 80 90 100 110 120 
AAAGCAGAAG AAAAAMCAAG TGAAGAATTC CAGGGAATCT TGGGAAGTGA GCATTGTATC 
TTTCGTCTTC TTTTTKGTTC ACTTCTTAAG GTCCCTTAGA ACCCTTCACT CGTAACATAG 
130 140 150 160 170 180 
CCTTTAAGGA ACCACCAGTG ACTTTATATT TTCAACAAAA ATAAAATCCA TACTTGCTAA 
GGAAATTCCT TGGTGGTCAC TGAAATATAA AAGTTGTTTT TATTTTAGGT ATGAACGATT 
190 200 210 220 230 240 
AATGTTTATA ATGTGACTTC AAAAGCAGTT TTAATGTAAG TTCCAAGAGA TGGCAATATC 
TTACAAATAT TACACTGAAG TTTTCGTCAA AATTACATTC AAGGTTCTCT ACCGTTATAG 
250 260 270 280 290 300 
ATGCAGACAA ACAATCAACT CGCCCGGACT GCAGTCTCAG CCCACCACAG TAATTGTGTG 
TACGTCTGTT TGTTAGTTGA GCGGGCCTGA CGTCAGAGTC GGGTGGTGTC ATTAACACAC 
310 320 330 340 350 360 
AACTTGCACA AATGATATGA TCTCCATGTA TGTACTTCTC TAAGTCACCG AGCGAGTGGG 
TTGAACGTGT TTACTATACT AGAGGTACAT ACATGAAGAG ATTCAGTGGC TCGCTCACCC 
370 380 390 400 410 420 
TATAACAATT GTAAGAGAAT GTGGGTGAGA AACGTGACAT TCCACGGAAA CAGTTCACAC 
ATATTGTTAA CATTCTCTTA CACCCACTCT TTGCACTGTA AGGTGCCTTT GTCAAGTGTG 
430 440 450 460 470 480 
GGTTCCATCA AGAAAAAAAC TCGGTAAATG CCAGCCAGTA TCTTCACACT ATGGCGCTCT 
CCAAGGTAGT TCTTTTTTTG AGCCATTTAC GGTCGGTCAT AGAAGTGTGA TACCGCGAGA 
<r  
490 500 510 520 530 540 
TGACATTCAC TGGGCTCCAA CCTCACTTGC TTCTTATCCT  
ACTGTAAGTG ACCCGAGGTT GGAGTGAACG AAGAATAGGA  




Estimated length of the fragment ：807 bp (Table 3 . 2 ) 
Arb itrary primer : TTG ACA AGC AAT GAG ACG ATG AG 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * 
TTGACAAGCA ATGAGACGAT GAGAAACCAG GGAAGCGAGT CATCGGCCCA CGAAAGAAAT 
AACTGTTCGT TACTCTGCTA CTCTTTGGTC CCTTCGCTCA GTAGCCGGGT GCTTTCTTTA 
70 80 90 100 110 120 
- - - — 
TCCACTGGGA TGACACCATC AGAACTTTGT TATGTAACCT TGTTGAGATC AAATTGGGAT 
AGGTGACCCT ACTGTGGTAG TCTTGAAACA ATACATTGGA ACAACTCTAG TTTAACCCTA 
130 140 150 160 170 180 
GCTATGAATT AGAGCCAAAT AAAAGCCAGT CTGCTGAGGA TTATCTTAAA TCCTTCATGG 
CGATACTTAA TCTCGGTTTA TTTTCGGTCA GACGACTCCT AATAGAATTT AGGAAGTACC 
190 200 210 220 230 240 
AGACGGAGGT GAAGCCACTG TGGCCTAAGG GCTGGATGCA GGCAAGAATG CTTTTTAAGG 
TCTGCCTCCA CTTCGGTGAC ACCGGATTCC CGACCTACGT CCGTTCTTAC GAAAAATTCC 
250 260 270 280 290 300 
AAAGCCGGAG TGTGCATAAT CATCTTACTT CTGCTCCGGC AAAGAAAAaG GTGATTCCTG 
TTTCGGCCTC ACACGTATTA GTAGAATGAA GACGAGGCCG TTTCTTTTtC CACTAAGGAC 
310 320 330 340 350 360 
CATCAAAACC CAAaGTTCAA GGMGKGT--- gap--- ---CACGGSY CAGACATCCA 
GTAGTTTTGG GTTtCAAGTT CCKCMCA GTGCCSR GTCTGTAGGT 
370 380 390 400 410 420 
TYGTTGCCTC AGCCAGCTCT AGCTCAGCAC CAGCCCAAGA AACCATCTGC CTTGATGACT 
ARCAACGGAG TCGGTCGAGA TCGAGTCGTG GTCGGGTTCT TTGGTAGACG GAACTACTGA 
430 440 450 460 470 480 
CCCTCGATGA AGACCTTTCT TTCCCCTCAG CCTCAMTGGA TCTTGTATCT GAAGCTCTAG 
GGGAGCTACT TCTGGAAAGA AAGGGGAGTC GGAGTKACCT AGAACATAGA CTTCGAGATC 
490 500 510 520 530 540 
CTGTCWWCAA CATGGGAACA AgGGCCCCTC CAGTTGGTTC AAGGCTAAAT GTGCCAACTA 
GACAGWWGTT GTACCCTTGT TcCCGGGGAG GTCAACCAAG TTCCGATTTA CACGGTTGAT 
550 560 570 580 590 600 
CAAAACCTCG KCCAGGACCK AGAGAAGAAA AGCTAGCAAG TATCATGAGT AAGTTACCAC 
GTTTTGGAGC MGGTCCTGGM TCTCTTCTTT TCGATCGTTC ATAGTACTCA TTCAATGGTG — 
610 620 630 640 650 660 
TGGCTACTCC CAAAAAACTA GATTCTACTC AGACTGCTCA CTCATCGTCT CATTGCTTGT 
ACCGATGAGG GTTTTTTGAT CTAAGATGAG TCTGACGAGT GAGTAGCAGA GTAACGAACA 
* * * * * * * * * * * * * * * * * * * * * 
670 680 690 700 710 720 
CAA  
GTT  
* * * 
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Fragment 1 0 7 C 1 0 
Estimated l ength of the fragment ：684 bp (Table 3 . 2 ) 
A r b i t r a r y primer ： TTG ACA AGC AAT GAG ACG ATG AG 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * _ ^ 
TTGACAAGCA ATGAGACGAT GAGCGAGCAA CAAATCAGGT GCTGACATGC CACGCTAAGG 
AACTGTTCGT TACTCTGCTA CTCGCTCGTT GTTTAGTCCA CGACTGTACG GTGCGATTCC 
70 80 90 100 110 120 
TGTATATAAG CAGCACCATT TTCTGGGGTT SGGGGTYTTC CTTCTGATGA AGCAATAAAG 
ACATATATTC GTCGTGGTAA AAGACCCCAA SCCCCARAAG GAAGACTACT TCGTTATTTC 
130 140 150 160 170 180 
CTTTGCTGAA GAAGAATCCG GTTGTCCTAG TGTATTCTTG CTGGCGAGAC ATWAGCTCGG 
GAAACGACTT CTTCTTAGGC CAACAGGATC ACATAAGAAC GACCGCTCTG TAWTCGAGCC 
190 200 210 220 230 240 
gap GTAGACDTGG GCATCTCTCT TCAATAGKAM ACACTGACTT 
CATCTGHACC CGTAGAGAGA AGTTATCMTK TGTGACTGAA 
250 260 270 280 290 300 
TAACTAACTT CCAAAAGGGG TCCATGTCAG GTCTCAACCA TTCTATACCT TAATCTTTGA 
ATTGATTGAA GGTTTTCCCC AGGTACAGTC CAGAGTTGGT AAGATATGGA ATTAGAAACT 
310 320 330 340 350 360 
GTCAGAGTCT CTCTCTGAAM CCTTTTCCGG CTTGGTTAGC CTGGCTTGCC AAATCTCCAT 
CAGTCTCAGA GAGAGACTTK GGAAAAGGCC GAACCAATCG GACCGAACGG TTTAGAGGTA 
370 380 390 400 410 420 
GGAGGTGTCT CCCCTTCTAC TTCCACAGCA CTGGAATTAT AGGTACAAGA TGCTGWGCAT 
CCTCCACAGA GGGGAAGATG AAGGTGTCGT GACCTTAATA TCCATGTTCT ACGACWCGTA 
430 440 450 460 470 480 
GGCTTGTTTA GTGGGTGCTG GGAACCTCAA CTCATCGTCT CATTGCTTGT CAA  
CCGAACAAAT CACCCACGAC CCTTGGAGTT GAGTAGCAGA GTAACGAACA GTT  




Estimated length of the fragment ：724 bp (Table 3 . 2 ) 
Arb itrary primer ： TTG TTG CTC AAA GAG AAG CCA TG 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * _^ 
TTGTTGCTCA AAGAGAAGCC ATGTAGACAA GGTGATAATG AAGCTGGGCA AGACAAGCTC 
AACAACGAGT TTCTCTTCGG TACATCTGTT CCACTATTAC TTCGACCCGT TCTGTTCGAG 
70 80 90 100 110 120 
CAAGGCTTCG GCCGAGATGC GGCAACGAAT GTGGAGCGTG GTGCAGAAGG ACCATCCGGA 
GTTCCGAAGC CGGCTCTACG CCGTTGCTTA CACCTCGCAC CACGTCTTCC TGGTAGGCCT 
130 140 150 160 170 180 
CCGGGAATTA ATTGACCCAT TTCCAATACC TCTGGTCATT ATTGGARGTA AATATGATAT 
GGCCCTTAAT TAACTGGGTA AAGGTTATGG AGACCAGTAA TAACCTYCAT TTATACTATA 
190 200 210 220 230 240 
TTTCCAGGAT TTTGWTCcTG AGAGGAGAAG GTGATATGTA aGACCCTGCG CTTTGTGGCA 
AAAGGTCCTA AAACWAGgAC TCTCCTCTTC CACTATACAT tCTGGGACGC GAAACACCGT 
250 260 270 280 290 300 
CAT gap ---TgACATT GGAAAACTTC AGGCCCACTC ACCTATGGRG 
GTA AcTGTAA CCTTTTGAAG TCCGGGTGAG TGGATACCYC 
310 320 330 340 350 360 
CTGTGGAAAA AGGTGTATGA AMAARCTCTT CCCACCAAAG AGTACCGGCA CCCTGAAGGC 
GACACCTTTT TCCACATACT TKTTYGAGAA GGGTGGTTTC TCATGGCCGT GGGACTTCCG 
370 380 390 400 410 420 
GGTCTAGGAC CCAGCCCGAG ACCCGCAGTA TGCAGAAAGC GAAGTCGATG AGATGAGGGT 
CCAGATCCTG GGTCGGGCTC TGGGCGTCAT ACGTCTTTCG CTTCAGCTAC TCTACTCCCA 
430 440 450 460 470 480 
TCAGAAGGAC CAGGAACTAG AACACTACAA GAGAAGCTCC TCTAAGACCT GGAAGCAAAT 
AGTCTTCCTG GTCCTTGATC TTGTGATGTT CTCTTCGAGG AGATTCTGGA CCTTCGTTTA 
^  
490 500 510 520 530 540 
CGAGCTGGAC TCCTGACCCG CTTCCCTGCT GTGGGCATGG CTTCTCTTTG AGCAACAA.. 
GCTCGACCTG AGGACTGGGC GAAGGGACGA CACCCGTACC GAAGAGAAAC TCGTTGTT. . 
* * * * * * * * * * * * * * * * * * * * * * * * * 
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Fragment 107C10 
Estimated length of the fragment ： 807 bp (Table 3 . 2 ) 
Arb itrary primer ： GAA TTC CCA GTG ATC ATA TGG GTA CC 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * 
TTCCCAGTGA TCATATGGGT ACAGGGGAAA CATTCCTGAA TAGAACAGCA ACGGCTTGTG 
AAGGGTCACT AGTATACCCA TGTCCCCTTT GTAAGGACTT ATCTTGTCGT TGCCGAACAC 
70 80 90 100 110 120 
CTGTAAGATC GAGAATTGAT AAATGGGACT TCATAAAATT GAAAAGCTTC TGCATAGCAA 
GACATTCTAG CTCTTAACTA TTTACCCTGA AGTATTTTAA CTTTTCGAAG ACGTATCGTT 
130 140 150 160 170 180 
AAGACACCAT CAATAAGACA AAAAGACCAC CAACAGTTTG GGAAAGGATG TTTACCTATC 
TTCTGTGGTA GTTATTCTGT TTTTCTGGTG GTTGTCAAAC CCTTTCCTAC AAATGGATAG 
190 200 210 220 230 240 
CCAAATCAGA TAGGGGACTA TTATCCAATA TATATAAAAA aCTCAAGAAG GTGGACTCCA 
GGTTTAGTCT ATCCCCTGAT AATAGGTTAT ATATATTTTT tGAGTTCTTC CACCTGAGGT 
250 260 270 280 290 300 
GAAAATCAAA TAACCCCATT TAAAAATGGG GCTCAGAGCT GAACAAAGAA TTTTCACCTG 
CTTTTAGTTT ATTGGGGTAA ATTTTTACCC CGAGTCTCGA CTTGTTTCTT AAAAGTGGAC 
310 320 330 340 350 360 
_> 
AGGAATACCA AATGGCAGAG AAGCACCTGA AAAAaTGTTC AACATCCTTA ATCATCAGG-
TCCTTATGGT TTACCGTCTC TTCGTGGACT TTTTtACAAG TTGTAGGAAT TAGTAGTCC-
370 380 390 400 410 420 
gap CCTTATCAyC AGGRATGSAA ATCAAAGAAC CCTGAGTCCA 
GGAATAGTrG TCCYTACSTT TAGTTTCTTG GGACTCAGGT 
430 440 450 460 470 480 
CCTCACTCCA GTCAGAATGC TAAGATCAAA ATTCAGGTGA CAGCAGATGC TGGCGAGTGG 
GGAGTGAGGT CAGTCTTACG ATTCTAGTTT TAAGTCCACT GTCGTCTACG ACCGCTCACC 
490 500 510 520 530 540 
ACACTTTGCC CTTCTTAGAA ATgGGAACAA AACACCCATG GAAGGAGTTA CAGAGACAAA 
TGTGAAACGG GAAGAATCTT TAcCCTTGTT TTGTGGGTAC CTTCCTCAAT GTCTCTGTTT 
550 560 570 580 590 600 
ATTTGGAGCT GCGACGAAAG GGTGGACCTT CTAGTGATTG CCATATGCAG GGTTCCATCC 
TAAACCTCGA CGCTGCTTTC CCACCTGGAA GATCACTAAC GGTATACGTC CCAAGGTAGG 
610 620 630 640 650 660 
CATAATCAGC TTCCAAACGC TAACAGCATT GCATACACTA GCAAGATTTT GCTGAAAGGA 
GTATTAGTCG AAGGTTTGCG ATTGTCGTAA CGTATGTGAT CGTTCTAAAA CGACTTTCCT — 
670 680 690 700 710 720 
CCCAGATATA GCTGTCTCTT GTGAGACTGT GCCAGGGCCT AGCAAACACA GAAGTGGATG 
GGGTCTATAT CGACAGAGAA CACTCTGACA CGGTCCCGGA TCGTTTGTGT CTTCACCTAC 
To be c o n t i n u e d . . . 
Chapter 3 
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730 740 750 760 770 780 
CTCACAGTCA GCTCTTGATT TGGTCACACG GCCCCCAATG GAGGAACTAG AGAAAGTACC 
GAGTGTCAGT CGAGAACTAA ACCAGTGTGC CGGGGGTTAC CTCCTTGATC TCTTTCATGG 
* * * * * * 
790 800 810 820 830 840 
CATATGATCA CTGGGAATT  
GTATACTAGT GACCCTTAA  
* * * * * * * * * * * * * * * * * * * * 
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Fragment 107C10 
Estimated length of the fragment :584 bp (Table 3 . 2 ) 
Arbitrary primer ： GAA TTC CCA GTG ATC ATA TGG GTA CC 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * * * _^ 
AATTCCCAGT GATCATATGG GTACAGAGAA CGTTCTTCTC ACTGTGCGTA TCCTGTGTTC 
TTAAGGGTCA CTAGTATACC CATGTCTCTT GCAAGAAGAG TGACACGCAT AGGACACAAG 
70 80 90 100 110 120 
TCCCCTGACA TAGTCCAGAA GGACTCTGTT CAGATGGTTC AATGGCATCA GGGTACTTCA 
AGGGGACTGT ATCAGGTCTT CCTGAGACAA GTCTACCAAG TTACCGTAGT CCCATGAAGT 
130 140 150 160 170 180 
CTATATTAAT GGCACGGRGC CCAAAGAGGG GCAGTGTGTG GTCTCTTTGG AGTTTGCAGC 
GATATAATTA CCGTGCCYCG GGTTTCTCCC CGTCACACAC CAGAGAAACC TCAAACGTCG 
190 200 210 220 230 240 
TAGCATGTAG CACACTTGGA AATACTAAAC TGAACCATTT TCGGATGCCT CAGATAACTA 
ATCGTACATC GTGTGAACCT TTATGATTTG ACTTGGTAAA AGCCTACGGA GTCTATTGAT 
250 260 270 280 290 300 
TCAGTTTTCA GAATATCTCC CAAAACAGGA GCAGGTCCTG CATCAGGTTC TGGCTGCTGA 
AGTCAAAAGT CTTATAGAGG GTTTTGTCCT CGTCCAGGAC GTAGTCCAAG ACCGACGACT 
310 320 330 340 350 360 
GCACWHCAG- gap CCCAAAACAG GAGCAGGTCC TGCATCAGGT 
CGTGWDGTC- GGGTTTTGTC CTCGTCCAGG ACGTAGTCCA 
370 380 390 400 410 420 
TCTKGSKGCT GAGCAGCCTC AGCTCTTGAC CAAAGGACAC CATAGCTGCC ATGGCAAACC 
AGAMCSMCGA CTCGTCGGAG TCGAGAACTG GTTTCCTGTG GTATCGACGG TACCGTTTGG 
430 440 450 460 470 480 
GAGGTAGGTT CTCTGAAAGA AGGAAGTCCC TGGGTGAAAT ACTGTAATAA GGCCATGCCA 
CTCCATCCAA GAGACTTTCT TCCTTCAGGG ACCCACTTTA TGACATTATT CCGGTACGGT 
490 500 510 520 530 540 
CATGCCGCAG GAAACTACTT ACCACAGAGA AGTGAACTCC TGCAACACCA GCAGCCTCTA 
GTACGGCGTC CTTTGATGAA TGGTGTCTCT TCACTTGAGG ACGTTGTGGT CGTCGGAGAT 
550 560 570 580 590 600 
GTCAATGCTG ATTGACCTCA GGACATAACT GGATGTATGA ACAGAGCTGC CCATTGTGAG 
CAGTTACGAC TAACTGGAGT CCTGTATTGA CCTACATACT TGTCTCGACG GGTAACACTC 
610 620 630 640 650 660 
CTGAATATCA GAGCCACCAA ATCCCAAGGA GGTACCCATA TGATCACTGG GAATT  
GACTTATAGT CTCGGTGGTT TAGGGTTCCT CCATGGGTAT ACTAGTGACC CTTAA  
^  




Estimated length of the fragment ： 684 bp (Table 3 . 2 ) 
Arbitrary primer : GAA TTC CCA GTG ATC ATA TGG GTA CC 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * * * 
AATTCCCAGT GATCATATGG GTACAACTTG TCCTGAGTTT GTTCGAGGCC TTGGGTTCAT 
TTAAGGGTCA CTAGTATACC CATGTTGAAC AGGACTCAAA CAAGCTCCGG AACCCAAGTA 
70 80 90 100 110 120 
CCCCAGCACC AGCCCCTGGC TTGAAATGTA AGCCAAACAA AATTGGCAGG ATGTCTCAGA 
GGGGTCGTGG TCGGGGACCG AACTTTACAT TCGGTTTGTT TTAACCGTCC TACAGAGTCT 
130 140 150 160 170 180 
^ 
GGTTAAGAGT ACTTGCTGCC CTTGCAGAGG ACCCAGGTTT GATTCCTAGC AATCATCTGG 
CCAATTCTCA TGAACGACGG GAACGTCTCC TGGGTCCAAA CTAAGGATCG TTAGTAGACC 
190 200 210 220 230 240 
AGGCCAAGAA CCATCTGTGA CTCCAGTTCC AGGGGATCCA ACCTTCTCTT CTGACTGCCA 
TCCGGTTCTT GGTAGACACT GAGGTCAAGG TCCCCTAGGT TGGAAGAGAA GACTGACGGT 
250 260 270 280 290 300 
GGGCACCAGG AAGTCACATG TCAGGCAAGC ACACATGAAG GCAAAAA gap 
CCCGTGGTCC TTCAGTGTAC AGTCCGTTCG TGTGTACTTC CGTTTTT  
310 320 330 340 350 360 
CCCCTTgGGA GGCARAGGCA GGKGGATTTC TGAGTTCGAG GCCAGCCTGG 
GGGGAAcCCT CCGTYTCCGT CCMCCTAAAG ACTCAAGCTC CGGTCGGACC 
370 380 390 400 410 420 
TCTACaAAGT GAGTTCCAGG ACAGCCAGGG CTGTACAGAG AAACCCTGTC TCGGAAAATC 
AGATGtTTCA CTCAAGGTCC TGTCGGTCCC GACATGTCTC TTTGGGACAG AGCCTTTTAG 
<r  
430 440 450 460 470 480 
AAAACTACTT TTCTAGAAGA CCAGAGTCTG ATTTCCAGTA CCCATATGAT CACTGGGAAT 
TTTTGATGAA AAGATCTTCT GGTCTCAGAC TAAAGGTCAT GGGTATACTA GTGACCCTTA 
* * * * * * * * * * * * * * * * * * * * * * * * * * 







Arbitrary primer ： GAA TTC CCA GTG ATC ATA TGG GTA CC 
10 20 30 40 50 60 
AATTGGTACC GGCCCCCCCY CGAGTCGACG GTATCGATAA GCTTGAWAAT CGAATTCCTG 
TTAACCATGG CCGGGGGGGR GCTCAGCTGC CATAGCTATT CGAACTWTTA GCTTAAGGAC 
70 80 90 100 110 120 
CAGCCCATTC CCAGTGATCA TATGGGTACA AAGTATATCT GGGTCCTCTG GAAGAGCAGA 
GTCGGGTAAG GGTCACTAGT ATACCCATGT TTCATATAGA CCCAGGAGAC CTTCTCGTCT 
130 140 150 160 170 180 
TGTTCTTAAC TGCTGAGCCA TTTTTCCAGC CCTCACCAGT ACAATATTAG TAGCTACTTA 
ACAAGAATTG ACGACTCGGT AAAAAGGTCG GGAGTGGTCA TGTTATAATC ATCGATGAAT 
190 200 210 220 230 240 
AAGTGAATCA AAGAAACTCC CTATAACCTT AGGATATCAT GCTATTTTAA AAACAGAAGC 
TTCACTTAGT TTCTTTGAGG GATATTGGAA TCCTATAGTA CGATAAAATT TTTGTCTTCG 
250 260 270 280 290 300 
AGTGTATCTG AGATAAATAC CTGCCCAGCT ACTGAGAGAC TTCCATGCAA AGCTTCTCCC 
TCACATAGAC TCTATTTATG GACGGGTCGA TGACTCTCTG AAGGTACGTT TCGAAGAGGG 
310 320 330 340 350 360 
TTTGTTTTCC CAAGAGAGTC ATTAAGGTAC CCATATGATC ACTGGGAATT  
AAACAAAAGG GTTCTCTCAG TAATTCCATG GGTATACTAG TGACCCTTAA  
* * * * * * * * * * * * * * * * * * * * * * * * * * * 
Sequence extend from 1 3 5 q 
reverse primer ^ 
^ Sequence extended 





Estimated length of the fragment ： 470 bp (Table 3 . 2 ) 
Arb itrary primer ： CTG TTC AGT CCA CTT GCC ATT G 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * 
CTGTTCAGTC CACTTGCCAT TGAAGAGGTA TAAAGAGTCA ACAAGCCTCA CTTGGATGAT 
GACAAGTCAG GTGAACGGTA ACTTCTCCAT ATTTCTCAGT TGTTCGGAGT GAACCTACTA 
70 80 90 100 110 120  
^ 
ATTTTACAAG CCGGTATAGT TGAACTCTCC AAGGTGGTTG TTTTTCTTGT AGGATAGTCC 
TAAAATGTTC GGCCATATCA ACTTGAGAGG TTCCACCAAC AAAAAGAACA TCCTATCAGG 
130 140 150 160 170 180 
TGTACAACAC TCCCTTAACT TATTTTAATT TGTATGGAAA AACTATTATA TGTTTTTGTT 
ACATGTTGTG AGGGAATTGA ATAAAATTAA ACATACCTTT TTGATAATAT ACAAAAACAA 
190 200 210 220 230 240 
TCCGTATGAT CTGGGAAAAG ACACTCAGAA CACTTCATGA GAGAAAATAA TGATAGCGAT 
AGGCATACTA GACCCTTTTC TGTGAGTCTT GTGAAGTACT CTCTTTTATT ACTATCGCTA 
250 260 270 280 290 300 
CAAAATGATG ATGATGATAA TTAACATTTA TCATGTTTTA CACTGTACCA CAAACTATGC 
GTTTTACTAC TACTACTATT AATTGTAAAT AGTACAAAAT GTGACATGGT GTTTGATACG 
310 320 330 340 350 360 
AGCACCTTTC CATGGACTTA AAGACTTCTC TTTCTATCAC TATTTTACAG AAACATGACC 
TCGTGGAAAG GTACCTGAAT TTCTGAAGAG AAAGATAGTG ATAAAATGTC TTTGTACTGG 
370 380 390 400 410 420 
CTCAAAGCTG TGGAAGTCAT TGTCCTAATA CATTCCACGT TCCATCACCA ATGGCAAGTG 
GAGTTTCGAC ACCTTCAGTA ACAGGATTAT GTAAGGTGCA AGGTAGTGGT TACCGTTCAC 
• * * * * * * * * * * * * * 
430 440 450 460 470 480 
ACTGAACAG  
TGACTTGTC  
* * * * * * * * * 
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Fragment 107C10 
Estimated length of the fragment ：650 bp (Table 3 . 2 ) 
Arb itrary primer ： CTG TTC AGT CCA CTT GCC ATT G 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * _^ 
CTGTTCAGTC CACTTGCCAT TGAGGAGTTA TAGGATGGGG ATTAGTTTTT GTCTGCTCTG 
GACAAGTCAG GTGAACGGTA ACTCCTCAAT ATCCTACCCC TAATCAAAAA CAGACGAGAC 
70 80 90 100 110 120 
TGAATTGAAC CCAGGACATT GCACAACCTG CTATGTAAGT ATTCTCCCAC TGTGCCCTCA 
ACTTAACTTG GGTCCTGTAA CGTGTTGGAC GATACATTCA TAAGAGGGTG ACACGGGAGT 
130 140 150 160 170 180 
TCCCCTATTA CTTTTAAAAA ATTCAACTGA TGGTTACAAA TGCTTATGCT ACAAGATATT 
AGGGGATAAT GAAAATTTTT TAAGTTGACT ACCAATGTTT ACGAATACGA TGTTCTATAA 
190 200 210 220 230 240 
YTTATAAGGG RGGCATGAGC AAATTGAGAG AGAGGATGGT GGCCAAAGAG CTTAGTTCTT 
RAATATTCCC YCCGTACTCG TTTAACTCTC TCTCCTACCA CCGGTTTCTC GAATCAAGAA 
250 260 270 280 290 300 
GGTGTGCTTG TAGTAGTTGG AGCAGCAACA GAAAGAAGAA A gap  
CCACACGAAC ATCATCAACC TCGTCGTTGT CTTTCTTCTT T  
310 320 330 340 350 360 
ARGAGGTAAG CCARGGAGGT GGAAGTGGCT ACAGCCTSCC ArGGATTTAT GGTGGAGGGT 
TYCTCCATTC GGTYCCTCCA CCTTCACCGA TGTCGGASGG TyCCTAAATA CCACCTCCCA 
370 380 390 400 410 420 
GGAGAGCTAT GAGTTCAATC CAACTCCAAA GTAGCCTTTG GAGGGTGGTA AGTGGGAAGA 
CCTCTCGATA CTCAAGTTAG GTTGAGGTTT CATCGGAAAC CTCCCACCAT TCACCCTTCT 
430 440 450 460 470 480 
TGTCATCCAA TTTGCATTTT AAAAAGATCA CTTTGTCAGG TGTGTGGAGA ATGGATTAGA 
ACAGTAGGTT AAA.CGTAAAA TTTTTCTAGT GAAACAGTCC ACACACCTCT TACCTAATCT 
490 500 510 520 530 540 
GGGGGAAAAG AATGGACTCT GAAATAACAG CTAAGAGTCC ATCATGGAGT GATACTGATG 
CCCCCTTTTC TTACCTGAGA CTTTATTGTC GATTCTCAGG TAGTACCTCA CTATGACTAC 
550 560 570 580 590 600 
AGGAATGTGG GTGGGTAGAT TTGAAGAATG TTCTGGAAGT AGAGCTACTG CTACACCACA 
TCCTTACACC CACCCATCTA AACTTCTTAC AAGACCTTCA TCTCGATGAC GATGTGGTGT 
<r  
610 620 630 640 650 660 
AGGGAAGGCT GAA.GGACCAA TGGCAAGTGG ACTGAA  
TCCCTTCCGA CTTCCTGGTT ACCGTTCACC TGACTT  
* * * * * * * * * * * * * * * * * * * * * 
Chapter 3 
今 1 4 0 
Fragment 107C10 
Estimated length of the primer ：579 bp (Table 3 . 2 ) 
Arb itrary primer ： TTC CCA TGA CTT CAA ATC CAA CC 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * 
TTCCCATGAC TTCAAATCCA ACCAAGGAAT TTTCCCCAGC GGACTTCAGT GTGTAACCAT 
AAGGGTACTG AAGTTTAGGT TGGTTCCTTA AAAGGGGTCG CCTGAAGTCA CACATTGGTA 
70 80 90 100 110 120 
> 
TTTAATTGGC GTGTATGACC TACAGACAGG CCTGCCCCTA ATGGGAGTCA TCAATCAGCC 
AAATTAACCG CACATACTGG ATGTCTGTCC GGACGGGGAT TACCCTCAGT AGTTAGTCGG 
130 140 150 160 170 180 
TTTTGCATCC CAAACCTAAC TACTTTAAGG TGGAGGGACA GTGCTACTGG GGCCTTTCGT 
AAAACGTAGG GTTTGGATTG ATGAAATTCC ACCTCCCTGT CACGATGACC CCGGAAAGCA 
190 200 210 220 230 240 
ACATGGGGAC AACATCCATT CCCTGCARCT CGCAWCTCTA AARGCG gap 
TGTACCCCTG TTGTAGGTAA GGGACGTYGA GCGTWGAGAT TTYCGC  
250 260 270 280 290 300 
TaDCGTCtTC TCCCGCGGCA GGGGCTGGCT ACAAGAGcCY YCTGTGTAAT 
AtHGCAGaAG AGGGCGCCGT CCCCGACCGA TGTTCTCgGR RGACACATTA 
310 320 330 340 350 360 
CCAAGGCTTG GCTGACATTT ACATCTTCTC CAGAGGACAC CACGTACAAG TGGGACTCCT 
GGTTCCGAAC CGACTGTAAA TGTAGAAGAG GTCTCCTGTG GTGCATGTTC ACCCTGAGGA 
370 380 390 400 410 420 
GTGCCGCCCA CGCCATTCTG AGGGCCATGG GTGGGGGCAT TGTGGACATG AAAGAGTGCT 
CACGGCGGGT GCGGTAAGAC TCCCGGTACC CACCCCCGTA ACACCTGTAC TTTCTCACGA — 
430 440 450 460 470 480 
TAGAGAGAAG TCCAGACACG GGGTTGGATT TGAAGTCATG GGAA  
ATCTCTCTTC AGGTCTGTGC CCCAACCTAA ACTTCAGTAC CCTT  




Estimated length of the fragment :807 bp (Table 3 . 2 ) 
Arbitrary primer ： TCC TGC AGA GCC AGA TTA TCT CTC 
10 20 30 40 50 60 
************************ 今 
CTGCAGAGCC AGATTATCTC TCTGTAATTC TGTCCTTGTG GCTGTGAGGC GAGTTAAGAG 
GACGTCTCGG TCTAATAGAG AGACATTAAG ACAGGAACAC CGACACTCCG CTCAATTCTC 
70 80 90 100 110 120 
CACTGAGTGT CTGCTGCCTA TAGCTATGGA CAGACCAGCT TAGCACACTT TTGTTCTAAG 
GTGACTCACA GACGACGGAT ATCGATACCT GTCTGGTCGA ATCGTGTGAA AACAAGATTC 
130 140 150 160 170 180 
TTCCTGGGTG CAGTTCTGAA AGATGGCCAC AAGAGGTGCC ATTTCTGAGC AGDVTCCACT 
AAGGACCCAC GTCAAGACTT TCTACCGGTG TTCTCCACGG TAAAGACTCG TCHBAGGTGA 
190 200 210 220 230 240 
GCTCTCTGTT TAGACTCAGG CCAAAATGAT tGAAAGGGTG CTTCATTTCT AGAAGGGAAG 
CGAGAGACAA ATCTGAGTCC GGTTTTACTA aCTTTCCCAC GAAGTAAAGA TCTTCCCTTC 
250 260 270 280 290 300 
TCGGGTATCC GATGTCATTA AACTGGAAAT ATTT ---gap AGGAAT 
AGCCCATAGG CTACAGTAAT TTGACCTTTA TAAA TCCTTA 
310 320 330 340 350 360 
GAAAGTAAGG ARACATAGGT CAGTTGGTAA AGTGCATGCC YGCCMCATAA GCATGAGGAC 
CTTTCATTCC TYTGTATCCA GTCAACCATT TCACGTACGG RCGGKGTATT CGTACTCCTG 
370 380 390 400 410 420 
CTGAGTTGAG CCCTAAAACC CACATACAGA GATGATATGT GCATGGTAGT GCAGTCTTTT 
GACTCAACTC GGGATTTTGG GTGTATGTCT CTACTATACA CGTACCATCA CGTCAGAAAA 
430 440 450 460 470 480 
GCTCCCAGGA CCACAGAGAC AGAGGTCAGG TGCCTGGGTC TTGCTGGCCA GGCATTCCAG 
CGAGGGTCCT GGTGTCTCTG TCTCCAGTCC ACGGACCCAG AACGACCGGT CCGTAAGGTC 
490 500 510 520 530 540 
TGAAGGCAGA GGAACATGAC TTATTCAGTA AAGCCGTGCC ATGCAAGCAT GAGAGTCTGT 
ACTTCCGTCT CCTTGTACTG AATAAGTCAT TTCGGCACGG TACGTTCGTA CTCTCAGACA 
<r  
550 560 570 580 590 600 
GTCCCATCCC GAGCAGCAAT GTGAGAATGA AGCTGAGCCC TGGGAAACAG TTGTGAGATA 
CAGGGTAGGG CTCGTCGTTA CACTCTTACT TCGACTCGGG ACCCTTTGTC AACACTCTAT 
* * * * * * 
610 620 630 640 650 660 
ATCTGGCTCT GCAGGA  
TAGACCGAGA CGTCCT  




Estimated length of the fragment ： 496 bp (Table 3 . 2 ) 
Arbitrary primer ： CTC ACC ATT ATC TTT ACT CAG TG 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * * * 
CTCACCATTA TCTTTACTCA GTGGGAAGAA GGTTATAAAC AGGAGGGGCC CAGTAAAACC 
GAGTGGTAAT AGAAATGAGT CACCCTTCTT CCAA.TATTTG TCCTCCCCGG GTCATTTTGG 
70 80 90 100 110 120  
^ 
TAAGGATATA TAGAAATTCA GAGAACATGG GACCATGTAA GTCAGAGTCA CTAGATGTTT 
ATTCCTATAT ATCTTTAAGT CTCTTGTACC CTGGTACATT CAGTCTCAGT GATCTACAAA 
130 140 150 160 170 180 
CATGGAGGAA GTTGCTTTCC AAGGAAATAA CAATTATAAA GGGAAWTTYM ATACCAAGAA 
GTACCTCCTT CAACGAAAGG TTCCTTTATT GTTAATATTT CCCTTWAARK TATGGTTCTT 
190 200 210 220 230 240 
TACTTCAAA.T TGSTTARCGG GGTGRATGGG ATGCATTCTA AAGGAGGCTC CAA.CCACCTG 
ATGAAGTTTA ACSAATYGCC CCACYTACCC TACGTAAGAT TTCCTCCGAG GTTGGTGGAC 
< 
250 260 270 280 290 300 
TCATAGGAGG ATGGGACTCA AAATGGCTTA TGTTAGATAA GCTGACAGCA CTGAGTAAAG 
AGTATCCTCC TACCCTGAGT TTTACCGAAT ACAATCTATT CGACTGTCGT GACTCATTTC 
* * * * * * * * * * * * * * * * 
310 320 330 340 350 360 
ATAATGGTGA G  
TATTACCACT C  




Estimated length of the fragment ： 305 bp (Table 3 . 2 ) 
Arb itrary primer ： CTC ACC ATT ATC TTT ACT CAG TG 
10 20 30 40 50 60 
* * * * * * * * * * * * * * * * * * * * * * * * * • 
CTCACCATTA TCTTTACTCA GTGGGGGTTC CTCTGTCAGA CTTGGTCATC AGTCCCAGTA 
GAGTGGTAAT AGAAATGAGT CACCCCCAAG GAGACAGTCT GAACCAGTAG TCAGGGTCAT 
70 80 90 100 110 120 
CACAGGTGCA GATCAGTGAC AGAACATGGG CAAAGAAAGC AGTGGGGAGG CAGGCTCTAG 
GTGTCCACGT CTAGTCACTG TCTTGTACCC GTTTCTTTCG TCACCCCTCC GTCCGAGATC 
130 140 150 160 170 180 
GGGGATGACC TGGAAGAGAT GGACAGGAGA AAGTGGCCAA GGATAAAAGG ATGGTGCTAC 
CCCCTACTGG ACCTTCTCTA CCTGTCCTCT TTCACCGGTT CCTATTTTCC TACCACGATG 
190 200 210 220 230 240 
AGAGAGTTGA TGCCCCTTGA TTGCTGTAGG GGAACTAGGC ATGCTCACTG AGTAAAGATA 
TCTCTCAACT ACGGGGAACT AACGACATCC CCTTGATCCG TACGAGTGAC TCATTTCTAT 
— * * * * * * * * * * * * * * * * 
250 260 270 280 290 300 
ATGGTGAG  
TACCACTC  
* * * * * * * * 
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3.4.4 Sequence analysis ofthe subcloned 
differentially amplified fragments 
The nucleotide sequences of the 15 subcloned differentially amplified 
fragment except fragment 107P5 were compared with the Genbank, EMBL, DDBJ, 
and PDB databases. Deduced amino acid sequences were compared with the CDS 
translations of the GenBank database and the amino acid sequences form the PDB, 
SwissProt, Spupdate and PIR databases. In both cases, the BLAST server (BLASTN 
and BLASTX) provided by the National Center for Biotechnology Information 
(National Library of Medicine, National Institute of Health) was used for the 
sequence analysis. The dbEST database provided by the NCBI was also compared by 
the BLASTN server. The results of searching the databases by BLASTN and 
BLASTX having significant homology with the differentially amplified fragment 
were shown in Figure 3.4 and summarized in Table 3.3. Among the 14 sequences of 
the differentially amplified fragment, only 5 matched with the known genes in the 
databases with significant homology while others were considered as novel genes. 
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Figure 3.4 (following 10 pages) Alignment of sequence homology search of 
differentially amplified fragments with known sequences. The nucleotide and the deduced 
amino acid sequences of the fragments were matched with the known sequences in the 
GenBank database which is maintained by NCBI, using the BLASTN and BLASTX program. 
Only alignment with significant homology were shown. 
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Fragment: 74B6 (before the gap) 
Length : 327 bp 
Program: BLASTX 
Database: Non-redundant GenBank+EMBL+DDBJ+PDB 
>giI726044 (U19346) VT4 [Homo sapiens] 
Length = 344 
Plus Strand HSPs: 
Score = 211 (97.1 bits), Expect = 5.3e-40, Sum P(2) = 5.3e-40 
Identities = 41/61 (67%), Positives = 48/61 (78%), Frame = +3 
Query: 138 NKSQSAEDYLKSFMETEVKPLWPKGWMQARMLFKESRSVHNHLTSAPAKKKVIPASKPKV 317 
NK+Q+ ED +K F++ EVKPLWPKGWMQAR LFKESR H HLTS AKKKV+ SK KV 
Sbjct: 193 NKAQAWEDCVKGFLDAEVKPLWPKGWMQARTLFKESRRGHGHLTSILAKKKVMAPSKIKV 252 
Query： 318 Q 320 + 
Sbjct: 253 K 253 
Score = 147 (67.6 bits), Expect = 5.3e-40, Sum P(2) = 5.3e-40 
Identities = 27/51 (52%), Positives = 37/51 (72%), Frame = +3 
Query: 3 DKQ*DDEKPGKRVIGPRKKFHWDDTIRTLLCNLVEIKLGCYELEPNKSQSA 155 
D++ D+EK G+R++GPRKKF W+D IR LLC +V+IKL +LE N A 
Sbjct: 147 DEEEDEEKGGRRIMGPRKKFQWNDEIRELLCQWKIKLESQDLERNNKAQA 197 
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Fragment Gene identity  
74B6* VT4 protein 
822* Soares mouse p3NMF19.5 Mus musculus cDNA clone 332667 5’ 
822印 EST192054 Normalized rat muscle, Bento Soares Rattus sp. 
107C10 Mouse LlMd-A13 repetitive sequence I Mouse LlMd-A2 repetitive 
sequence  
107E10^' Mouse B1 repeat 2.7 kb downstream from c-mos oncogene 
131B2 musculus inositol polyphosphate 1 -phosphatase mRNA 
Table 3.3 Summary of the result of sequence homology search of the 
isolated differentially amplified fragment with the nucleotide and amino acid sequence 
databases. Only those fragements shared significant homology with the known sequences 
were listed. *: specify the fragment before the gap; ^: specify the fragment after the gap (see 




3.5.1 Sequence analysis of the isolated gene 
• 
fragment 
The 15 subcloned differentially amplified fragments were sequenced (Figure 
3.3). Most of the fragments were not completely sequenced except 201, 64C2, 107P5, 
130F8, 178E3, 178S1. Nevertheless, an average of 300 bp sequence of the two ends 
of the fragments were determined. Upon analysis of the sequences of the fragments, 
the sequence of 107P5 shown to be resulted from recombination (Figure 3.3). Such 
phenomenon may be due to the errors in the subcloning procedure. Therefore, no 
further analysis of this cloned fragment was done. 
The partial sequence of the subcloned differentially amplified fragment 
obtained by automated sequencing were matched with the available nucleotide and 
protein sequence database in order to predict their possible gene function. Among 14 
of the subcloned differentially amplified fragment thus far sequenced, five fragments 
were matched with known nucleotide or amino acid sequences available in the 
sequence databases (Table 3.3). 
The deduced amino acid sequence of fragment 74B6 shares 78% homology 
with the human VT4 protein (Figure 3.4). The VT4 protein was isolated from the 
Hela cell line. The VT4 protein was encoded by the vt gene. The structural feature of 
the gene and the role ofVT4 in human were not characterized by published literature. 
Nevertheless, it was suggested that the sequence ofVT4 protein was related to that of 
the yemanuclein-alpha protein of Drosophila melanogaster. They share 44% 
homology. The yemanuclein-alpha is a Drosophila nuclear protein, which is encoded 
by the yG4.5 gene, a member of the yema gene cluster isolated in search for 
differentially expressed matemal genes which are involved in oogenesis and/or early 
embryogenesis. It is found to be specifically expressed in the oocyte nucleus and 
during oogenesis. It was shown that the yemanuclein-alpha RNA is an early marker 
of the oocyte. It has a dynamic localization pattem in the growing oocyte that the 
gene transcript is maintained at the anterior end of the oocyte, displaying an unusual 
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graded distribution along the antero-posterior axis of the oocyte and it becomes 
evenly distributed in the oocyte during late oogenesis and in early embryo. These 
features of the gene suggested that the yemanuclein-alpha gene plays a key role in egg 
organization. It was also found that the yemanuclein-alpha gene have DNA binding 
activity in vitro. Part of the yemanucelin-alpha amino acid sequence are likely to 
form secondary structures that can interact with DNA and shows some of the features 
of the transcriptional activators. Therefore, it was suggested the yemanuclein-alpha 
may belongs to the class of proteins which bear both DNA binding and the activator 
functions, of which a transcriptional regulator (Ait-Ahmed, et al., 1987; Ai't-Ahmed, 
et al., 1992). As the sequence ofVT4 is related to yemanuclein-alpha and that the 
deduced amino acid sequence of fragment 74B6 shares 78% homology with VT4, we 
speculate that the fragment may also share some features of DNA binding and 
regulatory activity but this remain to be verified after the full length cDNA of the 
fragment 74B6 is isolated. 
The nucleotide sequences of the two ends of the fragment 107C10 excluding 
the undetermined sequence of the gap in between respectively share 91% and 87% 
homology with stretch of the mouse LlMd-A13 repetitive sequence and also share 
91% and 87% homology with the mouse LlMd-A2 repetitive element (Figure 3.4). 
LlMd-A13 and LlMd-A2 are members of the mouse LINE-1 (LlMd) repetitive 
family. LINE-1 (L1) is one of the most abundant long interspersed repetitive 
sequence family comprises at least 10% of the mammalian genome. Mammalian 
genomes contain 20-50,000 copies o f L l and there are at least 10^ copies per mouse 
genome. Individual elements o f L l range in size up to 6.8 kb, although the majority 
are truncated such that they are missing varying amounts of their 5'end. In mouse L1 
elements, the long elements contain two significant open reading frames of 1137 bp 
and 3900 bp that overlap each other by 14 bp. The length and relationship of the two 
large open reading frame are conserved features of the LlMd. Also, the sequences 
exist in arrays of tandem direct repeats. Two types of repeat units, termed A-
monomers and F-monomers have been characterized in mouse L1 elements, and 
therefore define the two subfamilies of mouse L1, A and F. Within the A or F 
subfamily, there are length polymorphisms in the 0RF1 coding region in which the 
numbers of tandem repeats in the 5'end of the 0RF1 are varied. This length 
variations further define the subgroup o f L l elements, such as LlMd-A2 and LlMd-
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A13. The overall nucleotide homology between LlMd-A13 and LlMd-A2 is greater 
than 99%. The A-monomer has shown promoter activity but that of the F-monomer 
has not been tested yet. Most L1 elements have structural features like A-rich tracts at 
the 3'end and short direct repeats that flank the L1 element. Also, the second open 
reading frame encodes a protein with homology to reverse transcriptase. These 
structural features suggested that the L1 element is a type of transposable element, 
known as retroposon, that replicates via an RNA intermediate. The replication 
process, termed retroposition, is thought to involve transcription of a full length RNA, 
reverse transcription into DNA and insertion into a new genomic position. 
Nevertheless, the function o fL lMd are still unclear (Adey, et al., 1991). 
Due to the high copy number o f L l sequences in the genome, L1 is abundantly 
represented in the RNA population of most cells. Full length, sense strand L1 
transcripts and 0RF1 protein have been detected in both human and mouse cell lines, 
primarily teratocarcinoma or embryonal carcinoma, and also in mouse testis (Kolosha, 
et al, 1995). Considerable interest in L1 exists because of its pathological potential. 
In previous studies, it was shown that novel L1 insertions were identified in human 
cases of hemaophilia and breast carcinoma (Adey, et al., 1991). Moreover, 
insertional mutagenesis by L1 elements was revealed by retrotransposing of two 
active human L1 elements into the human factor VIII and dystrophin genes (Kolosha, 
et al., 1995). 
A stretch of nucleotide sequence of fragment 107E10 shares 92% homology 
with another mouse repetitive element, mouse B1 repetitive sequence (Figure 3.4). 
B1 sequences are a family of short interspersed repetitive mouse elements with 
50,000 members, and are a related sequence family of the human Alu sequence 
(Lewin, 1994). The Alu repeat family is the most prominent family of short 
interspersed repetitive DNA sequences, SENES，which are highly repetitive in the 
mammalian genome (Propst, et al, 1984). The human Alu sequence is a 300 bp 
dimer composed of two homologous 130 bp monomers arranged head-to-tail and 
joined by an oligo(dA)-rich linker. The two monomers are not identical, the left 
monomer contains a functional RNA polymerase III promoter, while the right 
monomer has a 31 bp insert interrupting the RNA polymerase III promoter. The 
mouse B1 repetitive sequence, in comparison, is a 130 bp monomeric unit which 
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resembles the right Alu monomer except that the 31 bp insert in the B1 element does 
not interrupt the RNA polymerase III promoter region (Moshier, et al., 1987). Within 
each species, individual repeats are usually more than 80% homology in nucleotide 
sequence, but none of them are identical. There are 10^ to 5 x 10^ copies ofmouse B1 
repeats per haploid genome (Propst, et al., 1984). The Alu/B 1 family members 
resemble transposons in being flanked by short direct repeats and contain poly dA 
tract at their 3'ends. Also, they contain an intragenic RNA polymerase III promoter. 
The dispersed repetitive sequence ofAlu and B1 can direct its own transcription and 
multiple times of retroposition and insert into each other at a new site throughout the 
genome, thus creating novel composite structures (Moisher, 1987). Human Alu 
repeats have been found interspersed among the structural genes, such as those in the 
globin region and in intergenic DNA, in introns, and in the untranslated 3'trailing 
regions of genes. The function ofthe human Alu and mouse B1 repetitive sequence is 
not yet possible to determined. It has been proposed that the human Alu family 
members might function as origins o fDNA replication since they contain a 14 base 
sequence homologous to viral origins of DNA replication, though some of the family 
members argue against this (Kalb, et al., 1983). 
The nucleotide sequence of the whole fragment 131B2 excluding the 
undetermined sequence in the middle shares 98% homology with the musculus 
inositol polyphosphate 1-phosphatase mRNA (Figure 3.4). Inositol polyphosphate 1-
phosphatase is a Mg2+-dependent/Li+-sensitive enzyme of the phosphatidylinositol 
signalling pathway for several types of cell activation such as the lymphocytes, that 
catalyzes the hydrolysis of the 1-phosphate from inositol 1，4-bisphosphate and 
inositol 1，3, 4-trisphosphate. Previous studies shown that the human inositol 
polyphosphate 1-phosphatase mRNA is expressed ubiquitously with highest levels in 
pancreas and kidney (York, et al., 1993). It was proposed that overexpressed inositol 
polyphosphate 1-phosphatase degrades a stimulatory inositol phosphate(s) and 
thereby inhibits DNA synthesis (York, et al, 1994). 
A stretch of fragment 822 share 97% homology with a partial sequence of a 
EST cDNA clone, mb48fD2.rl Soares mouse p3NMF19.5 musculus cDNA clone, 
332667 5' mRNA sequence, of 398 bp (Figure 3.4). Another stretch of fragment 822 
also matched with a part of the sequence of another EST cDNA clone, EST192054 
‘ Chapter 2 
+ 161 
normalized rat muscle, Bento Soares Rattus sp., cDNA clone RMUAD01 3' end 
mRNA sequence, of 423 bp with 89% homology (Figure 3.4). As the EST cDNA 
clones have not yet been characterized, we are not clear about their strucural features 
and function. 
The result of the homology search of the fragments with the sequence database 
ofknown genes only give us a clue to the putative function of the isolated fragment as 
the fragments were a short stretch of sequence of about several hundred bases, not the 
full length sequence of the transcript. Also, the rest of the differentially amplified 
fragment does not correspond to any already known gene. Therefore, cloning of the 
corresponding cDNA, which can be achieved using the fragment as a probe for the 
screening of a cDNA library or by a more effective strategy, the ‘rapid amplification 
of cDNA ends' (RACE), may help to characterize the gene structure and elucidate its 
putative function. 
At the moment, the sequence of the differentially amplified fragment 
determined can provide us the information for designing specific primer for the 
confirmation of the differential expression of these fragments and examination of 
their expression pattem. 
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CHAPTER FOUR … 
Expression Profile Of Isolated Genes Fragments 
In Myeloid Leukemia Cell, Mouse Embryo, And 
Tissues 
4.1 Introduction 
After two rounds of dot blot hybridization screening to eliminate the false 
positives, the differential expression of the gene fragments isolated from RNA 
fingerprinting by arbitrarily primed PCR were further confirmed by semi-quantitative 
reverse transcription-polymerase chain reaction with the specific primers designed 
from the determined sequence of the fragments. 
4.1.1 Quantitation of mRNA by Reverse 
transcription-polymerase chain reaction 
The most commonly used analytical methods for expression of specific 
eukaryotic mRNAs are northern blots, RNA dot/slot blots, RNase protection assays 
and in situ hybridization. Northern blotting is capable of simultaneous identification 
of mRNA size and therefore enable the study of alternative splicing pattems of 
mRNAs. Northern blots and the related slot blot and dot blot techniques are semi-
quantitative. However the method is insentitive in a way that it requires microgram 
quantities of purified polyadenylated RNA [poly(A)+RNA], and requires the use of 
specific probes for detecting filter transferred mRNA. RNase protection assays are 
more sensitive, however, they also require specifically labelled radioactive probes for 
detecting the blotted mRNA (Siebert, et al., 1995). Both of the mentioned methods 
are commonly employed for quantitative assessment ofmRNA levels, though they are 
labor intensive and require large quantities of RNA. The methods are rather 
insensitive for investigation of rare RNA transcripts and therefore limit the study of 
genes that are relatively highly expressed. In situ hybridization is very sensitive, but 
is the most technically quenching for analyzing RNA. 
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An alternative way for mRNA analysis is the adaptation of PCR technique 
which features speed, sensitivity, specificity and efficiency. It is termed variously as 
reverse transciption-polymerase chain reaction (RT-PCR), RNA phenotyping, and 
message amplification phenotyping (MAPPing). RT-PCR is a sensitive polymerase 
chain reaction (PCR)-based technique for the rapid determination of the mRNA 
phenotyping of small numbers of cells. It is widely used for amplifying cDNA copies 
oflow abundance mRNA. As illustrated in the flow chart, Figure 4.1，the first step in 
RT-PCR process is the isolation of total RNA from between one to a million cells. 
cDNA is then synthesized by using the isolated mRNA as the template for reverse 
transcription. The cDNA, in tum, is used as the template for the enzymatic 
amplification of target DNA fragments by PCR, using primers designed specifically 
to amplify a selected cDNA region. The product is then analyzed by agarose gel 
electrophoresis afterwards. Theoretically, the intensity of the amplified DNA band on 
an ethidium bromide stained agarose gel can help in determining the amount of a 
specific gene transcript. Comparisons of transcripts permit investigation of changes 
in gene expression. In this way, the overall pattem of mRNAs present in the cells can 
be determined. 
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Figure 4.1 Schematic outline of RT-PCR OReproduced from Larrick, 1992). 
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RT-PCR technique can be used in detection and comparison of the relative 
amounts of specific mRNAs from and between virtually any tissues or cell sources. 
Like other commonly used RNA analysis techniques, RT-PCR is semi-quantitative in 
a way that allows the comparison of the relative level of gene expression in different 
tissues, cell lines, or cells or growth factors treated cells. RT-PCR can yield 
reasonably precise information about relative changes in mRNA levels, provided that 
the exponential growth holds for PCR amplification. In this sense, the PCR product 
concentration should be proportional to the starting target DNA. It is not difficult to 
predict a decrease in the efficiency of PCR at the latter stages of amplification owing 
to depletion of reaction components, diminished enzymatic activity, and accumulation 
of products. Therefore, the quantitation of mRNA levels by PCR should be limited 
to the exponential phase of amplification, before the plateau phase of the ampification 
has been reached (Siebert, et al., 1995). To eam a much clearer picture of the 
. difference, analysis of PCR product should be performed at earlier cycle numbers 
during the amplification process (Dallman, et al., 1991). In order to estimate the 
extent of gene expression in concem, three pieces of information need to be known, 
including the amount ofRNA used for synthesis of cDNA, the amount of cDNA used 
for PCR, and the number of PCR cycles needed to generate a visible band on agarose 
gel (Siebert, et al., 1995). Recent advances of RT-PCR allows more precise 
quantitation of individual mRNA with the use of external standard or incorporation of 
intemal standard in the cDNA synthesis reaction or PCR amplification. 
As compared to other assays, the advantages of the RT-PCR technique include 
not only its versatility, sensitivity and rapid tum-around time, but it is time-saving and 
less material demanding (Table 4.1). An extra benefit in using RT-PCR is the 
elimination of the poly(A)+ mRNA purification step, since data can be obtained 
directly on total RNA. RT-PCR allows detection of specific mRNAs even at low 
copy number (Kramnik, et al.,X993). The technique provides a representation of 
mRNAs being produced by cells at a given time point. A spectrum of mRNA species 
can be quantitatively measured in a few cells. Hence, it is used extensively in 
biomedical research and diagnostics for cancer, metabolic diseases and autoimmune 
diseases (Larrick, 1992). 
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Sensitivity Advantages Disadvantages  
Northern blot  
5-10 ^ig poly(A)+ mRNA mRNA size could be Insensitive, specific probe 
estimated, for detecting filter 
semiquantitative transferred mRNA, 
radioactive detection  
RNase protection assay  
100 ng - 1 ^g poly(A)+ Sensitive, semiquantitive Requires specific probe f o r ^ 
mRNA detecting filter transferred 
mRNA, radioactive 
detection, special gels  
MAPPing  
< 1 ng total RNA, <104 Very sensitive, easy, fast, Too sensitive ？ 
cells total RNA can be directly 
used for anlaysis  
Table 4.1 Comparsion of techniques for quantitative/qualitative analysis of 
mRNA (Adapted from Larrick, 1992). 
We have used RT-PCR to analyze the expression pattem of the putative 
differentially expressed genes isolated from RAP-PCR in biochanin A induced JCS 
cells. As in another studies it was shown that biochanin A induced monocytic 
differentiation of JCS cell while midazolam induced granulocytic differentiation of 
JCS cells, the expression pattem of the genes isolated from RAP-PCR was also 
studied in midazolam induced JCS cells to investigate how these genes are regulated 
in the process of myeloid leukemia cell differentiation along different lineages. The 
expression profiles of those putative differentially expressed genes in various tissue 
was also studied to determine whether their expressions are tissue specific. Further, 
as embryogenesis is also an important developmental process involving cell 
differentiation and maturation, and evidence shown that some genes essential in 
embryo development are also found to be important for myeloid cell differentiation, 
such as the homeobox gene, therefore, we are also interested in studying the 
expression profile of those isolated genes during mouse embryo development. We 
used oligo(dT)i2-i8 as a primer for first strand cDNA synthesis for the analysis o f t he 
relative level of expression of a particular gene within a group of samples or tissues, 
so that the same batch of cDNA may be used to analyze multiple genes and usually 
full length cDNA can be produced. Furthermore, as RNA extraction and reverse 
transcription often have rather variable yields, it is necessary to normalize the amount 
of the synthesized cDNA in various samples. Housekeeping genes are assumed to be 
equally transcribed in various samples and their transcripts are reverse transcribed 
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with comparable efficiencies. Therefore, measuring housekeeping gene transcripts by 
PCR is a method to normalize the results. The measurements of the level of gene 
expression must be performed in the exponential stage during the amplification 
(K6hler, et al., 1995). An ubiquitously-expressed gene or housekeeping gene, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is used as the control to 
normalize the amount of RNA in various samples in the present study. 
4.1.2 Internal primer design by OLIGO™ ver 3.4 
The specific primer used in the RT-PCR reaction for analysis of RNA and 
gene expression are crucial to the success of the analysis, which specifically amplify 
the target genes. The specific primers for the analysis of the level of gene expression 
of the putative differentially expressed genes in various tissues and cells were 
designed by OLIGO™ version 3.4 according to the sequence of the isolated gene 
fragments. To choose optimal primers for DNA amplification, the following criteria 
should be considered : 
1) The upper and lower primer should be highly specific for the intended target 
sequence, not base pair to other regions within the template, that potential 
secondary priming site should be avoided. 
2) The size of the product which is flanked by the upper and lower primer should be 
appropriate. If the size is too large, there is a possibility that no molecule can be 
amplified. Moreover, as the cDNA may not be in full length during reverse 
transcription process, if the oligonucleotide primers were designed near at the 
5'end of cDNA, the gene may also not be amplified. This will lead to a false 
negative result. 
3) Both the upper and lower primers and target regions with internal secondary 
structure should be avoided. The primer should be non self-complementary 
(hairpin formation). 
4) The upper and lower primers do not contain complementary bases such that they 
could hybridize with themselves, forming primer-dimer. 
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5) The primer should have relatively higher melting temperature, and the melting 
temperature of upper and lower primer should be nearly the same. 
4.2 Materials 
Those chemicals which had been mentioned in previous chapters would not be 
listed in this section. 
4.2.1 Mice 
ICR pregnant mouse, 20 at 7.5 d.p.c, 3 at 9.5 d.p.c., 11.5 d.p.c., 15.5 d.p.c. and 
17.5 d.p.c. respectively, and 5 Balb/c postnatal day-20 mouse were obtained from the 
animal house, Faculty ofMedicine ofThe Chinese University ofHong Kong. 
4.2.2 Cell lysate 
The cell lysate ofWEHI 3B (JCS) cells induced by biochanin A (50^iM) for 0, 
1，5, 18, 48 hours of 1.2 x 10? cells/ml were prepared as described in section 2.3.1 by 
the colleagues in Dr. N.K. Mak's research laboratory in Department ofBiology, Hong 
Kong Baptist University and stored at -70°C until use. 
4.2.3 Total RNAs 
1.Total RNA from uninduced and midazolam induced WEHI-3B JCS cells for 
1，5, 18，48 hours were kindly prepared by Miss Irene, Y.Y Szeto. 
2.Total RNA from various mouse tissues, namely, brain, bone marrow, heart, 




4.3.1 Internal primer design by OLIGO™ ver 3.4 
The specific primers used for amplifying the gene fragments isolated from 
RNA fingerprinting by arbitrarily primed PCR and showed putative differential 
expression were designed by the computer program OLIGO^^ ver 3.4. The sequence 
of the gene fragment was fit in the program. The upper and lower primer were chosen 
within the sense and antisense sequence of the gene fragment respectively, with the 
criteria that, the primer have no secondary priming site other than the target gene and 
not self-complementary or complementary to the primer themselves. Moreover, the 
region of the arbitrary primer consisted in the sequence of the differentially amplified 
fragment would not be a good candidate for use as a specific primer. The length of 
the primer is around 21 mer - 23 mer and the melting temperature of the upper and 
lower primer should be more or less the same, between 64-68°C, calculated by 
2°C(A+T)+4�C(G+C). The designed primers were then synthesized by Integrated 
DNA Technologies Inc. 
4.3.2 Isolation of total RNA from biochanin A 
induced JCS ceils, mouse embryos and 
tissue 
4.3.2.1 Preparation of cell lysate from mouse embryo and 
postnatal mouse brain 
To prepare cell lysate of mouse embryos, the pregnant ICR mouse were 
dissected and the embryos were recovered and washed in PBS. Embryos at 7.5 days 
postcoitum (d.p.c.), 9.5 d.p.c., 11.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. were recovered 
and homogenized with 4M guanidium thiocyanate using the homogenizer. The cell 
lysates were centrifuged at 4000 r.p.m. in a benchtop centrifuge for about 10 minutes 
to remove the fatty tissues. The supernatant were then stored at -70°C until use. On 
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the other hand, to prepare the cell lysate of postnatal mouse brain, five Balb/c mouse 
at postnatal day-20 were dissected and their brain were recovered and washed in PBS. 
The brain tissues were then homogenized with 10 ml 4M guanidium thiocyanate in 
the homogenizer. The cell lysate was stored at -70°C until use. 
4.3.2.2 Isolation of RNA by guanidium thiocyanate 
cesium chloride method 
The total RNA from biochanin-A induced WEHI-3B JCS cells at 0, 1，5, 18, 
48 hours, brain of postnatal day-20 mouse (Balb/c) and mouse (ICR) embryos at 7.5 
d.p.c., 9.5 d.p.c., 11.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. were isolated from the 
prepared cell lysate by guanidium thiocyanate cesium chloride method as described in 
section 2.3.2. 
4.3.3 Preparation of saggital section of mouse 
embryo 
To verify the developmental stage of the recovered embryo, some of the 
mouse embryo at various stages 7.5 d.p.c., 9.5 d.p.c., 11.5 d.p.c., 15.5 d.p.c., 17.5 
d.p.c. recovered in section 4.3.2.1 were used to prepare the saggital section. The 
mouse embryo was fixed, dehydrated and embedded in paraffin wax. About 5 [xm 
saggital section was cut from the paraffin wax embedded mouse embryo. The section 
was then stained by Mayer's hematoxylin and Eosin (H&E staining). 
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4.3.4 Confirmation of differential expression of 
isolated genes fragments during biochanin 
A and midazolam induced WEHI 3B (JCS) 
differentiation and the expression profile in 
mouse tissues and during mouse embryo 
development by reverse transcription-
polymerase chain reaction 
The differential expression of the genes isolated from RNA fingerprinting by 
arbitrarily primed PCR during biochanin A induced JCS cells differentiation was 
confirmed by RT-PCR. Also, the expression profile of the genes during midazolam 
induced JCS cells differentiation, in various mouse tissues and during mouse embryo 
development were studied by RT-PCR. 
The total RNAs from various cell types were first reverse transcribed to first 
strand cDNA by reverse transcription as described in section 2.3.3.1. GAPDH were 
used as a control to normalize the amount of RNA among the samples as described in 
section 2.3.3.2. A total volume of 10 ul containing first strand cDNA derived from 
0.1 p,g total RNA was boiled for 10 minutes to denature the first strand cDNA and 
chill on ice immediately for 2 minutes. A 50 i^l PCR reaction was set up to amplify 
the target gene. 10 ul boiled first strand cDNA was added to 40 ul of PCR mix 
containing IX reaction buffer, 0.2 mM of each dNTP, 1.25 mM M g C l 2 , 0.25U 
ThermoprimePius DNA polymerase, and 1 pmole of each of the two specific primers. 
A negative control using d d H 2 O instead of cDNA template was performed to ensure 
there is no contamination of the reaction. The PCR reaction mixture was then 
subjected to amplification using the programmable thermocycler (MJ Research PTC-
lOO^M). A touchdown PCR profile was adapted to increase the specificity of the 
amplification of the target genes and reduce spurious bands. The reaction mixture was 
incubated at 94°c for 5 minutes for template denaturation. Then the touchdown PCR 
profile started at 94°c for 1 minute for denaturation; 66°c for 1 minute, reduced 
l%ycle for primer annealing; 72°c for 1 minute for primer extension for the first 10 
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cycles. Then the PCR amplification continued to carried out with annealing 
temperature at 56°C for 20，25 and 40 cycles depending the level of expression of 
individual gene. For amplification of GAPDH in various samples, the PCR reaction 
mixture was incubated at 94°C for 5 minute, and the PCR profile was : 94°C for 1 
minute, 56° for 1 minute and 72° for 1 minute for 20 cycles. 15 ul of the PCR 
product was electrophoresed in 2% agarose gel containing IX TAE buffer and 0.5 




4.4.1 Internal primer design of the sequenced 
fragments 
The specific primers used in RT-PCR for confirmation of differential 
expression of the 14 subcloned differentially amplified fragments were designed using 
OLIGO™ version 3.4 computer program (Table 4.2). The upper and lower primers 
were chosen within the sequence of the differentially amplified fragment with the 
criteria that there are no secondary priming site and self complementarily of the 
primers. The length of the primer was 20-23 bases and the melting temperatures of 
the primers were 64-68°C. 
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Fragment Primer sequence (5' to 3，） Tm Product Size 
(�C) (bp) 
GAPDH Upper ACC ACA GTC CAT GCC ATC AC ^ _ 7 s 2 
Lower TCC ACC ACC CTG TTG CTG TA ~ ^ ~ ~  
131B2~~ Upper "OCG GAC TTC AGT GTG TAA CCA TT —68 -495* 
Lower CAC TCT TTC ATG TCC ACA ATG CC 68  
178S1 ~ ~ Upper "OTT CCT CTG TCA GAC TTG GTC A 66 T ^ 
Lower TAC AGC AAT CAA GGG GCA TCA A 64  
107C1Q "Upper ATA CCA AAT GGC AGA GAA GCA CC —68 -376* 
Lower GCT ATA TCT GGG TCC TTT CAG CA 6 8 ~  
107D7~~ Upper GTT CTT CTC ACT GTG CGT ATC C 66 -529* 
Lower CTC CTT GGG ATT TGG TGG CTC T 68  
130F8~~ Upper AAG CCG GTA TAG TTG AAC TCT CC 68 ^ 3 7 
Lower TGG AAC GTG GAA TGT ATT AGG AC 66  
139D1 ~ Upper GTA ATT CTG TCC TTG TGG CTG TG 68 -688* 
Lower GGC ACG GCT TTA CTG AAT AAG TC 68  
74C1 Upper ACA AAT CAG GTG CTG ACA TGC C ~66 -627* 
Lower GTT CCC AGC ACC CAC TAA ACA A 66  
1 3 0 J 3 ^ Upper GAT GGG GAT TAG TTT TTG TCT GC ~66 -573* 
Lower AGC AGT AGC TCT ACT TCC AGA AC 68  
178E3~~ Upper GGC CCA GTA AAA CCT AAG GAT AT _66 309 
Lower TTG AGT CCC ATC CTC CTA TGA CA 68  
~W\ Upper GGG AAG TGC AGA GCC AAA TGA T “ 66 269 
Lower TGG GTG GGA TGA GAG CTA AAT C 66  
107E10 Upper AGG ATG TCT CAG AGG TTA AGA GT ^ ~ ~ -523* 
Lower TAG TTT TGA TTT TCC GAG ACA GG 64  
64C2 Upper CTA GAG CAA ATC CTG GAC ATT G “ 64 452 
Lower GCG CCA TAG TGT GAA GAT ACT G 66  
~ ^ Upper "GAT AAT GAA GCT GGG CAA GAC A ~64 -632* 
Lower ATT TGC TTC CAG GTC TTA GAG G 64  
74B6 Upper CGG CCC ACG AAA GAA ATT CCA C 68 � 7 1 1 * 
Lower GGA GTA GCC AGT GGT AAC TTA C 66  
Table 4.2 Sequences ofthe specific primers for amplifying the differentially 
amplified fragments by RT-PCR. The melting temperature (Tm) was calculated as : 2�C 
(A+T) + 4°C (G+C). For the position of the specific primer in the differentially amplified 
fragment, see Figure 3.4. * Estimated product size = length of the fragment estimated by 
restricted digestion of the plasmid clone with Bam HI and Pst I (see Table 3.2) - length o f the 
fragment before the upper primer - length of the fragment after the lower primer. 
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4.4.2 Spectrophotometric analysis of total RNA 
Total RNAs of WEHI 3B (JCS) cells at various time points after biochanin A 
exposure, mouse embryos at various stages and the postnatal mouse brain were 
isolated by the guanidium thiocyanate cesium chloride method (Chirgwin, et al., 
1979). Absorbance o f U V light at 260 nm and 280 nm were measured to analyze the 
yield and purity of the RNA samples (Table 4.3). The ratio of absorbance at 260 nm 
to absorbance at 280 nm among the JCS samples were roughly around 1.6-1.9, while 
that of the mouse embryo and the postnatal mouse brain sample were lower, about 
1.4-1.5. The amount oftotal RNA obtained from the JCS cells was about 360-750 |ig. 
Since the recovery of the early stage o fmouse embryo was quite technically difficult, 
the yield of total RNA of 7.5 d.p.c. and 9.5 d.p.c was very low, only a few 
micrograms could be obtained. 
JCS cells incubated with Mouse (ICR) embryo Mouse 
Biochanin A (50 ^iM) for tissue 
JCS 1 P p 8 ~ " p 8 T s ~ ~ r ^ ~ ~ 11.5 15.5 17.5~"Postnat 





OD260 1.872 1.584 1.808 1.31 0.915 0.036 0.398 0.956 T T ^ ~ ~ o 7 I 0 3 ^ 
OD280 - 1.181 T ^ 3 5 0.954 0.693 0.482 0.023 0.278~ 0.636 T T T ? ~ ~ ^ ~ ~ 0 ^ 
OD260/ i ^ ~ ~ r ^ ~ ~ L m ~ ~ r ^ hm~~L5^~~L4^~~L5W~~L3^~~L4H~~L369 
OD28O  
Conc. 7.49 6.336 7.232 5.24 3.66 0.144 1.592 3.824 ~ o I ^ ~ ~ L 6 4 ~ ~ L 4 ^ 
(^^g/^ l^)  
Yield (^lg) 749 633.6 723.2 524 366 7.2 79.6 191.2 32.6 82 ^ 4 ^ 
Table 4.3 Spectrophotometric analysis of RNA samples isolated from JCS 
cells at various time points after biochanin A induction, mouse embryos at various 
developmental stage and postnatal mouse brain. The yields of RNA samples were 
calculated : OD260 x dilution factor x 40 p,g/ml x 50 i^l as the RNAs were resuspended in 50 
|il ddH2O, where the dilution factor was 100. 
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4.4.3 Saggital section of mouse embryo 
The saggital sections of mouse embryo at various stages 7.5 d.p.c, 9.5 d.p.c., 
11.5 d.p.c., 15.5 d.p.c, 17.5d.p.c. were prepared as described in section 4.3.3 (Figure 
4.3). The gestation period for the mouse embryo is 19-20 days, depending on the 
strain. Figure 4.2 and Table 4.4 show the timing of the different stages. The features 
of the recovered embryos sections at various time points coincided to that of the 
mouse embryo at the corresponding time points as described. 
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Figure 4.2 Time course of mouse embryo development. (0-5 days) Cleavage 
and blastulation; (5-10 days) implantation, gastrulation, and early oraganogenesis; (10-14 
days) organogenesis; (14-19 days) fetal growth and development (Reproduced from Hogan, e! 
al., 1994) Chapter 4 
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Age (d.p.c.) Features  
7.5 Late primitive streak  
9.5 21-29 somites; forelimb bud at level ofsomites 8-12 
11.5 6-7 mm, forefoot plate  
15 — 12-14mm  
1 6 14-17 mm  
"TY" T7-20 mm 
T s — 19.5-22.5 mm 
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Figure 4.3 Saggital sections prepared from mouse (ICR) embryos at (A) 7.5 
d.p.c.，12.5X (B) 9.5 d.p.c., 10X (C) 11.5 d.p.c., 7.5X (D) 15.5 d.p.c., 3.5X (E) 17.5 d.p.c., 
2.4X by Mayer's hematoxylin and Eosin staining. 
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4.4.4 Normalization of RNA samples 
The amount of total RNA among various samples were normalized by 
detecting the expression level of the housekeeping gene GAPDH transcript in each 
RNA sample analyzed by RT-PCR as described in section 2.3.3.2. GADPH gene 
transcript was amplified in each RNA sample for 20 cycles. The PCR products were 
electrophoresed in a 2% agarose gel stained with ethidium bromide (Figure 4.4). The 
level of gene expression of GAPDH was roughly constant among the RNA samples of 
the JCS cells at different time point after biochanin A induction, the JCS cells at 
different time point after midazolam induction, the mouse embryos at different 
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Figure 4.4 Normalization of the amount of RNA samples derived from 
various cell types by the detection of the gene expression of GADPH analyzed by RT-
PCR. The GAPDH gene transcripts were amplified for 20 cycles in equal volume of cDNA 
template among (A) cDNAs derived from total RNAs of JCS cells (Oh), JCS induced with 
biochanin A for 1 hour (lh), 5 hours (5h), 18 hours (18h) and 48 hours, (B) cDNAs derived 
from total RNAs ofJCS cells (Oh), JCS cells induced with midazolam for 1 hour (lh), 5 hours 
(5h), 18 hours (18h) and 48 hours (48h), and also mouse embryos at various developmental 
stages, and (C) various mouse tissues. 15 p.1 ofPCR products were loaded on a 2% agarose 
gel and electrophoresed. The size of the PCR product of GAPDH gene transcript was 452 bp. 
M = 1 kb DNA size marker. A: postnatal day-20 mouse brain, B: brain, C: bone marrow, D: 
heart, E : kidney, F: lung, G : spleen, H: thymus. 
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4.4.5 Analysis of mRNA expression of 
differentially amplified fragments in 
biochanin A or midazolam induced JCS 
cells and mouse embryos by RT-PCR 
To confirm the differential expression of the fragments isolated by RAP-PCR 
in JCS cells at various time point after biochanin A induction, the pattem of 
expression of the 14 subcloned differentially amplified fragments in JCS cells at 
various time point after biochanin A induction was examined by RT-PCR. The 
expression of those fragments in midazolam-induced JCS cells and mouse embryos 
was also analyzed by RT-PCR. Total RNAs were isolated from JCS cells after 
biochanin A or midazolam induction for 0 hour, 1 hour, 5 hours, 18 hours and 48 
hours, and mouse embryos at 7.5 d.p.c., 9.5 d.p.c., 11.5 d.p.c., 15.5 d.p.c. and 17.5 
d.p.c. The transcripts encoding the 14 subcloned differentially amplified fragments 
were amplified in the cDNAs sample derived from the various total RNAs isolated 
with the designed specific primers by RT-PCR assay. One to three different cycle 
numbers ranged from 30-50 were performed (Figure 4.5, Table 4.5). 
Among the 14 subcloned differentially amplified fragments, four types of 
expression pattem in JCS cells after biochanin A induction were observed. Five out 
of the 14 subcloned differentially amplified fragments, including 178S1, 74C1, 
107D7, 74B6 and 130J3, were downregulated at 1 hour, 5 hours and 48 hours after 
biochanin A induction of JCS cells (Figure 4.5A). 201 was up-regulated at 48 hours 
after biochanin A induction (Figure 4.5B). Five genes, including 178E3, 107E10, 
822, 131B2 and 130F8, were constitutively expressed during the course of biochanin 
A treatment, in which 131B2 expressed in a very low level (Figure 4.5C). Finally, the 
level of expression of 139D1, 64C2 and 107C10 were undetectable in untreated and 
biochanin A treated JCS cells (Figure 4.5D). Totally, there were 5 out of the 14 
subcloned differentially amplified fragments demonstrated to be differentially 
expressed during the course ofbiochanin A treatment. 
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4.4.5.1 Genes downregulated at 1 hour, 5 hours and 48 
hours after biochanin A induction of JCS cells 
While 178S1, 74C1, 107D7, 74B6 and 130J3 were downregulated in JCS cells 
after induction with biochanin A for 1 hour, 5 hours and 48 hours, their expression 
pattem during the course of midazolam treatment of JCS cells and during mouse 
embryo development were different. The expression patterns of 178S1 and 107D7 
during the course of midazolam treatment of JCS cells were the same. Both of them 
showed constitutive expression in untreated JCS cells and JCS cells treated with 
midazolam for 1 hour but were downregulated to an undetectable level at 5 hours after 
midazolam induction of JCS cells and thereafter. Similarly, 130J3 were constitutive 
expressed in untreated JCS cells and JCS cells treated with midazolam for 1 hour, 5 
hours and 18 hours but downregulated at 48 hours after midazolam induction o f JCS 
cells. The expression of 74C1 was steadily down-regulated during the course of 
midazolam treatment of JCS cells. On the other hand, 74B6 was constitutively 
expressed during the course ofmidazolam treatment ofJCS cells. 
During mouse embryo development, the expression patterns of 178S1 and 
107D7 were also similar. Their expression were upregulated in 9.5 d.p.c., 15.5 d.p.c. 
and 17.5 d.p.c. in which the expressions in 15.5 d.p.c were particularly high. The 
expressions of74B6 and 130J3 were transiently up-regulated in 15.5 d.p.c. while the 
expression o f74Cl were upregulated in 15.5 d.p.c. and 17.5 d.p.c. in which the level 
of expressions were higher in 15.5 d.p.c during mouse embryo development. 
4.4.5.2 Genes up-regulated at 48 hours after biochanin A 
induction 
While 201 was transiently upregulated at in JCS cells after 48 hours 
incubation with biochanin A, the level of expression in JCS cells after incubation with 




4.4.5.3 Genes constitutively expressed during the course 
of biochanin A treatment 
While 131B2, 130F8, 178E3, 107E10 and 822 were constitutively expressed 
during the course ofbiochanin A induction, similar expression pattem of some of the 
genes fragments in midazolam induced JCS cells was also observed. 131B2 and 
107E10 were also constitutively expressed during the course of midazolam induction 
of JCS cells. The expression of 130F8 in midazolam induced JCS cells was slightly 
downregulated during the course of midazolam induction whereas the expression of 
822 was transiently upregulated at 1 hour but downregulated progressively thereafter. 
The expression of 178E3 was downregulated at 5 hours after midazolam induction of 
JCS cells and thereafter. During mouse embryo development, the level of expression 
of 131B2 was undetectable. On the other hand, the expressions of 130F8 and 107E10 
were upregulated at 9.5 d.p.c. and 15.5 d.p.c during mouse embryo development, in 
which the level of expression of 130F8 was much higher in 15.5 d.p.c. embryo. The 
expression of 178E3 was transiently upregulated at 15.5 d.p.c. whereas 822 was 
demonstrated to be expressed in 7.5 d.p.c and the level of expression were particularly 
higher in 15.5 d.p.c. and 17.5 d.p.c,. 
4.4.5.4 Genes showing undetectable level of expression in 
biochanin A induced JCS cells 
The expression of 139D1, 64C2, 107C10 were undetectable in untreated and 
biochanin A induced JCS cells after 50 cycles of RT-PCR. The expressions of 64C2 
and 107C10 were also undetectable during the course of midazolam treatment o f JCS 
cells and during mouse embryo development, in which incorrect size of PCR product 
from 107C10 was amplified in midazolam treated cells. Nevertheless, the expression 
of 139D1 was downregulated at 5 hours after midazolam induction o f J C S cells and 
the expression were detected in 7.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. during mouse 
embryo development. 
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Figure 4.5 (following 2 pages) RT-PCR analysis of the expression of the 
subcloned differentially amplified fragments in JCS cells at various time points after 
biochanin A or midazolam induction and in mouse embryos at various developmental 
stages. The fragments were amplified in the cDNA derived from 0.1 )ig of total RNA of 
various cell types for several cycles by RT-PCR. M : 1 kb DNA size marker. - : negative 
control. + : positive control using plasmid subcloned with fragements as template. A) 
fragement downregulated at 1 hour, 5 hours, and 48 hours after Biochanin A induction of JCS 
cells. B) fragments up-regulated at 48 hours after Biochanin A induction. C) fragments 
constitutively expressed during the course of Biochanin A treatment. D) fragments showing 
undetectable level of expression in Biochanin A induced JCS cells. 
The number shown on top of each of the photo indicates the time point of the sample 
while the number shown on the bottom of the photo indicates the cycle no. of the RT-PCR. 
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Biochanin A Midazolam Embryo 
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C B i o c h a n i n A Midazolam Embryo 
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4.4.6 Tissue expression of the biochanin A 
induced-differentially expressed fragments 
by RT-PCR 
While five out of the 14 subcloned differentially amplified fragment, including 
178S1, 107D7, 74B6, 74C1 and 130J3, were shown to be differentially expressed 
during the course ofbiochanin A induction of JCS cells, the expression of these genes 
in various mouse tissues were examined by RT-PCR (Figure 4.6). Eight types of 
mouse tissues were studied, including brain, spleen, kidney, thymus, heart, lung, bone 
marrow and postnatal day-20 mouse brain. The expression levels of 107D7 were 
roughly the same in mouse brain, bone marrow, kidney, lung, spleen and thymus, but 
the expression levels in postnatal day-20 mouse brain and heart were relatively lower 
than that in other tissues studied. Fragment 178S1 were constitutively expressed in 
mouse kidney, lung and spleen. The levels of expression of fragment 178S1 were 
slightly lower in mouse brain, bone marrow and thymus and that in postnatal day-20 
mouse brain and heart were the lowest among the tissues examined. The expression 
level of 74C1 was higher in mouse brain, bone marrow and kidney than in lung and 
spleen, but the expressions were even lower in postnatal day-20 mouse brain, thymus 
and heart. The expressions of 130J3 in brain, bone marrow, kidney and lung were 
highest among the various mouse tissues studied. The expressions of 130J3 in mouse 
spleen and thymus were higher than that in postnatal day-20 mouse brain and heart. 
74B6 has higher level of expression in mouse brain and bone marrow than in spleen. 
The expressions of 74B6 in kidney, lung, postnatal day-20 mouse brain and thymus 
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Figure 4.6 Expression of the biochanin A-induced differentially expressed 
fragments in various mouse tissues. The differentially amplified fragments were amplified 
in various mouse tissues using cDNA derived from O.l^g total RNA of postnatal day-20 
mouse brain (A), brain (B), bone marrow (C), heart (D), kidney (E), lung (F), spleen (G), 
thymus (H) as template by RT-PCR.. I ： negative control. 15 i^l of the PCR products were 




Fragment Induction of JCS cells Induction of JCS cells Mouse embryo 
with Biochanin A by midazolam  
107C10 Undetectable Undetectable Undetectable 
expression expression expression  
107D7 Downregulation at 1 Downregulation Upregulation at 15.5 
hour, 5 hours, 48 starting from 5 hours d.p.c. 
hours  
107E10 Constitutive Constitutive Transient expression~" 
expression expression at9.5d.p.c .&15.5 
d.p.c.  
130F8 Constitutive Slightly Dramatic upregulation 
expression downregulation at 15.5 d.p.c.  
130J3 Downregulation at 1 Constitutive Transient upregulation 
hour, 5 hours, 48 expression followed at 15.5 d.p.c. 
hours by downregulation at 
48 hours  
131B2 Constitutive Constitutive Constitutive 
expression expression expression  
139D1 Undetectable Downregulation Dramatic upregulation 
expression starting from 5 hours at 15.5 d.p.c.  
178E3 Constitutive Constitutive Transient upregulation 
expression expression at 15.5 d.p.c.  
178S1 Downregulation at 1 Downregulation Upregulation at 9.5, 
hour, 5 hours, 48 starting from 5 hours 15.5 and 17.5 d.p.c. 
hours  
201 Upregulation at 48 Undetectable Undetectable 
hours expression expression  
64C2 Undetectable Undetectable Undetectable 
expression expression expression  
74B6 Downregulation at 1 Constitutive Transient expression 
hour, 5 hours, 48 expression at 15.5 d.p.c. 
hours  
74C1 Downregulation at 1 Steady downregulation Transient upregulation 
hour, 5 hours, 48 at 15.5 d.p.c. 
hours  
822 Constitutive Upregulation at 1 hour Upregulation at 7.5, 
expression followed by 15.5, 1.5 d.p.c.  
downregulation  
Table 4.5 Summary of the expression profile of the subcloned differentially 
amplified fragments in JCS cells at various time point after biochanin A or midazolam 




4.5.1 Expression profiles of isolated differentially 
amplified fragments 
In our studies RAP-PCR was used in the identification of candidate genes that 
are differentially regulated in response of JCS cells to biochanin A treatment, and 
therefore provide insight on further studies of the potential genes that are 
transcriptionally regulated during the biochanin A-induced JCS cells differentiation. 
The pattem of expression of the 14 subcloned differentially amplified fragments in 
biochanin A or midazolam induced JCS cells and in mouse embryos were examined 
by RT-PCR analysis with the use of the specific primers designed from the sequence 
o f the fragments. Five fragments, including 74B6, 178S1, 74C1, 107D7, and 130F8 
were shown to be differentially expressed during the biochanin A-induced JCS cell 
differentiation and maturation, demonstrated that the RAP-PCR method we adapted in 
our present study is a feasible way to identify genes that are differentially regulated 
during developmental processes. The expressions of the five differentially expressed 
fragments in various mouse tissues were also studied by RT-PCR analysis to examine 
whether the fragments are specifically expressed in myeloid leukemia cell and 
determine if their expression are tissue specific. 
A. Genes differentially expressed in biochanin A induced JCS cells 
Previous studies demonstrated that biochanin A and midzolam could drive 
JCS cells to differentiate into different lineages of myeloid cells, in which biochanin 
A could induce JCS cells to differentiate along the monocytic lineage while 
midazolam could induce JCS cells to differentiate along both monocytic and 
granulocytic lineage. The expressions of fragment 74B6, of which a stretch of the 
deduced amino acid sequence matched with part of the human VT4 amino acid 
sequence with 78% homology, were demonstrated to be down-regulated at 1 hour, 5 
hours and 48 hours after induction of JCS cells by biochanin A. On the other hand, 
this fragment was constitutively expressed during the course of midazolam induction 




74B6 at early stages and then increased expression at 18 hours may be specific for the 
differentiation of JCS cells into monocytic lineage induced by biochanin A 
Fragment 74B6 was also found to be transiently expressed in mouse embryo at 15.5 
d.p.c.. During mouse embryo development, late organogensis and liver as the major 
site of hematopoiesis started at 11.5 d.p.c. It suggested that the gene may also be 
involved in mouse embryo development and may be required for organogenesis or 
fetal liver hematopoiesis of a particular stage. Among the various mouse tissues 
studied, the fragment expressed in highest level in mouse brain and bone marrow 
while the level of expression in mouse spleen was higher than that in mouse kidney, 
lung, thymus, postnatal-day 20 mouse brain and the expression level in heart was 
barely detectable. 
When JCS cells were induced to differentiate into monocytic lineage by the 
treatment of biochanin A, the expressions of fragment 178S1 and 107D7, were 
downregulated at 1 hour, 5 hours and 48 hours after induction ofJCS by biochanin A, 
as that of fragment 74B6. The expressions of the two fragments, 178S1 and 107D7, 
were also downregulated to an undetectable level at 5 hours after midazolam 
induction of JCS cells and thereafter. It suggested that the downregulations of 
fragment 178S1 and 107D7 at early stage may be both required for biochanin A and 
midazolam induced JCS cells differentiation into either monocytic or granulocytic 
lineage, but increased in the level of expression of the two fragments at 18 hours were 
only be required for biochanin A induced differentiation of JCS cells into mature 
monocytes. The two genes were found to be expressed in 9.5 d.p.c., 15.5 d.p.c. and 
17.5 d.p.c mouse embryos in which the level of expression was particularly high in 
15.5 d.p.c. During mouse embryo development, early organogenesis and 
hematopoietic precursor cell activities in aortic/gonady'mesonephros region (AGM) 
occur at 9.5 d.p.c while the site of hematopoiesis switched from liver to bone marrow 
and late organogenesis occur at 17.5 d.p.c.. It suggested that the two genes may be 
involved in the process of organogenesis and hematopoiesis along the embryo 
developmental stages. The fragment 178S1 were constitutively expressed in mouse 
kidney, lung and spleen, but the expression levels in thymus, brain and bone marrow 
were lower. The expression levels of fragment 178S1 in postnatal day-20 mouse 
brain and heart were lowest among the tissues studied. Whereas the expression levels 
of 107D7 were roughly the same in mouse brain, bone marrow, kidney, lung, spleen 
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and thymus, but their expression levels in postnatal day-20 mouse brain and heart 
were relatively lower than that in other tissues studied. Again, like fragment 74B6, 
the expressions of fragment 178S1 and 107D7 in various mouse tissues we thus far 
studied were different in the level of expression. 
Likewise, the expression of fragment 74C1 were downregulated during 
biochanin A induced JCS cells differentiation at 1 hour, 5 hours and 48 hours. The 
expression of the gene was also downregulated steadily during midazolam induced 
JCS cells differentiation. The result suggested, as that observed for fragment 178S1 
and 107D7, downregulation of fragment 74C1 may be required for both biochanin A 
induced and midazolam induced JCS cells differentiation but later increase of 
expression at 18 hours may be only required for biochanin A induced monocytic 
differentiation of JCS cells. Moreover, the gene fragment were expressed in 15.5 
d.p.c and 17.5 d.p.c mouse embryos that the level of expression was higher in 15.5 
d.p.c. embryo, suggesting that the gene may be involved in late fetal growth including 
organogensis and hematopoiesis during mouse embryo development. The levels of 
expression of the gene varied in various mouse tissues. The expression levels of 
74C1 were higher in mouse brain, bone marrow and kidney than in lung and spleen, 
but the expressions were even lower in postnatal day-20 mouse brain, thymus and 
heart. 
As those gene fragments demonstrated differential expression during 
biochanin A induced JCS cells differentiation described above, the expressions of 
fragment 130J3 were also downregulated during biochanin A induced JCS cells at 
lhour, 5 hours and 48 hours differentiation but the expression level was increased at 
18 hours after biochanin A induction. On the other hand, the gene was constitutively 
expressed during midazolam induced JCS cells differentiation except at 48 hours after 
midazolam induction of JCS cells the expression was downregulated. The result 
suggested that downregulation of the gene and increased expression level at 18 hours 
were specific for biochanin A induced JCS cells differentiation into monocytic 
lineage. The downregulation of the gene at later stage during both biochanin A and 
midazolam induced JCS cells differentiation may be associated with the function of 
the mature myeloid cells. The gene was also transiently expressed at 15.5 d.p.c 
mouse embryo suggesting that it may be involved in mouse embryo development 
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required in particular stage of late organogensis and hematopoiesis during mouse 
embryo growth. Fragment 130J3 were expressed in brain, bone marrow, kidney and 
lung in highest level among the various mouse tissues studied. Comparatively, the 
gene were expressed in mouse spleen and thymus in a higher level than that in 
postnatal day-20 mouse brain and heart. 
The result of the RT-PCR analysis of the expression profile of the 
differentially expressed gene fragments in various mouse tissues indicated that those 
differentially expressed genes were not specifically expressed in myeloid leukemia 
cell but also expressed in normal tissues. 
B. Gene upregulated at 48 hours after biochanin A induction of JCS 
cells 
Fragment 201 was upregulated at 48 hours after biochanin A induction of JCS 
cells. The expression of this gene was not detectable during the course of midazolam 
induced JCS cells differentiation. The results suggested that the gene may not be 
associated with the early differentiation process of JCS cells but associated with the 
function of the mature monocyte. The expression of the gene was not detectable 
during mouse embryo development suggested that the gene may not be involved in 
mouse embyogenesis. 
C. Genes constitutively expressed during biochanin A induction of JCS 
cells 
Fragment 822, of which stretches of the nucleotide sequence matched with the 
sequence of two mouse cDNA clones reported in the dbest database with over 90% 
homology, was constitutively expressed during the course of biochanin A induction 
of JCS cells. However, the gene was upregulated at 1 hour after midazolam induction 
of JCS cells but then downregulated thereafter during the course of midazolam 
induced JCS cells differentiation. It suggested that the differential regulation of the 
gene may be specific for midazolam induced JCS cells differentiation. During mouse 
embryo development, the gene were expressed at 7.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. 
embryos suggested that it may be involved in mouse embryo development especially 
in late organogenesis and the development ofhematopoietic system in mouse embryo. 
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The expression level of fragment 130F8 was constant during biochanin A 
induction of JCS cells differentiation. Nevertheless, the expression of the gene was 
slightly downregulated during the course of midazolam induction of JCS cells, 
suggested that the downregulation of the gene may be associated with the midazolam 
induced JCS cells differentiation, but not the biochanin A induced JCS cells 
differentiation into monocytic lineage. The gene were expressed in 9.5 d.p.c. and 
15.5 d.p.c. mouse embryo, in which the expression level was higher in 15.5 d.p.c. 
embryo, suggested that it may be involved in mouse embryo development and 
especially required for late organogenesis and liver hematopoiesis. 
No distinctive alteration of the levels of expression of fragment 107E10, 
which was matched with a part of the mouse B1 repetitive sequence, and 178E3 were 
observed during the course of biochanin A and midazolam induction of JCS cells. 
Therefore, it was suggested the transcript of 107E10 and 178E3 may not be taking a 
determining part in biochanin A or midazolam induced monocytic and granulocytic 
differentiation of JCS cells. While fragment 107E3 was constitutively expressed 
during biochanin A induction of JCS cells, its expression was downregulated at 5 
hours after induction of JCS cells with midazolam and thereafter, suggesting the 
fragment may be involved in midazolam induced JCS cells differentiation and lineage 
commitment. Fragment 107E10 expressed in mouse embryos from 7.5 d.p.c to 15.5 
d.p.c. with relatively higher level of expression in 9.5 d.p.c and 15.5 d.p.c embryos. It 
suggested that the gene may be involved in organognesis during mouse embryo 
development. Whereas fragment 178E3 expressed only in 15.5 d.p.c mouse embryo. 
Therefore, the two genes , 107E10 and 178E3, may be involved in mouse embryo 
development. 
Fragment 131B2, which shares 99% homology with the inositol 
polyphosphate-1 polyphosphatase sequence, was constitutively expressed during the 
biochanin A and midazolam induced JCS cells differentiation. The expression level 
of the gene was not detectable in mouse embryos. The results suggested that the gene 
may not be transcriptionally regulated in biochanin A or midazolam induced 
monocytic/granulocytic differentiation ofJCS cells and mouse embryo development. 
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D. Genes showing undetectable expression in biochanin A induced JCS 
cells 
The expression level of fragment 139D1 was undetectable in JCS cells during 
the course of biochanin A induction. The expression of the gene was downregulated 
at 5 hours after midazolam induction of JCS cells and thereafter. The results 
suggested that the downregulation of fragment 139D1 may be specific for midazolam 
induced JCS cells differentiation, and it may not be involved in biochanin A induced 
JCS cells differentiation into monocytic lineage. The gene was expressed in 7.5 
d.p.c., 15.5 d.p.c and 17.5 d.p.c. mouse embryos demonstrated that the gene may be 
associated in mouse embryo development. 
The expression of fragment 107C10, of which a stretch of nucleotide sequence 
shares 91% homology with a part o f the mouse UNE-1 repetitive sequence, was not 
detectable during biochanin A and midazolam induced JCS cells differentiation but 
non-specific PCR products were amplified in both biochanin A and midazolam 
induced JCS cells. The expression was also undetectable in mouse embryos. The 
expression of another fragment 64C2 was also undetectable in both biochanin A and 
midazolam induced JCS cells and mouse embryos. The results suggested that the 
specific primers used in the RT-PCR analysis were not good, or the expression levels 
of the genes were too low to be detected, or the genes were not be involved in the 
induced JCS cells differentiation and mouse embryo development. The RT-PCR 
analysis may be repeated using another pair of specific primers to verify the 
expression pattem of the gene during induced JCS cells differentiation. 
In conclusion, based on the RT-PCR analysis, we observed that among the 14 
isolated gene fragments studied thus far, five of them were shown to be differentially 
expressed during biochanin A induced JCS cells differentiation. The rest of the gene 
fragments, though not differentially expressed in biochanin A induced JCS cells, 
interestingly, some of them were differentially expressed in midazolam induced JCS 
cells. Those five genes fragments, not only differentially expressed in biochanin A 
induced JCS cells, but also demonstrated to be differentially expressed during mouse 
embryo development and the time point ofhigher level ofexpression of these genes in 




4.5.2 Comparison ofthe expression profiles of the 
isolated gene fragments analyzed by dot 
blot hybridization screening and RT-PCR 
In comparing the expression profiles of the RAP-PCR isolated gene fragments 
in biochanin A induced JCS cells assessed by dot blot hybridization screening and 
RT-PCR analysis, we found that there were discrepancies in the expression pattems of 
the gene fragments shown by the two methods (Table 4.6). Among the 14 isolated 
gene fragments analyzed by RT-PCR, the expression pattems of six of the gene 
fragments that were differentially expressed, namely 201, 74B6, 74C1, 107D7, 130J3 
and 178S1, analyzed by dot blot hybridization screening and RT-PCR were 
completely different. Another five gene fragments, 822, 107E10, 130F8, 131B2 and 
178E3, shown constitutive expression in the RT-PCR analysis, however differential 
expressions were revealed in the second round of dot blot hybridization screening. 
The expressions of the remaining three gene fragments, 64C2, 107C10 and 139D1, 
were undetectable in the RT-PCR analysis while differential expressions were 
observed in the dot blot hybridization screening. 
In the dot blot hybridization screening which we adopted in our study to 
screen out the false positives of the RAP-PCR isolated differentially expressed genes, 
the isolated gene fragments were reamplified and dot blotted on membranes and 
hybridized with complex cDNA probes derived from poly(A) RNA of the biochanin 
A induced JCS cells. As the target gene fragments blotted on the membranes were in 
great excess, the intensity of the hybridization signal could then be used to evaluate 
the relative abundance of the corresponding gene in the probe derived from different 
cells. However, drawback of the method is possed when the target sequences are 
repeated sequences, or sequences belong to a gene family with high homology 
between members. Target sequences ofthese types may be cross-hybridized to many 
sequences in the cDNA probe. Also, target sequence containing poly (A) tail could 
pose a similar problem. As the cDNA probe is derived from the poly (A) RNA 
therefore the probe begins as poly(T) and continued as specific mRNA sequence, the 
cDNA probe containing the poly(T) may hybridized to unrelated target sequences 
through the poly(A) stretch. These factors could cause hybridization artifact and lead 
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to inconclusive results (Nguyen, et al., 1995). In our cases, the isolated gene 
fragments were generated by arbitrary priming of the cDNA which in tum derived 
from the oligo(dT) priming of the poly(A) RNA, therefore the isolated gene fragments 
would mainly derive from 3，end of the transcripts which would contain poly(A) 
stretches. Also, sequence analysis of some of the gene fragments shown that they 
share significant homologies with the repeated sequences. In these cases, those target 
sequences containing poly(A) stretches or repeated sequences would hybridized to 
unrelated sequences in the cDNA probes. On the other hand, specific primers, which 
is designed specifically from the sequences of the gene fragments, were used in 
amplifying the gene fragments in the RT-PCR analysis. These factors may account 
for the inconsistency of the expression patterns of the gene fragments revealed by dot 
bot hybridization and RT-PCR. 
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Fragment 2"^ round screening of dot blot RT-PCR 
hybridization 
201 Transient down at 5 hours Upregulation at 48 hours 
64C2 Biphasic upregulation at 1 hour Undetectable expression 
and 5 hours 
74B6 Steady upregulation Downregulation at 1 hour, 5 hours, 
48 hours 
74C1 Upregulation start from 1 hour Downregulation at 1 hour, 5 hours, 
48 hours 
822 Upregulation at 18 hours Constitutive expression 
107C10 Upregulation at 18 hours Undetectable expression 
107D7 Upregulation from 5 hours Downregulation at 1 hour, 5 hours, 
48 hours 
107E10 Steady upregulation Constitutive expression 
107P5 Upregulation at 18 hours Not applicable 
130F8 Biphasic upregulation at 1 hour Constitutive expression 
and 18 hours 
130J3 Biphasic upregulation at 1 hour Downregulation at 1 hour, 5 hours, 
and 5 hours 48 hours 
131B2 Upregulation starting from 1 Constitutive expression 
hour 
139D1 Steady upregulation Undetectable expression 
178E3 Upregulation starting from 1 Constitutive expression ‘ 
hour 
178S1 Biphasic upregulation at 1 hour Downregulation at 1 hour, 5 hours, 
and 18 hours 48 hours 
Table 4.6 Comparsion of the expression patterns of the isolated gene 
fragments analyzed by second round dot blot hybridization screening and RT-PCR. 
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CHAPTER FIVE … 
General Discussion 
The continuous production ofblood cells formation to replenish the loss of the 
short-lived blood cells is vital to the normal functioning and development of an 
individual. Any abnormality in the normal development program for blood cell 
formation results in hematological diseases including leukemia. The regulation of 
blood cell production is a complex process whereby a hierarchy of hematopoietic 
progenitor cells in the bone marrow proliferates and differentiates along multiple, 
distinct heamatopoietic cell lineages, including proliferation and differentiation of 
myeloid precursor cells into mature granulocytes and macrophages. In the present 
study, the molecular mechanism underlying the biochanin A induced myeloid 
leukemia cells WEHI 3B (JCS) differentiation into monocytic lineage was 
investigated. Study of the molecular mechanism of the induced myeloid leukemia 
cell differentiation may give hints to the molecular biology of the regulation of 
normal myeloid cell differentiation, promoting terminal differentiation and growth 
arrest of cells and, concomitantly, how blocks in differentiation can arise and the 
lesion that afflict it in leukemia and upon its progression. 
Assessment of the strategy for the isolation and screening of differentially 
expressed genes 
A modified RAP-PCR protocol was adopted in our study to identify genes that 
are transcriptionally regulated during the biochanin A induced JCS cells 
differentiation so as to dissect the molecular mechanism underlying the biochanin A-
induced JCS cells monocytic differentiation. As demonstrated in the present study, 
RAP-PCR can provide a powerful tool for the identification of candidates genes, 
which may be previously uncharacterized, that are being regulated in different 
biological processes, thus providing insights on the selection of potential genes for 
further analysis, and also examining how the population of gene transcripts is being 
regulated without cloning a gene. However, using RAP-PCR method in identifying 
differentially expressed genes in many cases need further confirmation of the 
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differential expression of the isolated gene fragments, which is ususally done by 
Northern hybridization. As hundreds of gene fragments generated by RAP-PCR have 
to be screened in searching for the differentially expressed genes, confirmation of 
differential expression of a large number of gene fragments by Northern hybridization 
is not feasible. Dot blot hybridization screening probed with labelled total cDNA, or 
'reverse northem' hybridization, which was employed in our study to eliminate the 
significant rate of false positives of differentially expressed gene fragments generated 
by RAP-PCR, provide a quick and simple way in the analysis of the expression of a 
large number of genes simultaneously. The strategy, also named differential cDNA 
screening, high density cDNA filter analysis or cDNA microarray hybridization in 
other previous studies, was used in many area of investigations for large scale semi-
quantitative analysis of the expression of genes which involved in many biological 
processes, including lymphopoiesis and tumorigenesis (DeRisi, et al., 1996; Hess, et 
al., 1998; von Stein, et al., 1997)，and was also applied in monitoring the expression 
of a wide array of genes in different tissues (Zhao, et al, 1995) and plant (Schena, et 
al., 1995). cDNA clones from the cDNA library were blotted on membranes and 
hybridized with the radioactive-labelled cDNA derived from the poly(A) RNA of the 
different types of cells to be analyzed. The relative abundances of the corresponding 
sequences in the probe were then estimated by the intensities of the hybridization 
signals. It was demonstrated in several studies in analyzing differential gene 
expression, that the results of differential cDNA screening were confirmed by 
Northern analysis (DeRisi, et al., 1996; von Stein, et al., 1997). In other studies in 
identifying differentially expressed genes using differential display or RAP-PCR 
performed in other laboratory (Mou, et al., 1994) and in our laboratory (Szeto, 1996), 
the same dot blot or slot blot hybridization screening method was adopted in 
eliminating false positives of the identified differentially expressed genes. In the 
study of identification of genes differentially expressed during midazolam induced 
JCS cells differentiation performed by Szeto, Y.Y. in our laboratory, the expression 
patterns of some of the isolated gene fragments analyzed by dot blot hybridization 
screening could be confirmed by RT-PCR analysis. Despite the fact that the strategy 
we used, dot blot hybridization screening, have shown to be successful in analyzing 
differential gene expression with a high rate of true positive in many studies, some 
drawbacks are posed. When the target sequence contain poly(A) stretch, repetitive 
element, or sequence belong to a gene family with high homology between members, 
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it would cross-hybridized to many sequences that also contain those types of 
sequences in the complex cDNA probes derived from the poly(A) RNA ofthe cells to 
be analyzed, leading to inconclusive results of the hybridization signals. Nonetheless, 
the dot blot hybridization screening probed with total cDNA is an efficient and quick 
way in the analysis of a wide array of gene expression and screening of differentially 
expressed genes, provided that the target sequence is unique sequence which only 
hybridize to its own cDNA, but not contain repeated sequence, poly(A) stretch or 
sequence belongs to gene family with homology between members. In this sense, 
when using RAP-PCR in identifying differentially expressed genes, the arbitrarily 
chosen primer used in RAP-PCR may better be totally random, that is not designed 
specifically to amplify certain genes, therefore minimize the chance in handling 
sequences that are repetitive elements or sequences belong to gene family with high 
homology between members. In our study, some of the gene fragments isolated by 
RAP-PCR contain repetitive sequence. In addition, the arbitrarily chosen primers that 
we used are particularly designed for amplifying cytokine genes, which may lead to a 
bias amplification of certain gene family and result in the inconsistencies of the 
expression patterns of the gene fragments analyzed by dot blot hybridization and RT-
PCR we observed. In this case, RT-PCR analysis was used in our study to confirm 
the differential expression of the gene fragments screened by dot blot hybridization. 
Expression profiles of the isolated differentially expressed fragments in 
biochanin-A and midazolam induced JCS cells, mouse embryos and tissues. 
Among the five gene fragments which are differentially expressed during 
biochanin A induced JCS cells differentiation, all of them were downregulated at 1 
hour, 5 hours and 48 hours after biochanin A induction of JCS cells. Most 
interestingly, one of these gene fragments, fragment 74B6, contained a stretch of 
deduced amino acid sequence which share 78% homology with the amino acid 
sequence ofhuman VT4 protein while the rest of the five gene fragments are putative 
novel genes. The function and features of the VT4 protein and its corresponding 
gene, vt, have not been yet characterized by any published data. Nevertheless, it was 
suggested that the sequence of the VT4 protein is related to that of the yemanuclein-
alpha protein in Drosophila melanogaster. Yemanuclein-alpha protein is suggested to 
play a role in egg organization and exhibit DNA binding activity and some features of 
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the transcriptional activator. Therefore, it suggested that fragment 74B6 may be 
related to certain DNA binding protein family. This gene fragment was shown to be 
constitutively expressed during midazolam induced JCS cells differentiation. In 
addition to the differential expression of this gene fragment during biochanin A 
induced JCS cells differentiation was demonstrated, differential expression of the 
gene fragment during mouse embryo development was also observed. 
During myeloid cell differentiation along- different lineages under the 
influence of different inducers, the expression of many genes were commonly or 
uniquely regulated. Study on the expression pattem of the isolated gene fragment in 
midazolam induced JCS cells by RT-PCR demonstrated that, three of the gene 
fragments which are differentially expressed during biochanin A induced JCS cells 
differentiation, including 178S1, 74C1, and 107D7, shown similar expression pattem 
in midazolam induced JCS cells as that in biochanin A induced JCS cells. The 
expression of 178S1 and 107D7 were downregulated at 5 hours after midazolam 
induction of JCS cells and thereafter, while that of 74C1 were gradually 
downregulated during the course of midazolam-induced JCS cells differentiation. 
The results suggested that the downregulation of the expression of 178S1, 74C1 and 
107D7 may be a common event for both biochanin A-induced and midazolam-
induced JCS cells differentiation or monocytic and granulocytic differentiation. 
On the other hand, there are isolated gene fragments showing different 
expression pattem in biochanin A-induced and midazolam-induced JCS cells. While 
fragment 130J3 and 74B6 were downregulated at 1 hour, 5 hours and 48 hours after 
biochanin A induction, the expression of 130J3 was downregulated at 48 hours after 
midazolam induction of JCS cells. Fragment 74B6, as mentioned previously, was 
constitutively expresssed in midazolam induced JCS cells. Moreover, fragments 
130F8, 822 and 139D1 were shown to be differentially expressed during the course of 
midzolam induction of JCS cells differentiation but the level of expression of these 
gene fragments were remained unchanged during biochanin A induced JCS cells 
differentiation. Fragment 201 was shown to be upregulated at 48 hours after 
biochanin A induction of JCS cells but its expression in midazolam induced JCS cells 
was not detected. All together, the different expression pattem of these gene 
fragments in biochanin A induced and midazolam induced JCS cells suggested that 
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the regulation of these genes may be specifically required for particular inducer 
induced JCS cells differentiation and involved in the lineage commitment. 
The study of the expression o f the isolated gene fragments in various stages of 
mouse embryos by RT-PCR analysis demonstrated that, most, if not all, of the 
isolated gene fragments which shown to be differentially expressed during induced 
myeloid leukemia cell differentiation were also regulated during mouse embryo 
development. Among the five gene fragments differentially expressed during 
biochanin A induced JCS cells differentiation, fragment 178S1 and 107D7 were 
expressed in 9.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. embryos with particularly high level 
of expression in 15.5 d.p.c. embryo, while fragment 74C1 were expressed in 15.5 
d.p.c. and 17.5 d.p.c., and fragment 74B6 and 130J3 were only expressed in 15.5 
d.p.c. embryos. Fragments 130F8, 139D1 and 822，were differentially expressed in 
midazolam induced JCS cell differentiation and also differentially expressed in 
various stages of mouse embryos. The expression of fragment 822 and 139D1 were 
detected in 7.5 d.p.c., 15.5 d.p.c. and 17.5 d.p.c. mouse embryos, of which the level of 
expression of fragment 139D1 was particularly high in 15.5 d.p.c. embryo. Fragment 
130F8 were expressed in 9.5 d.p.c. and 15.5 d.p.c. mouse embryos with higher level 
of expression in 15.5 d.p.c. mouse embryo. From these results, it was observed that 
the time point of high level of expression of these gene fragments coincided with the 
stages of mouse fetal hematopoiesis. As these gene fragments were isolated from the 
myeloid leukemia cell line, taken together, the differential expression of these gene 
fragments in various stages of mouse embryos suggested that these genes may also 
play certain roles in the mouse embryo hematopoietic development as well. 
Future studies of the isolated differentially expressed fragments 
Our study resulted in the identification of candidate genes that may be 
involved in the biochanin A induced myeloid leukemia cell differentiation. Also, 
examination of the expression patterns of the RAP-PCR identified differentially 
expressed fragments in biochanin A- or midazolam- induced JCS cells by RT-PCR 
give us a general idea on how the expression of these genes in JCS cells are regulated 
during the course of biochanin A or midazolam induction, and therefore provide 
insight on their putative roles in the induced JCS cells differentiation. However, we 
cannot conclude from the results obtained thus far that the regulation of the 
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expression of these genes in JCS cells upon induction to differentiation indeed play a 
regulatory role or is essential for the induced JCS cells differentiation process, or that 
the alteration of the expression of those genes during the induction of JCS cells with 
biochanin A or midazolam may be inducer effect. Further analysis is required to 
characterize the identified putative novel genes and determine their functional roles in 
the JCS cells differentiation process. 
Among the isolated five gene fragments differentially expressed during 
biochanin A induction of JCS cells, one of them, 74B6, matched a part of the amino 
acid sequence of the VT4 protein in human, whereas the rest of them are putative 
novel genes, not corresponding to any known gene in the GenBank. As the 
differentially amplified fragments identified by our modified RAP-PCR protocol may 
be derived from the 3，noncoding region of the corresponding mRNAs, the sequence 
of these identified fragments does not give enough information for us to make any 
justification on whether the fragments correspond to characterized gene or novel 
genes. Therefore, in order to facilitate further analysis of the differentially expressed 
fragments and elucidate their putative functions, it is necessary to isolate the full 
length cDNA of the corresponding gene, which may be achieved by using the 
fragment as a probe for the screening of a cDNA library or, using the ‘Rapid 
Amplification of cDNA Ends' (RACE) technique. 
To investigate how the identified genes differentially expressed during 
biochanin A induction of JCS cells relate to the biochanin A-induced JCS cells 
differentiation and to determine whether these genes are essential to the induced JCS 
cells differentiation, functional studies of the genes in induced JCS cells 
differentiation may help answer the question. As the differentially expressed 
fragments identified are all downregulated at 1 hour, 5 hours and 48 hours after 
biochanin induction of JCS cells, the effect of continuous expression of the gene 
corresponding to the identified fragment on the ability of the JCS cells to be induced 
to terminally differentiate can be studied. Moreover, the impact of the disruption of 
the normal expression of the genes by antisense technique on the biochanin A induced 
JCS cells differentiation can be analysed. If the continuous expression or disruption 
of the normal expression of the gene block the terminal differentiation of JCS cells 
induced by biochanin A, it indicates that the downregulation of the gene play an 
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important role in the biochanin A induced JCS cells differentiation. On the other 
hand, if the biochanin A-induced JCS cells could still terminally differentiate with 
continuous expression of the gene, then indicated that the gene was not involved in 
the biochanin A induced JCS cells differentiation process, or the gene may exert its 
effect on the differentiation program synergistically with other genes. In addition, the 
roles of these genes in midazolam induced JCS cell differentiation program may also 
be studied so as to work out the possible relationship of the regulatory pathways of 
the biochanin A-induced monocytic differentiation and midazolam-induced 
monocytic/granulocytic differentiation. 
Moreover, as we observed that genes differentially expressed during biochanin 
A induced JCS cells differentiation also shown differential expression in various 
stages of mouse embryos, which cast some light on other aspects of functions ofthese 
genes in the mouse embryo development. To determine their particular role in the 
mouse embryogenesis, the spatial expression of these genes in the mouse embryos at 
various stages may be first investigated by in situ hybridization. The functional 
studies of these genes in the mouse embryo developmental process could also be 
performed. 
Knowledge of the molecular mechanism of the induced differentiation of 
myeloid leukemia cell would ultimately illuminate our understanding on the 
regulation of normal myeloid cell differentiation and concurrently, the nature of the 
molecular abnormalities responsible for the blocks in differentiation that will lead to 
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A1. Ambiguity codes in sequencing 
Code 1 Unresolved Bases  
~M Tzzz~r^ 
R = = = : = T X 6  
W i"AT  
"s =====回  
Y ：： ：：……j"CT  
K ====:=TSf  •••::::=::=::==:=:::=::因【:  
::[:::=::=::=:==:::::::[猛〒:  
" 5 … . … … : : : = : : = : = : : : : : : : : : | A G T  
. S . : = = = = : : = = : = : = : : ] : 5 5 f  
"N iACGT  
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A2. Details of manufacturer's products 
MegaprimeTM DNA labelling system Amersham RPN 1606 
• Primer solution : random nanamer primers in aqueous solution 
• Labelling buffer : dATP, dGTP and dTTP in Tris-HCl, pH 7.5，2-
mercaptoethanol and M g C l 2 
• Reaction buffer : 10X concentrated buffer containing Tris-HCl, pH 7.5, 2-
mercaptoethanol and M g C l 2 
• Enzyme solution : 1 U/^il DNA polymerase I Klenow fragment (cloned) in 50 
mM potassium phosphate pH 6.5, 10 mM 2-mercaptoethanol and 50% glycerol 
Nick column Pharmacia Biotech 52-2076-00 
• 0.9 X 2.0 cm gel bed containing Sephadex G-50 DNA grade in distilled water 
with 0.15% Kathon CG as preservative. 
QIAGEN plasmid midi kit Qiagen 12143 
• Buffer P1 : 50 mM Tris-HCl, pH 8.0; 10 mM EDTA 
• Buffer P2 : 200 mM NaOH, 1 % SDS 
• Buffer P3 : 3.0 M Potassium acetate, pH 5.5 
• Buffer QBT : 750 mM NaCl; 50 mM MOPS, pH 7.0; 15% ethanol; 0.15% 
Triton X-100 
• Buffer QC : 1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% ethanol 
• Buffer QF : 1.25 M NaCl; 50 mM Tris-HCl, pH 8.5; 15% ethanol 
• QIAGEN tips : The tips was regenerated by 5 ml buffer QF and soaked with 
70% ethanol at 4 °C. A collection of tips was autoclaved at 121 °C at 1 kgcm'^ 
and dried at 60 °C. The regenerated tips were kept at room temperature and 
ready for use. 
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AutoRead Sequencing Kit Pharmacia XY-056-00-02 
• A mix : 5 ^iM ddATP, lmM dATP, lmM dCTP, lmM dTTP, lmM c7dGTP, 50 
mM NaCl and 40 mM Tris-HCl, pH 7.6 ‘ 
• C mix : 5 ^iM ddCTP, lmM dATP, lmM dCTP, lmM dTTP, lmM c7dGTP, 50 
mM NaCl and 40 mM Tris-HCl, pH 7.6 ‘ 
• G mix : 5 ^iM ddGTP, lmM dATP, lmM dCTP, lmM dTTP, lmM c7dGTP, 50 
mM NaCl and 40 mM Tris-HCl, pH 7.6 ‘ 
• T mix : 5 ^iM ddTTP, lmM dATP, lmM dCTP, lmM dTTP, lmM c7dGTP, 50 
mM NaCl and 40 mM Tris-HCl, pH 7.6 
• T7 DNA polymerase : 8 units/^il in 25 mM Tris-HCl, pH 7.5, 0.25 M NaCl, 3 
mM DTT and 50 % glycerol 
• Enzyme dilution buffer : 20 mM Tris-HCl, pH 7.5, 5 mM DTT, 10 ^g/ml BSA 
and 5% glycerol 
• M13 universal primer : 5'-fluorescein-d[ CGA CGT TGT AAA ACG ACG GCC 
AGT ]-3' in aqueous solution, 1.5 ^iM (2.1 pmol; 0.55 A260unit/ml) 
• M13 reverse primer : 5'-fluorescein-d[CAG GAA ACA GCT ATG AC]-3' in 
aqueous solution, 2.1 ^iM (2.1 pmol/^il; 0.42 A260 unit/ml) 
• Annealing buffer : 1 M Tris-HCl, pH 7.6 and 100 mM MgCl2 
• Extension buffer : 304 mM citric acid, 324 mM DTT and 40 mM MnCl2 
• DMSO : Dimethyl sulfoxide 
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